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Abstract 
 
 Antimicrobial resistance is a growing problem worldwide, with extended-spectrum β-
lactamase (ESBL)-producing organisms remaining an important cause of cephalosporin 
therapy failure. The main purpose of the work presented in this dissertation was to search for 
the molecular diversity of Ambler class A β-lactamase encoding genes in clinical Klebsiella 
pneumoniae and Escherichia coli isolates and its consequences.  
In a first step, the evaluation of ESBL detection and confirmation methods for K. 
pneumoniae, using different guidelines, was performed, with nucleotide sequencing allowing 
the identification of a new ESBL (SHV-55). The enzymatic properties of this new β-lactamase 
confirmed a higher affinity towards extended-spectrum cephalosporins, which is 
characteristic of ESBLs, contrasting to the parental enzyme SHV-1. 
For the new β-lactamase SHV-72, the higher value of 50% inhibitory concentration of 
clavulanic acid than for SHV-1 correlated with the values of higher afinity towards penicillins, 
which are characteristic of an inhibitor resistance enzyme. Simulation of molecular dynamics 
suggested that the Lys234Arg substitution in SHV-72 was responsible for stabilizing an 
atipical conformation of the Ser130 side chain, which may decrease susceptibility to 
clavulanic acid by preventing cross-linking between Ser130 and Ser70.  
Among the collection of K. pneumoniae strains studied, we identified several genes 
coding for different enzymes belonging to the CTX-M, GES, LEN, OKP, OXA, TEM, and SHV 
families and, among them, 35 were new β-lactamases. Among ESBL-producing isolates from 
1999 and 2006, we detected the presence of CTX-M enzymes only in the latest period. 
Overall, the complex molecular diversity of the blaSHV genes detected impelled us to 
propose a classification for this gene family, based on nucleotide synonymous mutations and 
the presence or absence of the nonsynonymous mutation T92A. 
Finally, among E. coli isolates colected in Portugal, a predominat multidrug resistant 
clone, producing TEM, OXA and CTX-M enzymes, was present in different hospital wards 
and community environments. The high dissemination of the CTX-M enzymes detected could 
also be associated with horizontal transfer of plasmids or mobile elements, like ISEcp1. In 
Algeria, we identified the same insertion sequence in clinical E. coli strains producing TEM 
and either CTX-M-3 or CTX-M-15 β-lactamases. 
In conclusion, the results from this dissertation extended our knowledge about the 
most important mechanism of resistance – the β-lactamases production – focusing on the 
phenotypic characteristics, biochemical properties, structure-function relationships, molecular 
diversity and dissemination, which are of most importance to the comprehension of the 
general resistance scenario in Portugal and worldwide. 
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Resumo 
 
 A resistência aos antimicrobianos é um problema crescente a nível mundial, sendo 
os organismos produtores de β-lactamases de espectro alargado (extended-spectrum β-
lactamase, ESBL), uma causa importante da falência terapêutica de cefalosporinas. A 
presente dissertação teve como principal objectivo investigar sobre diversidade molecular 
dos genes que codificam β-lactamases da classe A de Ambler em isolados clínicos de 
Klebsiella pneumoniae e Escherichia coli e avalias sobre as suas consequências. 
 Numa primeira fase, foram avaliados métodos de detecção e confirmação de ESBLs 
em K. pneumoniae, utilizando diferentes normas, onde a sequenciação nucleotídica permitiu 
a identificação de uma nova ESBL (SHV-55). As propriedades enzimáticas desta β-
lactamase evidenciaram a sua maior afinidade para as cefalosporinas de espectro alargado, 
característico das ESBLs, em contraste com a enzima parental SHV-1. 
 A nova β-lactamase SHV-72, apresentou um valor superior de concentração de ácido 
clavulânico do que SHV-1 para a inibição de 50% da actividade enzimática, estando este de 
acordo com os valores superiores de afinidade que também evidencia para as penicilinas, 
sendo estes caracteristicos das enzimas resistentes aos inibidores. Simulações de dinâmica 
molecular sugeriram que a substituição aminoacídica Lys234Arg presente em SHV-72 era 
responsável pela estabilização da conformação da cadeia lateral da Ser130, impedindo a 
ligação entre esta e a Ser70, o que poderá diminuir a susceptibilidade ao ácido clavulânico. 
 Na colecção de isolados de K. pneumoniae estudados, foram identificados vários 
genes que codificam diferentes enzimas pertencentes às famílias CTX-M, GES, LEN, OKP, 
OXA, TEM, e SHV, das quais 35 eram novas β-lactamases. Entre os isolados produtores de 
ESBLs de 1999 e de 2006, apenas foi evidenciada a presença de enzimas CTX-M no último 
período. 
 A complexa diversidade molecular detectada nos genes blaSHV, levou-nos a propor 
uma classificação para esta família de genes, baseada nas mutações nucleotídicas 
sinónimas e na presença ou ausência da mutação não-sinónima T92A. 
Finalmente, entre os isolados de E. coli colectados em Portugal, foi detectado um 
clone multirresistente predominante, em diferentes serviços hospitalares e comunidade, 
produtor de enzimas TEM, OXA e CTX-M. A elevada disseminação de enzimas CTX-M 
detectada poderá estar igualmente associada à transferência horizontal de plasmídeos ou 
de elementos móveis, como ISEcp1. Na Algéria foi identificada a mesma sequência de 
inserção em isolados de E. coli produtores de β-lactamases TEM e CTX-M-3 ou TEM e CTX-
M-15. 
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Em conclusão, os resultados apresentados na presente dissertação ampliam o nosso 
conhecimento sobre o mais importante mecanismo de resistência – a produção de β-
lactamases – evidenciando características fenotípicas, propriedades bioquímicas, relação 
estrutura-função, diversidade molecular e disseminação, as quais são da maior importância 
para a compreensão da resistência em Portugal e no mundo. 
 
 
 
Palavras-Chave: Klebsiella pneumoniae; Escherichia coli; diversidade molecular; 
disseminação; Portugal; β-lactamases; resistência aos antimicrobianos. 
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Thesis Outline 
 
β-Lactamase-producing Enterobacteriaceae are a growing concern in human 
medicine today. The studies presented in this PhD dissertation are focused on the molecular 
diversity of bla genes in clinical isolates of Klebsiella pneumoniae and Escherichia coli from 
community and hospital environments, and its consequences at the biochemical and 
epidemiological levels. 
 The order of presentation of each chapter in the present PhD dissertation does not 
necessarily reflect a chronological order, since some of the works described below were 
done simultaneously and the results obtained during one particular work would influence the 
progress of the other and vice-versa. 
 
Chapter I briefly describes the current knowledge of β-lactam resistance mechanisms. 
Special attention was given to the mode of action of β-lactamases, their structure and 
properties, the resistance they confer and distribution of different families. 
Chapter II describes the occurrence of a novel SHV-type enzyme (SHV-55) in isolates of K. 
pneumoniae in a comparitive study for the evaluation of the production of extended-spectrum 
β-lactamases. 
Chapter III reports the biochemical characterization of SHV-55, an extended-spectrum class 
A β-lactamase. 
Chapter IV describes the role of the Lys234Arg substitution in SHV-72 as a determinant for 
resistance to inhibition by clavulanic acid; this substitution is essential to better comprehend 
the functionality of the serine β-lactamase active site. 
Chapter V presents the molecular epidemiology and antimicrobial susceptibility of extended- 
and broad-spectrum β-lactamase-producing K. pneumoniae isolates in Portugal. 
Chapter VI describes the detection and characterization of OKP and LEN β-lactamases 
produced by clinical K. pneumoniae strains in this country. 
Chapter VII reports the high diversity of blaSHV genes based on nucleotide synonymous 
mutations and the presence or absence of the nonsynonymous mutation T92A, which led to 
the proposal of a classification. 
Chapter VIII describes, for the first time in Portugal, the co-expression of CTX-M-15, OXA-30 
and TEM-1 β-lacatamases in clinical E. coli isolates.  
Chapter IX reports the dissemination of extended-spectrum β-lactamase CTX-M-producing 
clinical E. coli isolates in community and nosocomial environments in Portugal. 
Chapter X reports the identification of CTX-M-3 and CTX-M-15 extended-spectrum β-
lactamases in isolates of E. coli from a hospital in Algiers, Algeria. 
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Chapter XI presents an overall discussion of the results described in this PhD dissertation, 
as well as several questions raised along the course of this work. 
 
Chapters II to X may be read separately. They contain reproductions of the following 
publications: 
 
Mendonça N, Ferreira E & Caniça M (2006) Occurrence of a novel SHV-type enzyme (SHV-
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Dis 56: 415−420. (Chapter II). 
Mendonça N, Manageiro V, Bonnet R & Caniça M (2008) Biochemical characterization of 
SHV-55, an extended-spectrum class A β-lactamase from Klebsiella pneumoniae. 
Antimicrob Agents Chemother 52: 1897−1898. (Chapter III). 
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General Abreviations 
 
ARSIP  Antibiotic Resistance Surveillance Program in Portugal  
bla   β-Lactamase coding gene 
BSAC  British Society for Antimicrobial Chemotherapy 
CLSI  Clinical and Laboratory Standards Institute 
CR   Common Region 
CRG  Commissie Richtlijnen Gevoeligheidsbepalingen 
DAP  Diaminopimelic Acid 
DIN  Deutsches Institut für Normung 
EDTA  Ethylenediaminetetraacetic Acid 
ESBL  Extended-Spectrum β-Lactamase 
EUCAST  European Committee on Antimicrobial Susceptibility Testing 
IC50  Fifty Percent Inhibitory Concentration 
IEF  Isoelectric Focusing 
IS   Insertion Sequence 
ISCR  Insertion Sequence Common Region 
kcat   Catalytic Activity Constant 
Km    Michaelis Constant 
KpI  Klebsiella pneumoniae group I 
KpII  Klebsiella pneumoniae group II 
KpIII  Klebsiella pneumoniae group III 
MIC  Minimal Inhibitory Concentration 
MDSs  Molecular Dynamic Simulations 
NAG  N-acetylglucosamine 
NAM  N-acetylmuramic 
NCCLS  National Committe for Clinical Laboratory Standards 
NIH  National Institute of Health 
NWGA  Norwegian Working Group on Antibiotics 
Omp  Porine, “Outer Membrane Protein” 
ORF  Open Reading Frame 
PBP  Penicillin-Binding Protein 
pCMB  p-Chloromercuribenzoate 
PCR  Polymerase Chain Reaction 
Abreviations  
 xii 
PCR-RFLP Restriction Fragment Length Polymorphism - Polymerase Chain 
Reaction 
PCR-SSCP Single Strand Conformation Polymorphism - Polymerase Chain 
Reaction 
PFGE  Pulsed-Field Gel Electrophoresis 
RLC  Reference Laboratory Criteria 
RND  Resistance Nodulation Division 
RMSD  Root Mean Squared Deviation 
SFM  Société Française de Microbiologie 
SRGA  Swedish Reference Group of Antibiotics 
 
 
Amino Acid Abreviations: 
 
Ala  Alanine  
Arg Arginine 
Asn Asparagine  
Asp Aspartic Acid 
Cys Cysteine 
Gln Glutamine  
Glu Glutamic Acid 
Gly Glycine 
His  Histidine 
Ile  Isoleucine 
Leu Leucine  
Lys Lysine  
Met Methionine 
Phe Phenylalanine  
Pro Proline 
SDN Serine, Aspartic Acid, Asparagine 
Ser Serine  
Thr Threonine 
Trp Tryptophan  
Tyr  Tyrosine  
Val  Valine 
Xaa Variable amino acid 
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β-Lactamase Abreviations: 
 
BEL  Belgium ESBLs 
BES Brazilian ESBLs 
BIL Named After the Patient Bilal 
CMS Complex Mutant SHV 
CMT Complex Mutant TEM 
CMY Active on Cephamycins 
CTX-M Active on Cefotaxime, First Isolated at Munich 
GES Guyana ESBLs 
GIM German Imipenemase 
IBC Integron-Borne Cephalosporinase 
IMP Active on Imipenem 
IRS Inhibitor Resistant SHV 
IRT Inhibitor Resistant TEM 
KLUA From Kluyvera ascorbata 
KLUC From Kluyvera cryocrescens 
KLUG From Kluyvera georgiana 
LAT Named After Patient 
LEN From K. pneumoniae Strain LEN-1 
MIR Discovered at Miriam Hospital 
OKP Other K. pneumoniae β-Lactamase 
OXA Active on Oxacillin 
PER Pseudomonas Extended Resistant 
PIT From the Author’s Name Pitton 
PSE Psedomonas-Specific Enzyme 
SFO Serratia fonticola 
SHV Sulphydryl Reagent Variable 
TEM Named After Patient Temoniera 
TLA Tlahuicas (Indian tribe) 
VEB Vietnam ESBLs 
VIM Verona Integron-Encoded Metallo-β-Lactamase 
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CHAPTER I           
 
 
General Introdution 
 
  
  General Introduction 
 
 3
1. Historical perspective 
 
The initial discovery of antibiotics is generally attributed to Alexander Fleming in 1928, 
whose observations of a diffusible bacteriolytic substance produced by a mould strain 
permitted the identification of penicillin (Fleming, 1929). Using the filtrate of liquid cultures of 
Penicillium notatum, he determined the antibacterial activity of this antibiotic in vitro, as well 
as its non-toxicity when injected into mice and rabbits. Nevertheless, since no studies with 
bacterial infected animals were performed, Fleming failed to demonstrate the penicillin’s 
ability to overcome these types of infections (Rolison, 1998). 
 With yet underdeveloped techniques, attempts to obtain purified penicillin in the 
1930s were mostly unsuccessful, which would condemn the interest in this drug. However, a 
study in 1940 showed what Fleming failed to demonstrate. Penicillin was highly effective 
against a streptococcal infection in mice. The consequent introduction of penicillin into 
clinical use in humans motivated the discovery of other antibiotics. β-Lactams expansion 
began only in the early 1960s, with the development of the semisynthetic penicillins, followed 
by semisynthetic cephalosporins, as well as other β-lactam antibiotics (Rolison, 1998). 
 
2. β-Lactams 
2.1. Structure 
 β-Lactam antibiotics are composed of an isolated ring, as in monobactams, or 
associated in bicyclic ring structures in other classes. While penicillins are a group of natural 
or semisynthetic antibiotics, in which the β-lactam ring is fused with a thiazolidine ring, in 
cephalosporins the β-lactam ring are merged with a dihydrothiazine ring (Figure 1.1). In the 
carbapenems, the β-lactam ring is combined with a hydroxyethyl side chain, lacking an 
oxygen or sulphur atom in the bicyclic nucleus. 
Overall, modifications of the R and R’ groups (Figure 1.1), alter the pharmacokinetic 
and antibacterial properties in different β-lactam antibiotics. For example, modifications at 
position 7 of cephalosporins increase the penetration into the periplasmatic space and the 
stability against β-lactamases, but may reduce antibiotic activity (Donowitz & Mandell, 1988). 
In contrast to the antibiotic, the clavulanic acid, a β-lactamase inhibitor, is composed of a β-
lactam ring fused with an oxazolidine ring and does not possessed an amide function. 
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Figure 1.1 - Chemical structures of β-lactam antibiotics (adapet from Yao & Moellering, 
2003). 
 
2.2. Mechanism of action 
β-Lactam antibiotics act on bacteria by inactivating the enzyme located in the 
citoplasmatic membrane which catalyses synthesis of the cross-linked peptidoglycan. Wall 
structure is different in Gram-positive and Gram-negative bacteria: in Gram-positive, a large 
layer of peptidoglycan involving the cell is followed by the citoplasmatic membrane, while in 
Gram-negative an outer membrane involves a thin layer of peptidoglycan followed by the 
inner or citoplasmatic membrane.  
The peptidoglycan is composed of alternating chains of N-acetylglucosamine (NAG) 
and N-acetylmuramic acid (NAM) linked by β-(1,4)-glycoside units. The carboxyl group of 
muramic acid is usually replaced by an aminoacid chain composed of four aminoacids. The 
most common are L-alanine, D-alanine, D-glutamic acid, D-glutamine and L-lysine or 
diaminopimelic acid (DAP). Cross-linkage occurs directly in Gram-negative organisms 
between the diamino residues of one peptide chain and the D-alanine of the adjacent peptide 
chain. This cross-linking with the elimination of the terminal D-alanine is designated the 
transpeptidase reaction. D,D-carboxypeptidases are responsible for the removal of the 
terminal D-alanine from the peptide chain, which could become a donor in the 
transpeptidation reaction. These penicillin-binding proteins (PBPs), transpeptidase and 
   Cyclopentene ring 
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carboxypeptidase, are subject to inhibition by β-lactam antibiotics, because penicillins act as 
analog of D-alanyl-D-alanine (Tipper & Strominger, 1965). These transpeptidases and 
carboxypeptidases react with acyl-D-alanyl-D-alanine to form the acyl-D-alanyl-enzyme 
complex, with the elimination of the terminal D-alanine. β-Lactam-enzyme complex, formed 
after interaction between the enzyme and the β-lactam antibiotic, would act as competitor to 
the formation of the normal acylated enzyme. The β-lactam-enzyme complex is very stable, 
and culminates with the inactivation of the PBP’s functions (Ghuysen, 1988). This 
interference with the normal cross-linking in the cell wall results in cellular lysis. Besides 
having transpeptidade and carboxypeptidase functions, PBPs also present a 
transglycosylase function, responsible for the polymerization of the glycan chain in 
peptidoglycan, which is not sensitive to β-lactams (Waxman & Strominger, 1983). 
Different bacteria species present diverse PBPs, which are polypeptides with 40 to 
120 kDa. Generally, in Enterobacteriaceae, the number of PBPs varies from six to eight, 
Escherichia coli specifically shows seven enzymes and Klebsiella pneumoniae presents six 
(Georgopapadakou & Lin, 1980; Spratt, 1983). In E. coli, the inactivation of PBPs with higher 
molecular weight, normally with transpeptidase or transglycosylase functions, ultimately 
leads to bacterial death. While inhibition of PBP1 leads to cellular lysis (Spratt, 1983), the 
inhibition of PBP2 results in the formation of spherical cells and that of PBP3 to the formation 
of filaments (Spencer et al., 1987). The inactivation of PBPs with lower molecular weight, 
normally with carboxypeptidase functions, does not seems lethal to the cell (Spratt, 1983). 
PBPs present different affinities towards β-lactams, according to the substitutions 
present in the β-lactam ring. Thus, in E. coli, penicillin derived β-lactams show higher 
affinities to PBP1 (amoxicillin), PBP2 (mecillinam and piperacillin), PBP3 (mezlocillin and 
piperacillin) and to PBP4, while all cephalosporins show higher affinities to PBP1, and some 
to PBP2 and PBP3 (cefotaxime) or just to PBP3 (ceftazidime) (Bryan & Godfrey, 1991). 
Similarly to the β-lactamases from class A, C and D, PBPs possess a serine residue 
in the active site responsible for binding (Ambler, 1980; Jaurin et al., 1981;Joris et al., 1988; 
Ouellette et al., 1987). This active site is composed of three conserved motifs responsible for 
the catalytic activity of these enzymes: Ser-Xaa-Xaa-Lys (which contains the active site 
serine and Xaa correspondes to a variable amino acid), (Ser/Tyr)-Xaa-Asn and 
(Lys/Arg/His)-(Thr/Ser)-Gly (Frère et al., 1991). Forming the active site in the tertiary 
structure by folding of the polypeptide chain, these motifs are always disposed in the same 
order and with similar spacing in the primary protein structure (Ghuysen, 1991; Goffin & 
Ghuysen, 1998; Massova & Mobashery, 1998). 
While in serine β-lactamases and lower molecular weight PBPs the active-site serine 
is situated close to the amino terminus of the peptide, in higher molecular weight PBPs the 
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active-site serine is located more centrally (Ghuysen, 1988; Keck et al., 1985). In all of these 
types of enzymes, the conservation of motifs within the active-site and in other specific 
regions of the sequence may play an important role in the three-dimensional orientation of 
the active-site to form the presumptive active centre (Bryan & Godfrey, 1991). 
 
2.3. Mechanisms of resistance to β-lactam antibiotics 
Resistance to β-lactam antibiotics is still a continuing problem in therapeutic failure. 
Since the introduction of penicillin, this phenomenon aroused and continues to grow. With 
the introduction of penicillin into clinical use in humans, the first enzyme capable of destroy 
this antibiotic appeared (Abraham & Chain, 1988). With the introduction of semisynthetic 
penicillins in 1950-60, followed by cephalosporins as well other β-lactam antibiotics in 1970-
80, bacteria continued to adapt and evolve, using mechanisms of mutations, genetic 
transference or natural selection (Frère et al., 1991; Jacoby & Archer, 1991).  
Therefore, there are four independent mechanisms of resistance to β-lactam 
antibiotics that can also act together. A first mechanism is target modifications, which implies 
a decrease in affinity, resulting in a low level of resistance. A second mechanism is based on 
the permeability of the outer membrane and implies a reduction of the penetration rates of 
the β-lactam, resulting in an intermediate level of resistance. A third mechanism is based on 
efflux pumps and implies the transport of the antibiotic from within the cell to the external 
environment, resulting in an intermediate level of resistance. A fourth mechanism, by far the 
most important and concerning mechanism of resistance, is the production of enzymes 
responsible for the hydrolysis of the antibiotic present in the periplasmatic space.  
 
2.3.1. PBPs modifications 
Modifications of PBPs have been described in both Gram-negative and Gram-positive 
organisms, assuming a more important role in Gram-positive bacteria. These modifications 
are associated with at least four mechanisms. A first mechanism is an aminoacid substitution 
that can reduce the affinity of the enzyme towards β-lactam. Nevertheless, the protein must 
remain capable of interacting with the D-alanyl-D-alanine under the risk of losing usefulness 
to the bacteria. However, since the majority of β-lactams have a large spectrum towards 
PBPs, aminoacid modifications in one or two enzymes will have very little effect on the 
resistance level. In E. coli, three different aminoacid substitutions within the transpeptidase 
domain of the PBP3, conferred resistance to cephalexin but not to other cephalosporins, 
penicillins or monobactams (Hedge & Spratt, 1985; Frère et al., 1991). 
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A second mechanism is the acquisition of foreign PBP resistant to β-lactam 
antibiotics. Nevertheless, this acquired foreign PBP have the same capability of performing 
many of the funcions of a normal PBP. The emergence of methicillin-resistant 
Staphylococcus aureus, where an acquired PBP2a confers resistance to β-lactam antibiotics, 
is a good example (Hackbarth & Chambers, 1989).  
A third mechanism of resistance is through recombination between susceptible PBPs 
and those of less susceptible species. This hybrid protein, is originated in an interspecies 
homologous recombination, presents a slightly less susceptibility to β-lactams (Dougherty, 
1986).  
Overexpression of a PBP is fourth mechanism. When PBP5 is overexpressed in 
Enterococcus hirae, increased levels of penicillin resistance are detected (Fontana et al., 
1983). In another study, strains with 50-fold increase of PBP3, in E. coli, showed increased 
of minimal inhibitory concentrations (MICs) of growth for aztreonam and ceftazidime (Hedge 
& Spratt, 1985)  
 
2.3.2. Permeability-based resistance 
Another mechanism of resistance is the decrease of permeability of the outer 
membrane. If in Gram-positive bacteria the β-lactam can easily reach the citoplasmatic 
membrane, in Gram-negative the crossing of the outer membrane is essentially done through 
protein channels, the porins (Nikaido, 1989). This outer membrane acts as a barrier to 
hydrophobic compounds in general and for hydrophilic compounds that exceed a low 
molecular weight.  
β-Lactams penetration is done essentially by porins OmpF and OmpC, which are 
proteins inserted into the outer membranes that act as water-filled, non-specific, 
transmembrane diffusion channels for hydrophilic molecules (Sawai et al., 1982). Being 
larger than OmpC, the OmpF channel is a major responsible for the penetrations of β-lactam 
antibiotics. Bacteria where the gene ompF is mutated, resulting in a modified OmpF, present 
a low level of resistance to β-lactam and the diffusion occurs through OmpC (Yoshimura & 
Nikaido, 1985). 
Overall, hydrophobicity, size and charge of the molecule influence the rate of 
penetration. As an example, cephalosporins, which are less hydrophobic than penicillins, 
possess a better penetration rate. Nevertheless, modifications of the R and R’ groups of 
each antibiotic may imply differences in the penetration rates (Nikaido, 1989). 
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2.3.3. Efflux pump 
The third mechanism involved in resistance to β-lactam antibiotics is the expression of 
efflux pumps. These proteins transport the antibiotic from within the cell to the external 
environment (Webber & Piddock, 2003). A characteristic of efflux pumps is the variety of 
molecules they may transport, due to poor substrate specificity. Thus, this multidrug efflux 
system plays an important role in providing resistance to a very wide range of compounds in 
Gram-negative bacteria (Nikaido, 1996). 
One of these multidrug efflux pumps is the resistance nodulation division (RND), a 
secondary active transporter. Examples of this superfamily include the AcrAB system of E. 
coli and the MexAB-OprM system of Pseudomonas aeruginosa (Li et al., 1995; Ma et al., 
1993). Previous studies pointed out that the inactivation of the specific components of efflux 
pumps decrease the MIC values of some β-lactams. For example, inactivation of mexA, in P. 
aeruginosa, decreased the MICs of ceftriaxone, cefoperazone, azlocillin and carbenicillin (Li 
et al., 1995). Another study suggests that clavulanic acid was also accommodated by the 
MexAB-OprM system (Li et al., 1998). In E. coli, deletion of acrAB decreased MIC values of 
ampicillin and benzylpenicillin (Ma et al., 1993). Overall, these results appear to suggest that 
such systems increase the resistance to β-lactam antibiotics. 
 
2.3.4. Enzyme production 
The fourth and most important mechanism of resistance to β-lactam antibiotics is the 
production of enzymes capable of structurally modifying the antibiotic. These enzymes 
constitute three major groups: the esterases, which hydrolyse the C3 acetil group of the 
dihydrothiazine ring in cephalosporins, originating a product with reduced antibiotic activity; 
the acilases, which hydrolyse the amide bond of the side-chain of penicillins and 
cephalosporins and which are more important in vitro, for the production of semi-synthetics 
penicillins, than in vivo (Sykes & Matthew, 1976); the third and by far the most important 
group of this type of  enzymes is the β-lactamases, which irreversibly inactivate the antibiotic, 
hydrolysing the cyclic amide bond of the β-lactam ring. With penicillins, the product of the 
reaction is the penicilloic acid, while with cephalosporins it is cephalosporoic acid. Reactions 
catalysed by β-lactamases are the most important mechanism of resistance to β-lactam 
(Livermore, 1995). 
 
  General Introduction 
 
 9
3. β-Lactamases 
 
Originally designated by the Nomenclature Committee of the International Union of 
Biochemistry as “enzymes hydrolysing amides, amidines and other C-N bonds … separated 
on the basis of the substrate: … cyclic amides”, the β-lactamases (EC 3.5.2.6) are the most 
common cause of bacterial resistance to β-lactam antimicrobial agents (Webb, 1984). With 
the discovery of the first β-lactamase in 1940, prior to the release of penicillin for clinical 
practice, it became rapidly apparent that bacteria were already one step ahead (Abraham & 
Chain, 1988). In 1965, a plasmid-mediated β-lactamase isolated from a patient named 
Temoniera presented ampicillin resistance and was subsequently designated TEM (Datta & 
Kontomichalou, 1965).  
 
3.1. Classification 
 Several classification schemes for β-lactamases have been developed over the years. 
A first consensual classification scheme was proposed in 1968, with penicillinases and 
cephalosporinases (Sawai et al., 1968). In 1970, Jack & Richmond (1970) proposed another 
classification scheme, which was updated in 1973 by Richmond & Sykes (1973), with five 
major groups based on the substrate profile. In 1976, Sykes & Matthew (1976) extended this 
last scheme to include plasmid-mediated β-lactamases differentiated by isoelectric focusing 
(IEF). In 1981, Mitsuhashi and Inoue (1981) proposed a scheme where they added the 
category “cefuroxime-hydrolyzing β-lactamase” to the “penicillinase and cephalosporinase” 
classification. However, with the discovery of new enzymes every year, it became necessary 
to propose a new classification. In 1989, Bush (1989a; 1989b; 1989c) updated the existing 
classification and tried to correlate substrate and inhibitory properties with molecular 
structure. Molecular structure classification was first proposed by Ambler in 1980 with 
classes A and B (Ambler, 1980). In 1981, Jaurin & Grundstrom described class C (Jaurin & 
Grunström, 1981), and in the late 1980s, class D, constituting oxacillin-hydrolyzing enzymes, 
were segregated from the other serine β-lactamases (Huovinen et al., 1988; Ouellette et al., 
1987). Finally, in 1995, new entries were done to the Bush classification scheme of 1989 
(Bush et al., 1995). This last scheme, updated in 1995, continues to attempt to correlate the 
functional characteristics with the molecular structure (Table 1.1). The four groups of β-
lactamases are: 
- Group 1: Chromosome encoded cephalosporinases that are not fully inhibited by clavulanic 
acid; 
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- Group 2: β-Lactamases belonging to classes A and D that are generally inhibited by active 
site-directed β-lactamase inhibitors; 
- Group 3: Metallo-β-lactamases that hydrolyse penicillins, cephalosporins and carbapenems, 
not fully inhibited by β-lactamase inhibitors, except for ethylenediaminetetraacetic acid 
(EDTA) and p-chloromercuribenzoate (pCMB), which require the presence of zinc or another 
heavy metal; 
- Group 4: Penicillinases that are not inhibited by clavulanic acid.  
 
 When compared with the classification proposed by Bush in 1989, this new proposal 
suggests the formation of two sub-groups derived from 2b: the 2be sub-group, which 
includes a growing number of enzymes from the TEM, SHV and, more recently, the CTX-M 
family; and the 2br sub-group, which includes enzymes with reduced affinity to β-lactamase 
inhibitors. The new proposal also suggests the formation of group 2f, consisting of 
carbapenems-hydrolysing enzymes closely related to metallo-β-lactamases from group 3, but 
with an active site serine. 
 This last classification scheme is widely accepted, as is Ambler’s proposal for 
molecular structure. As such, this work also follows these classification schemes (Table 1.1). 
 
3.2. Active site 
 The four classes defined by the molecular structure, A to D, have essential 
differences in their active sites, responsible for their different catalytic properties. While in 
classes A, C and D an active site serine is responsible for the β-lactam hydrolysis, in class B, 
enzymes require zinc or another heavy metal to catalyse antibiotics. 
 
3.2.1. Serine β-lactamases 
 Class A enzymes display four conserved motifs that create a complex hydrogen-bond 
network to fix the β-lactam in the substrate-binding pocket or active centre (Matagne et al., 
1998). Residues Ser70-Xaa-Xaa-Lys73, Ser130-Asp131-Asn132 (SDN Loop), and 
Lys/Arg234-Thr/Ser235-Gly236 define the conserved residues which are essential for β-
lactam binding and hydrolysis. 
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In the active centre, the oxyanion hole, defined by the NH group backbone of Ser70 and 
Ala237, is also used to attract β-lactams for hydrolysis (Knox, 1995) (Figure 1.2). Amino 
acids 160 to 179 define the Ω loop, where Glu166 acts as a general base in the catalytic 
process (Strynadka et al., 1992). 
 Compared to class A, class C enzymes possess a larger active centre, which allows 
the binding of the bulky extended-spectrum cephalosporins (oxyimino-β-lactams) (Crichlow et 
al., 1999). This conformational flexibility facilitates the hydrolysis of oxyimino-β-lactams by 
providing more space for water molecules to attack the acyl-enzyme intermediate. As in 
class A β-lactamases, the first element contains the active site serine (Ser-Xaa-Xaa-Lys), a 
second element contains a Ser-Xaa-Asn or Tyr-Xaa-Asn pattern that corresponds to the 
SDN loop of class A enzymes and on the opposite side of the active-site, a third element 
contains (Lys/Arg/His)-(Thr/Ser)-Gly. The Ω loop of class C enzymes is not readily apparent, 
but its function could be performed by the tyrosine of the second element. 
 
K73
S130
N132
E166
K234
S70
T235
R244
A237
E240
G238
G236
D131
E104
N170
L169
 
Figure 1.2 - Schematic diagram showing the hidrogen bonding site motifs of a class A β-
lactamase (adapted from Medeiros, 2000). 
 
 Segregated from the other class with active site serine in the late 1980s, class D 
enzymes possess only 16% of aminoacid identities with class A or class C enzymes. 
Nevertheless, a significant characteristic is the practically perfect symmetry between class A 
and class D enzymes for all atoms that constitute the catalytic mechanism for acylation 
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(example: Ser67, Lys70, Ser115 and Lys205 in OXA-10 and Ser70, Lys73, Ser130, and 
Lys234 in TEM-1, respectively). However, an extension of the binding site seems to exist in 
OXA-10, were the “oxyanion hole” is provided by the main chain nitrogen atoms of Ser67 and 
Phe208. Another difference from class A enzymes is the involving of the Lys70 residue in 
acylation and deacylation (Maveyraud et al., 2000). 
 
3.2.2. Metallo-β-lactamases 
Class B metallo-β-lactamases require a zinc or another type of heavy metal ion to 
hydrolyse β-lactam antibiotics, and their activity is inhibited by chelating agents like EDTA or 
pCMB (Rasmussen & Bush, 1997). At least two models have been proposed for 
chromosomal metallo-β-lactamases from Bacillus cereus and from Bacteroides fragilis. The 
model proposed for metallo-β-lactamase II from B. cereus presents a structure where the 
histidine residues at positions 86, 88 and 149, act as ligands to a single Zn2+ moiety located 
within the active site (Carfi et al., 1995) (Figure 1.3). First, this metal ion activates the water 
molecule for nucleophilic attack on the peptide carbonyl, in which Asp90 acts as a general 
base to remove a proton from the water molecule and, secondly, the Zn2+ binds and 
polarizes this carbonyl group. Asp90 and Cys168 maintain the position of the water molecule 
which allows the nucleophilic attack. 
H210
D90
H86 C168
H149
H88
D183
N180
 
Figure 1.3 – Active site of the metallo-β-lactamase present in B. cereus. The Zn2+ ion and 
the water molecule (Wat1) are represented by an orange and a white sphere, respectively 
(Adapted from Carfi et al., 1995). 
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The model proposed for metallo-β-lactamases from B. fragilis is based on the 
presence, at the active site, of two zinc atoms sharing a water (hydroxide) moiety that serves 
as a ligand for both ions (Concha et al., 1996). It was proposed that this hydroxide could be 
responsible for the nucleophilic attack on the carbonyl carbon of the β-lactam. The 
tetrahedral intermediate which is formed is thought to be stable as a result of the formation of 
an oxyanion hole, flanked by the side chain of the conserved Asn193 and the tetrahedral zinc 
(Concha et al., 1996). 
 
3.3. Structure, properties, conferred resistance and distribution of 
different β-lactamase families 
β-Lactamases can be found encoded in the chromosome, plasmids or transposons and 
produced in a constitutive or inducible mode. With the exception of the Salmonella genus, 
chromosomal β-lactamases are almost always ubiquitous in Enterobacteriaceae (Livermore, 
1995). Whether constitutive or inducible, the production of chromosomal β-lactamases varies 
in quantity between low and high production levels, thus affecting the degree of resistance 
conferred (Table 1.2).  
Clinical relevant enzymes confer resistance to a wide range of β-lactams and 
combination of β-lactam with β-lactamase inhibitors. Several types of chromosomal enzymes 
are expressed by Enterobacteriaceae. However, three major groups are of special 
importance: AmpC β-lactamases, which are constitutive in E. coli and Shigella; SHV, LEN 
and OKP enzymes, constitutive in K. pneumoniae; and KLUA, KLUC and KLUG β-
lactamases, which are constitutive in Kluyvera ascorbata, K. cryocrescens and K. georgiana, 
respectively, and probably the progenitors of some plasmid-mediated CTX-M enzymes 
(Decousser et al., 2001; Humeniuk et al., 2002, Poirel et al., 2002c). 
 Resistance to β-lactams increased with the natural selection of bacteria expressing β-
lactamases after the general introduction of antibiotics in clinical practice. This increase was 
also due to the spread of self-transferable plasmids responsible for resistance phenotypes. 
The report of the first TEM-type enzyme conferring transferable ampicillin resistance was 
followed, in 1974, by the identification of a transposon containing a blaTEM gene as the first 
mobile element responsible for dissemination of ampicillin resistance (Datta & 
Kontomichalou, 1965; Hedges & Jacob, 1974). Almost 20 years later, in 1992, the first 
transposon carrying genes that encode extended-spectrum β-lactamases (ESBL), which 
confer resistance to third generation cephalosporins, was described (Heritage et al., 1992). 
Confirming this idea is the association between blaCTX-M genes, which code for one of the 
most important families of β-lactamases, and insertion sequences located upstream and 
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downstream in the majority of bla genes of this family (Bonnet, 2004). This overall very 
recent dissemination of plasmid-mediated β-lactamases in Gram-negative bacteria is a good 
example of fast-paced evolution. 
 
Table 1.2 - Chromosomal β-lactamases and their expression in enterobacteria (adapted from 
Livermore, 1995) 
Mode of expressiona 
Constitutive Organism Name Class
Bush 
group Inducible 
Minimal Moderate High 
E. coli AmpC C 1 - ● - ○ 
Shigellae AmpC C 1 - ● - ○ 
Enterobacter spp. AmpC C 1 ● ○ - ● 
Citrobacter freundii AmpC C 1 ● ○ - ● 
Morganella morganii AmpC C 1 ● - - ● 
Providencia spp. AmpC C 1 ● ○ - ○ 
Serratia spp AmpC C 1 ● - - ● 
K. pneumoniae SHV-1 A 2b - - ● ○ 
Klebsiella oxytoca K1 A 2be - - ● ● 
Citrobacter diversus  Ab 2e ● ○ - ○ 
Proteus vulgaris Cxasec A 2e ● - - ○ 
Proteus penneri CXase A 2e ● - - ○ 
Proteus mirabillis  ?d ?d - ● - - 
a ●, Normal mode of production, typical of the species; ●, frequently encountered, variable among 
countries, hospitals, and units, but seen in 10 to 50% of isolates in most recent surveys; ○, rare, 
seen in fewer than 10% of isolates; -, unknown or isolated reports only. Minimal production: 
denotes that enzyme is detectable but causes no significant resistance; moderate: denotes that the 
enzyme contributes to resistance to good substrates; high: denotes huge levels of enzyme (up to 
3% of total cell protein in some Enterobacter) able to confer resistance even to weak substrates. 
b Production of class C enzymes has been seen in a few C. diversus isolates (Jones et al., 1994). 
c CXase, cefuroximase belonging to Bush-Jacoby-Medeiros’s group 2e (Bush et al., 1995). 
d No particular chromosomal β-lactamase has been defined as being typical of P. mirabilis. 
 
3.3.1. AmpC β-lactamases 
AmpC β-lactamases are chromosome-encoded cephalosporinases found in E. coli, 
which are not strongly inhibited by clavulanic acid, and that can be found in group 1 of Bush-
Jacoby-Medeiros classification scheme and in class C according to molecular structure 
(Bush et al., 1995; Jaurin & Grundström, 1981). With minimal expression in E. coli (Normak 
et al., 1980), these enzymes do not confer resistance to ampicillin and first generation 
cephalosporins, thus being rarely involved in clinical failure of β-lactams. This is because the 
gene ampC, which encodes for AmpC β-lactamase, is regulated by a weak promotor (Olsson 
et al., 1983) and a transcription attenuator (Jaurin et al., 1981). In E. coli, the ampC gene 
overlaps the fumarate reductase (frdD) gene, with the transcriptional terminator for the frdD 
operon located in the ampC gene, acting as an attenuator for this β-lactamase encoding 
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gene (Jaurin et al., 1981). When ampC is preceded by a strong promotor, an increase in the 
transcription fosters the hyperproduction of AmpC β-lactamases (Nelson & Elisha, 1999). 
Two separate mutations in E. coli also induce the hyperproduction of this type of enzymes 
(Bennett & Chopra, 1993). Overall, hyperproducers of AmpC enzymes account to less than 
2% of E. coli strains in several studies (Livermore, 1995).  
Detection of plasmid-mediated ampC genes in Enterobacteriaceae that produce 
AmpC-type β-lactamases has become quite common with the identification of MIR-1 
(discovered at Miriam Hospital) and CMY-1 (active on cephamycins) in K. pneumoniae, BIL-1 
(named after the patient Bilal), LAT-3 and LAT-4 (named after patient) in E. coli, among 
others (Bauernfeind et al., 1989; Fosberry et al., 1994; Gazouli et al., 1998; Papanicolaou et 
al., 1990). In general, plasmid-mediated AmpC enzymes fall into at least six phylogenetic 
groups (Perez-Perez & Hanson, 2002). 
 The occurrence of plasmid-mediated AmpC β-lactamases has been reported 
worldwide (Coudron et al., 2000; Li et al., 2008; Muratani et al., 2006; Song et al., 2006; 
Woodford et al., 2007). The most successful plasmid-mediated AmpC β-lactamases – the 
CMY enzymes – are derived from the chromosomal cephalosporinases of Citrobacter 
freundii (Miriagou et al., 2004). The association of CMY-encoding genes with mobile 
elements, such as orf513 or IS26, may be the reason behind this worldwide spread (Chen et 
al., 2007). 
 Overall, strains producing plasmid-mediated AmpC enzymes are generally resistant 
to penicillins, extended-spectrum cephalosporins, monobactam and cephamycins, but are 
susceptible to cefepime, cefpirome and carbapenems (Philippon & Jacoby, 2002). 
Nevertheless, it is very difficult to distinguish between plasmid-mediated AmpC-producing 
organisms and ESBL-producing organisms using phenotypic susceptibility testing methods 
alone.  
 
3.3.2. TEM β-lactamases 
 The TEM family is the most diverse family of β-lactamases, presenting over than 163 
different enzymes, according to the internet site of the Lahey Clinic 
(http://lahey.org/studies/temtable.asp), maintained by Prof. George Jacoby and Prof. Karen 
Bush and last updated in 20 of August 2008. 
The first member belonging to the TEM family, TEM-1, is able to hydrolyse ampicillin 
at a greater rate than carbenicillin, oxacillin, or cephalothin, presents negligible activity 
against extended-spectrum cephalosporins, and is inhibited by clavulanic acid. Considered 
as one of the parental or progenitor enzymes of ESBL-TEM enzymes, plasmid-mediated 
TEM-1 is by far the most prevalent β-lactam inactivating enzyme found in enteric bacilli (Liu 
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et al., 1992). The second parental enzyme of this family is TEM-2, which differs from TEM-1 
in an aminoacid substitution at position 39 (Gln39Lys), but confers a similar phenotype of 
resistance (Ambler & Scott, 1979; Jacoby & Sutton, 1985; Jacoby & Carreras, 1990).This 
substitution changes the isoelectric point from 5.4 in TEM-1 to 5.6 in TEM-2. 
Another difference between TEM-1 and TEM-2 is the strength of the promoters 
upstream of the blaTEM genes, which encode for these β-lactamases. The blaTEM-2 gene 
presents a promoter which is stronger than the promoter of the blaTEM-1 gene. Bacterial 
strains expressing a TEM-2 enzyme present a higher enzymatic activity when compared to 
TEM-1 producing strains (Chaïbi et al., 1996; Jacoby & Carreras, 1990). Another feature 
related to the genetic environment of the blaTEM genes is found in the blaTEM-6 gene, which 
presents a 116 bp IS1-like element upstream of the coding region (Goussard et al., 1991). 
This element is responsible for the high-level synthesis of this enzyme. TEM variants are 
derived from parental enzymes TEM-1a to TEM-1h and TEM-2, and from these TEM-1a, 
TEM-1b and TEM-2 are encoded in three transposons, Tn3, Tn2 and Tn1, respectively 
(Archambault et al., 2006; Partridge & Hall, 2005). 
The majority of the TEM family is composed of ESBL enzymes which are derived 
from parental enzymes TEM-1 and TEM-2 (Table 1.3). Specific amino acid substitutions at 
positions Asp104, Arg164, Ala237, Gly238 and Glu240 cause variations in the level of 
resistance to several compounds and confer the ESBL phenotype. As an example, TEM-3 
with substitutions Gln39Lys, Asp104Lys and Gly238Ser provides resistance to all extended-
spectrum cephalosporins and monobactams (Jacoby & Carreras, 1990). In SHV enzymes, 
the presence of the Gly238Ser in the active site pushes the β-strand out and away from the 
reactive Ser70 residue, resulting in a slightly expanded active site, which could improve 
binding and accommodate cephalosporins with bulky side-chains (Huletsky et al., 1993; 
Matagne et al., 1998). 
On the other hand, TEM-10, which presents Arg164Ser and Glu240Lys substitutions, 
hydrolyses ceftazidime preferably over cefotaxime (Quinn et al., 1989). This last mutation is 
responsible for the increase in hydrolysing activity against ceftazidime, based on a change of 
the electrostatic charge of the exposed group at position 240 (Huletsky et al., 1993; 
Randegger et al., 2000). 
Although mutation Glu104Lys improves the ability of the enzyme to hydrolyse 
cephalosporins and monobactams, it is not sufficient to confer true resistance. When 
associated with at least one mutation in another part of the active site (e.g., Arg164Ser), the 
combined effect of the two mutations is responsible for increasing the hydrolytic capability of 
the enzyme towards third-generation cephalosporins (Sowek et al., 1991). 
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It has been suggested that the ammonium group of the long Lys side-chain interacts with the 
carboxylic group of the oximino substituents of ceftazidime and aztreonam (Knox, 1995). 
Another study suggests that Lys104 might modify the precise positioning of the SDN loop, 
which is involved in the binding and catalysis of the substrate (Petit et al., 1995). 
Amino acid substitutions at position Arg164 are the most common mutations in TEM 
enzymes (Table 1.3). Substitutions with either serine or histidine allow a greater flexibility of 
the Ω loop, opening the active site for bulky β-lactam variants. A TEM-1 mutant prepared by 
site-directed mutagenesis and containing the Arg164Ser substitution, showed increased 
catalytic efficiency for cefotaxime, ceftazidime and aztreonam (Sowek et al., 1991). 
Another amino acid substitution associated with the ESBL phenotype is the 
Ala237Thr. This substitution is found in TEM-5 and TEM-24 (Chanal et al., 1992), and it 
improves binding of the enzyme to cefotaxime by facilitating the creation of a hydrogen bond 
between the Thr237 and the cefotaxime molecule (Kuzin et al., 1995). 
Besides potentially conferring an ESBL phenotype, TEM enzymes can also present 
reduced affinity to β-lactamase inhibitors, conferring an inhibitor resistant TEM (IRT) 
phenotype. These types of enzymes normally confer a phenotype of resistance to β-
lactam/β-lactamase inhibitor combinations and susceptibility to third generation 
cephalosporins. On the other hand, IRT enzymes confer less resistance to narrow-spectrum 
cephalosporins than parental enzymes. Amino acid substitutions in TEM at positions Met69, 
Ser130, Arg244, Arg275 and Asn276 are usually associated with the resistance to β-
lactamase inhibitors (Table 1.4). 
The side chain of the Met69 residue forms the back hole of the oxyanion pocket, and 
the substitution of this residue by others of different size and degree of hydrophobicity could 
deform the attractive properties of the oxyanion hole (Knox, 1995). Furthermore, the Met69Ile 
substitution may move the amide side chain of Asn170 and Glu166, displacing the water 
molecule coordinated by Asn170, Ser70 and Glu166, thus diminishing the catalytic efficiency 
(Farzaneh et al., 1996). Another study suggests that substitutions at Met69 could be 
responsible for the displacement of Ser130 or even Ser70 (Wang et al., 2002). 
Situated in the SDN loop, the Ser130 residue plays a crucial role in the structure and 
function of class A β-lactamases (Jacob et al., 1990), particularly in the inactivation process 
by β-lactamase inhibitors (Bermudes et al., 1999). By PCR mutagenesis of TEM-1, 
Ser130Gly substitution was showed to confer resistance to β-lactamase inhibitors, 
associated with a high decrease of ampicillin resistance (Vakulenko et al., 1998). 
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Table 1.4 - TEM enzymes presenting amino acid substitutions associated with IRT 
phenotype (according to website http://lahey.org/studies/temtable.asp) 
Amino Acid at position  β-Lactamase 
(Secondary 
names) 21 39 69 80 114 127 130 165 182 196 221 244 262 265 275 276 
pIa 
TEM-1 Leu Gln Met Val Thr Ile Ser Trp Met Gly Leu Arg Val Thr Arg Asn 5.4 
TEM-30 (IRT-2)            Ser     5.2 
TEM-31 (IRT-1)            Cys     5.2 
TEM-32 (IRT-3)   Ile      Thr        5.4 
TEM-33 (IRT-5)   Leu              5.4 
TEM-34 (IRT-6)   Val              5.4 
TEM-35 (IRT-4)   Leu             Asp 5.2 
TEM-36 (IRT-7)   Val             Asp 5.2 
TEM-37 (IRT-8)   Ile             Asp 5.2 
TEM-38 (IRT-9)   Val            Leu  5.2 
TEM-39 (IRT-10)   Leu     Arg        Asp 5.4 
TEM-40 (IRT-11)   Ile              5.4 
TEM-44 (IRT-13)  Lys          Ser     5.4 
TEM-45 (IRT-14)   Leu            Gln  5.2 
TEM-51 (IRT-15)            His     5.2 
TEM-54            Leu     nd 
TEM-58            Ser Ile    5.2 
TEM-59 (IRT-17)  Lys     Gly          5.6 
TEM-65 (IRT-16)  Lys          Cys     5.4 
TEM-67 Ile Lys          Cys     5.2 
TEM-73 (IRT-18) Phe           Cys  Met   5.2 
TEM-74 (IRT-19) Phe           Ser  Met   5.2 
TEM-76 (IRT-20)       Gly          nd 
TEM-77 (IRT-21)   Leu         Ser     nd 
TEM-78 (IRT-22)   Val     Arg        Asp nd 
TEM-79            Gly     nd 
TEM-80 (IRT-24)   Leu   Val          Asp 5.2 
TEM-81   Leu   Val           nd 
TEM-82   Val            Gln  nd 
TEM-83   Leu     Cys       Gln  nd 
TEM-84                Asp nd 
TEM-97   Val              nd 
TEM-99            Ser     nd 
TEM-103 (IRT-28)               Leu  5.2 
TEM-108    Glu      Ser      Ser nd 
TEM-122               Gln  5.25 
TEM-145           Met His     nd 
TEM-146     Pro       His     nd 
TEM-159 Phe  Ile      Thr        nd 
TEM-160  Lys Val              nd 
a Isoeletric point. 
nd, not determined. 
 
Another residue associated with the resistance to β-lactamase inhibitors, especially to 
clavulanic acid, is Arg244. In studies performed in inactivation by clavulanic acid, this 
conserved residue appears to be in position to induce a water molecule to provide proton for 
the formation of an acyclic intermediate (Knox, 1995). Substitutions of Arg244 by Cys or Ser 
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by site-directed mutagenesis were reported to confer resistance to inactivation by clavulanic 
acid (Imtiaz et al., 1994). Clinical isolates of E. coli, resistant to amoxicillin plus clavulanic 
acid, were also reported (Vedel et al., 1992). However, the association of double mutations 
Ser244 and Ser164 reverses the resistance to clavulanic acid (Imtiaz et al., 1994).  
 Residue Arg275 is also believed to increase resistance to β-lactamase inhibitors 
when associated with Met69Leu (Caniça et al., 1997a). In IRT-14 (Table 1.4), Arg275Gln is 
expected to destabilize the active site, due to a decrease of restriction in movements of 
Arg244, important in maintaining the integrity of the active site (Caniça et al., 1997a). This 
mutation can be found in different enzymes other than IRT-14, such as TEM-82, TEM-83 and 
TEM-122. In this last enzyme, identified in the United States, the Arg275Gln substituition was 
found alone and confers an IRT phenotype (Kaye et al., 2004). 
 Next to Arg275, the residue Asn276 has a direct effect on substrate affinities. The 
Asn276Asp amino acid substitution leads to a loss of affinity to clavulanic acid and to a 
slightly decrease of catalytic efficiencies (Saves et al., 1995). With penicillins, catalytic 
efficiencies for the mutant enzyme carrying Asn276Asp were reduced two to six fold 
compared with TEM-1, while with cephalosporins, the mutant enzyme presented higher 
catalytic efficiencies than the parental enzyme (Caniça et al., 1998). 
Besides ESBL and IRT enzymes, there are some TEM family enzymes which 
possess these two types of phenotype simultaneously. The combination of substitutions 
associated with ESBL phenotypes and substitutions related with IRT phenotypes form a 
group known as complex mutant of TEM enzymes (CMT) (Table 1.5). 
First described in France in 1997 (Sirot et al., 1997), CMT-1, also known as TEM-50, 
presented the ESBL substitutions of TEM-15 and the IRT-substitutions of IRT-4. However, 
when compared to these enzymes, CMT-1 presented lower level of resistance to ceftazidime 
and to amoxicillin plus clavulanic acid than TEM-15 and IRT-4, respectively (Sirot et al., 
1997). Other enzymes presenting amino acid substitutions of ESBL and IRT enzymes were 
also described in Poland and other regions of France (Fiett et al., 2000; Poirel et al., 2004; 
Robin et al., 2007). Overall, CMT enzymes tend to maintain the level of resistance of ESBL 
or IRT enzymes, but often it is possible to verify the decrease of resistance towards one or 
both types of phenotypes. 
 The emergence of CMT enzymes, possibly associated with the clinical use of third 
generation cephalosporins and β-lactamase inhibitors, constitutes an alarming factor in β-
lactamase evolution towards resistance to β-lactam antibiotics.  
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3.3.3. SHV β-lactamases 
SHV enzymes are classified in groups 2b and 2be of the Bush-Jacoby-Medeiros 
classification scheme and in Ambler class A, and they are constitutive of the majority of K. 
pneumoniae strains which possess chromosomal-mediated β-lactamases. Once believed to 
be ubiquitous of this species, SHV-1 (sulphydryl reagent variable) confers resistance to 
ampicillin, amoxicillin, carbenilcillin and ticarcillin (Babini & Livermore, 2000; Livermore, 
1995). First called PIT-2 (from the author’s name Pitton), this enzyme was also detected in 
other Enterobacteriaceae as a plasmid-mediated β-lactamases (Matthew, 1979; Pitton, 
1972). 
The great majority of K. pneumoniae strains possesses a chromosomal copy of either 
blaSHV-1 or blaSHV-11 or close relatives, encoding non-extended-spectrum enzymes (Chaves et 
al., 2001; Lee et al., 2006b). Plasmid-mediated blaSHV genes are possibly descendent from 
genome to plasmid mobilization events mediated by IS26 (Ford & Avison, 2004). One such 
event resulted in an IS26 insertion 2 kbp upstream of the blaSHV coding sequence, such as it 
can be seen in the plasmid-mediated SHV-5 enzyme (Gutmann et al., 1995). Another event 
resulted in IS26 insertion into the blaSHV promoter as can be identified in plasmid-mediated 
SHV-2a, SHV-11 and SHV-12 (Nüesch-Inderbinen et al., 1997; Podbielski et al., 1991b). 
Furthermore, some studies suggested that this IS26 insertion increases promoter strength 
through the introduction of a different –35 region (Podbielski et al., 1991a). Other studies 
demonstrated the importance of plasmid-mediated non-ESBL-encoding blaSHV genes as 
percussors to ESBL-encoding genes (Hammond et al., 2008; Lee et al., 2006b). 
Several studies have showed that the hyperproduction of SHV-1 enzymes associated 
or not with the impermeability mechanism of resistance, could lead to the false identification 
of ESBL production, such as the case of TEM-1 (Fu et al., 2007; Miró et al., 1998; Wu et al., 
2001). Overall, over 110 SHV β-lactamases have now been identified, according to the 
Lahey Clinic internet server (http://lahey.org/studies) (Table 1.6). In contrast to the TEM 
family, the vast majority of SHV enzymes are penicillinases and only 33 enzymes possess 
amino acid substitutions which confer an ESBL or IRS (inhibitor resistance SHV) phenotype.  
Phylogenetic studies suggest that TEM and SHV enzymes diverged from each other 
300-400 million years ago (Hall & Barlow, 2004). Furthermore, SHV probably evolved in the 
antibiotic era from an as-yet-unidentified common ancestor. These descendants include both 
penicillinases and extended-spectrum β-lactamases (Hall & Barlow, 2004). Sharing 67% of 
sequence identity with TEM enzymes, the SHV-1 substrate binding cavity is 0.7-1.2 Å larger 
than in TEM-1 (Kuzin et al., 1999; Reynolds et al., 2006). 
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SHV β-lactamases may present amino acid substitutions which can be responsible for 
increasing the levels of resistance to narrow and extended-spectrum cephalosporins and 
monobactams, as well as to β-lactamase inhibitors. Amino acid substitutions in residues 
Asp179, Gly238 and Glu240 have been found in clinical strains presenting resistance to third 
generation cephalosporins (Table 1.6). Studies based on site saturation mutagenesis for 
residue Asp104 show that, just like in TEM, this amino acid plays an important role in 
substrate binding and recognition of oxyimino-cephalosporins (Bethel et al., 2006). 
Residue Asp179, also associated to the ESBL phenotype, is located in the Ω loop of 
the SHV active site. Amino acid substitution of Asp179 by Ala (SHV-6), Asn (SHV-8) and Gly 
(SHV-24) possibly increase the movement of the Ω loop, expanding the binding site and 
destabilizing the Glu166 (Knox, 1995). This substitution conferred high-level resistance to 
ceftazidime but not to cefotaxime in enzymes isolated in France (SHV-6), Japan (SHV-24) 
and United States (SHV-8) (Arlet et al., 1997; Kurokawa et al., 2000; Rasheed et al., 1997). 
In contrast to the TEM enzymes, SHV β-lactamase substitutions of the residue 
Gly238 are of greater importance in conferring high-level resistance against extended-
spectrum cephalosporins. As mentioned above, the Gly238Ser pushes the β-strand out and 
away from the reactive Ser70, which expands the active site even more when compared to 
TEM, and permits greater substrate versatility against penicillins and cephalosporins (Hujer 
et al., 2001). Other site-directed mutagenesis studies corroborate these findings (Huletsky et 
al., 1993; Hujer et al., 2002). 
Enzymes such as SHV-2, SHV-2A and SHV-3, among others, confer higher level of 
resistance to cefotaxime than to ceftazidime (Barthélemy et al., 1988; Nicolas et al., 1989; 
Podbielski et al., 1991b). Once again, just like in TEM enzymes, the amino acid substitution 
of residue Glu240 increases the hydrolysing activity against ceftazidime. Resistance to this 
antibiotic is increased in enzymes such as SHV-5 and SHV-12, which possess at least both 
Gly238Ser and Glu240Lys substitutions (Gutmann et al., 1995; Nüesch-Inderbinen et al., 
1997). Other residues, like Thr182 that occurs naturally in SHV enzymes may stabilize the 
overall structure of the proteins (Huang & Palzkill, 1997; Wang et al., 2002). 
Contrary to what happens in TEM β-lactamases, there are few SHV that present 
resistance to β-lactamase inhibitors. Until now, only four enzymes were detected in Europe 
and Taiwan which present mutations that can confer loss of susceptibility to these antibiotics. 
Amino acid substitutions of residues Met69 and Ser130 confer an increase of resistance 
against clavulanic acid associated with the loss of affinity to penicillins and narrow-spectrum 
cephalosporins, just like in TEM enzymes (Dubois et al., 2004; Prinarakis et al.; 1997). While 
Met69 has been detected in SHV-49 and SHV-92 (Table 1.7), Ser130 was detected in SHV-
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10 and was associated with the high decrease of activity against extended-spectrum β-
lactamases (Prinarakis et al.; 1997). 
 A different amino acid substitution, Ala187Thr, was also associated with low level 
resistance to β-lactamase inhibitors in SHV-26 (Chang et al., 2001). However, the Ala187 
residue is located relatively far from the active site and the authors do not explain the 
molecular mechanism implied in it. Other SHV mutants were constructed in vitro by site-
saturation mutagenesis based in the observations of the effect of specific amino acid 
substitutions in positions 166, 244 and 276 of naturaly occuring TEM enzymes (Padayatti et 
al., 2005; Randegger & Hächler, 2001a; Thomson et al., 2006). In an attemp to construct 
complex mutant SHV enzymes, with amino acid substitutions involved in ESBL and IRS 
phenotypes, it was concluded that SHV enzymes do no benefit proportionally from the 
simultaneous presence of amino acid substitutions in residues associated with these 
phenotypes (Randegger & Hächler, 2001a). 
 
Table 1.7 - SHV enzymes presenting amino acid substitutions associated with IRS 
phenotype (according to website http://lahey.org/studies) 
Amino acid at position β-Lactamase 
35 54 69 112 130 140 141 187 192 193 238 240 
pIa 
SHV-1 Leu Gly Met His Ser Ala Thr Ala Lys Leu Gly Glu 7.6 
SHV-10  Del   Gly Arg   Asn Vel Ser Lys 8.2 
SHV-26        Thr     7.6 
SHV-49   Ile          nd 
SHV-92 Gln   Ile       Ile           nd 
a Isoeletric point. 
nd, not determined. 
 
 According to the identification of amino acid substitutions that confer resistance to 
extended-spectrum cephalosporins and/or to β-lactamase inhibitors, more than 53 SHV β-
lactamases are penicillinases, while TEM family present no more than 20 enzymes of this 
type. Nevertheless, the lesser number of ESBL-encoding SHV enzymes is distributed 
worldwide, such as the case of TEM enzymes. Enzymes like SHV-2, SHV-2A, SHV-5 and 
SHV-12 have been detected in strains of Enterobacteriaceae, Pseudomonadaceae and 
Moraxellaceae isolated in hospitals, in the community, animals and food samples from 
Europe, Africa, Asia and Oceania (Chiaretto et al., 2008; Damjanova et al., 2007; Jouini et 
al., 2007; Paterson & Bonomo, 2005). 
 
3.3.4. LEN and OKP β-lactamases 
Instead of SHV enzymes, K. pneumoniae strains can express two other types of 
enzymes, whose encoding genes may be located in the chromosome. These two other β-
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lactamases are LEN (from K. pneumoniae strain LEN-1) enzymes and OKP (other K. 
pneumoniae β-lactamase) enzymes (Arakawa et al., 1986; Hæggman et al., 2004), both also 
conferring resistance to ampicillin.  
According to phylogenetic studies performed with gyrA, K. pneumoniae strains can be 
distributed in three clusters: groups KpI, KpII and KpIII, which express SHV, OKP and LEN 
enzymes, respectively (Brisse & Verhoef, 2001; Hæggman et al., 2004). Studies performed 
in K. pneumoniae strains identified more than 80% of strains as belonging to group KpI, while 
groups KpII and KpIII were equally represented with 10% each (Brisse & Verhoef, 2001; Fu 
et al., 2007). Hæggman et al. (2004) estimated the time of divergence of the phylogenetic 
groups KpI and KpIII as occurring between 6 and 28 million years ago.  
The OKP family, found in group KpII, is more heterogeneous than the SHV and LEN 
families, presenting 88-89% similarity to SHV-1 and LEN-1. More recently, the K. 
pneumoniae phylogenetic group KpII was sub-divided into two subgroups, KpII-A and KpII-B, 
each one expressing an OKP type enzyme (Fèvre et al., 2005). With 95% of similarity 
between them, OKP-A and OKP-B are expressed by strains belonging to subgroups KpII-A 
and KpII-B, respectively. 
All of these β-lactamases are usually produced at low levels, conferring resistance to 
ampicillin, amoxicillin, carbenicillin and ticarcillin, with MIC values of 32 to 256 µg/mL for 
enzyme producers. However, strains of K. pneumoniae which do not possess a constitutive 
enzyme, were reported with MICs values of 2 µg/mL to ampicillin and to ticarcillin, which 
constitute extremely rare phenotypes (Livermore, 1995). Overall, LEN and OKP enzymes 
have been detected in America, Europe and Japan, but only in sporadic cases (Hæggman et 
al., 2004; Fèvre et al., 2005; Arakawa et al., 1986; Melano et al., 2006). 
 
3.3.5. KLUA, KLUC and KLUG β-lactamases 
The enterobacterial Kluyvera genus is composed of four species, Kluyvera ascorbata, 
Kluyvera cryocrescens, Kluyvera georgiana, and Kluyvera cochleae and presents a 
chromosomally encoded class A β-lactamase in at least three of them (Decousser et al., 
2001; Farmer, 1999; Humeniuk et al., 2002, Poirel et al., 2002c). Although phylogenetically 
related, Kluyvera species produce different β-lactamases sharing similar substrate profiles. 
The KLUA-1 β-lactamase confers low level resistance to penicillins, cephalothin and 
cefuroxime, and is inhibited by clavulanic acid, while KLUC-1, in the natural strain, confers 
resistance to amoxicillin and ticarcillin and reduced susceptibility to cephalothin and 
cefuroxime (Decousser et al., 2001; Humeniuk et al., 2002). Once cloned, this enzyme 
conferred resistance or reduced susceptibility to cefotaxime, ceftriaxone, cefpirome and 
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aztreonam. A K. georgiana strain producing KLUG-1 presented intermediate susceptibility to 
amoxicillin, ticarcillin and cephalothin and, once cloned, KLUG-1 also conferred resistance or 
reduced susceptibility to piperacillin, cefotaxime, ceftriaxone, cefepime, cefpirome and 
aztreonam, which is the same profile as that which is observed for plasmid-mediated CTX-M-
8 (Bonnet et al., 2000b; Poirel et al., 2002c). 
Chromosomal encoded β-lactamases from Kluyvera spp. seem to be closely related 
with rapidly expanding plasmid-mediated CTX-M (active on cefotaxime, first isolated at 
Munich) enzymes (Bauernfeind et al., 1990). Overall, KLUC-1 shares only 86% similarity with 
CTX-M-1, while KLUA-1 and KLUG-1 shares 99% similarity with CTX-M-2 and CTX-M-8, 
respectively. Considered as probable progenitors of specific sub-groups of CTX-M enzymes, 
Klyuvera β-lactamase encoding genes present upstream and downstream regions with high 
similarity with genes encoding for CTX-M enzymes (Decousser et al., 2001; Humeniuk et al., 
2002, Poirel et al., 2002c). Mobilization elements such as ISEcp1 and IS10-like have been 
identified upstream of blaCTX-M and of blaKLU-type genes, increasing the relationship between the 
two families (Bonnet et al., 2000b; Karim et al., 2001). 
 
3.3.6. CTX-M β-lactamases 
Enzymes of the CTX-M family have become, in the past decade, the most prevalent 
ESBL, both in nosocomial and community settings (Cantón & Coque, 2006). Initially reported 
in the second half of the 1980s, their rate of dissemination among bacteria and in most parts 
of the world has increased dramatically since 1995. First detected in Japan in 1986 and later 
designated as CTX-M-1 in 1989 in Germany, the rapidly growing CTX-M family of β-
lactamases now consists of more than 80 members (Bauernfeind et al., 1990; Matsumoto et 
al., 1988). 
 CTX-M β-lactamases divide into five major groups based on sequence homology: the 
CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-25 groups 
(http://www.lahey.org/studies/webt.stm) (Table 1.8). Members of each group share more 
than 94% identity, and members of different groups less than 90% (Bonnet, 2004). According 
to phylogenetic studies, the CTX-M-1 group includes widely disseminated enzymes like CTX-
M-1, CTX-M-3 and CTX-M-15, while the CTX-M-2 group includes less disseminated 
enzymes like CTX-M-2, CTX-M-4 and CTX-M-6. The also highly disseminated CTX-M-9 
group consists of enzymes like CTX-M-9 and CTX-M-14 (Cantón & Coque, 2006).  
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Table 1.8 - Different CTX-M clusters and origin of blaCTX-M (adapted from Cantón & Coque, 
2006) 
CTX-M Group Year (enzyme, country)a Enzymes Origin 
CTX-M-1 1989 (CTX-M-1, Germany) CTX-M-1, -3, -10, -11, -12, -15, -22, 
-23 -29, -30, -32, -33, -28, -36, -54, 
UOE-1 
K. ascorbata 
CTX-M-2 1986 (FEC-1, Japan) CTX-M-2, -4, -6, -7, -20, -31, -44 
(previously TOHO-1), FEC-1 
K. ascorbata 
CTX-M-8 1996 (CTX-M-8, Brazil) CTX-M-8, -40 K. georgiana 
CTX-M-9 1994 (CTX-M-9, Spain) CTX-M-9, -13, -14, -16, -17, -18, -19, 
-24, -27, -45 (previously TOHO-2), 
-46; -47, -48, -49, -50 
K. georgiana 
CTX-M-25 2000 (CTX-M-25, Canada) CTX-M, -26, -25, -39, -41 ND 
a Year of first isolation or description (first enzyme described and country of isolation); CTX-M-14 and CTX-M-18 are identical. 
ND, not defined. 
 
Enzymes from the CTX-M-1 and CTX-M-2 groups may have evolved from the 
Kluyvera ascorbata chromosomal genes blaKLUA, while other studies suggest that enzymes 
from the CTX-M-8 and CTX-M-9 groups derived from the Kluyvera georgiana chromosomal 
gene, blaKLUG (Olson et al., 2005; Rodriguez et al., 2004). Futhermore, several studies prove 
that the neighbouring sequences of the blaCTX-M-2, blaCTX-M-9, and blaCTX-M-10 genes exhibit high 
nucleotide identity with those surrounding Kluyvera chromosomal β-lactamase genes (Oliver 
et al., 2001; Olson et al., 2005; Power et al., 2005). 
 Plasmids encoding CTX-M enzymes are often highly transmissible, a property that 
can explain the easy dissemination of blaCTX-M-harbouring plasmids (Baraniak et al., 2002b). 
However, in the case of non-self-transmissible plasmids harbouring blaCTX-M genes, transfer 
can still occur by transformation or by the influence of coexisting conjugative plasmids (Cao 
et al., 2002; Tassios et al., 1999). High identities between the regions surrounding K. 
georgiana chromosomal blaKLUG genes or the  K. ascorbata chromossonal blaKLUA gene and 
the regions surrounding the plasmid-mediated blaCTX-M-8 gene or genes belonging to CTX-M-2 
group suggest the mobilization of this type of β-lactamase-encoding gene from the 
chromosome to plasmids (Humeniuk et al., 2002; Poirel et al., 2002c). This process could 
explain the later expansion of CTX-M enzymes, in opposition to TEM and SHV ESBLs, which 
derived from widespread plasmid-mediated enzymes. 
 Among the elements that are involved in the mobilization of blaCTX-M genes, insertion 
sequences (IS, e.g., ISEcp1 or ISEcp1-like) have repeatedly been observed upstream of 
ORFs encoding the several blaCTX-M genes (Perez et al., 2007). Some studies have 
suggested that the ISEcp1 element not only confers mobility to blaCTX-M genes, but also 
probably provides the promoter for expression of these genes (Cao et al., 2002; Karim et al., 
2001; Poirel et al., 2005). A specific sequence located downstream of Orf513 has been 
proposed to be a recognition site for the Orf513 putative recombinase. A 17-bp fragment of 
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this sequence has been identified downstream of certain ISEcp1 sequences (Saladin et al., 
2002), suggesting a complex mobilization process involving the Orf513 putative recombinase 
and the ISEcp1 insertion sequence. 
Other CTX-M-encoding genes have been observed in class 1 integrons, like blaCTX-M-2 
(Arduino et al., 2002). This gene is located in a complex sul1-type integron, termed In35 
which includes Orf513. It is suggested that the blaCTX-M-2 gene, which shares high homology 
with the chromosomal blaKLUA-1 gene, was possibly acquired by a plasmid through an 
uncharacterised recombinational event in which Orf513, the so-called CR (common region) 
element, could be involved (Arduino et al., 2002; Partridge & Hall, 2003). This new type of 
genetic element was recently identified as being closely associated with the spread of many 
antibiotic resistance genes (Toleman et al., 2006). ISCR elements can be divided into two 
groups: ISCRs1 are those that form complex class 1 integrons and ISCRs-2 to -13 are those 
associated with non-class 1 integrons (Bebrone, 2007). Furthermore, a study based on 
multiple clinical isolates, identified the ISCR1 next to blaCTX-M-2 in all blaCTX-M-2-containing 
Gram-negative isolates (Arduino et al., 2003). The authors suggested that this IS element is 
strongly associated with the emergence and dissemination of the blaCTX-M-2 gene in South 
America. In Europe, blaCTX-M-9 is most commonly associated with ISCR1 elements as part of a 
complex class 1 integron, In60 (Toleman et al., 2006).  
Mobile elements, such as IS10 and IS26, have been observed upstream of blaCTX-M-8 
(Bonnet et al., 2000b) and blaCTX-M-1, respectively, while an IS903-like element was observed 
downstream of the blaCTX-M-14 and blaCTX-M-17 genes (Cao et al., 2002; Pai et al., 2001; Saladin 
et al., 2002). 
It is possible to detect isolates producing CTX-M enzymes all over the world, 
particulary CTX-M-15, CTX-M-14, CTX-M-3, CTX-M-2, CTX-M-9, among others (Figure 1.4). 
Although some countries present only sporadic reports of CTX-M producing isolates, other 
regions face endemic situations. CTX-M-2 was detected in Brazil and Argentina, among 
others CTX-M-type enzymes (Bonnet, 2004). Among community isolates from Bolivia and 
Peru, E. coli harbouring CTX-M-15 and CTX-M-9 were predominant (Pallecchi et al., 2007). 
In the Far East, surveys conducted in Japan showed that CTX-M-2 and CTX-M-3 were 
predominant, while in China, CTX-M-3, CTX-M-13 and CTX-M-14 enzymes were already the 
most frequent ESBL in 1997 and 1998 (Chanawong et al., 2002; Yagi et al., 2000; Yamasaki 
et al., 2003). In India, the most successful and widespread CTX-M-15 was detected in a two 
month period of the year 2000 and already in three different species of the 
Enterobacteriaceae family (E. coli, K. pneumoniae and Enterobacter aerogenes) (Karim et 
al., 2001). 
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Figure 1.4 - Dominant and frequent CTX-M β-lactamase types in different global regions 
(adapted from Cantón & Coque, 2006). 
 
 In the United Kingdom, France, Spain and Italy, surveillance studies detected an 
increasing frequency of production of CTX-M-15 among clonally related E. coli strains 
(Brigante et al., 2005; Lavigne et al., 2007; Livermore & Hawkey, 2005; Mugnaiol et al., 
2006). Nevertheless, CTX-M-2, CTX-M-3, CTX-M-9 and CTX-M-14, among others, were also 
detected in Europe, but in a lesser frequency (Figure 1.5). 
CTX-M enzymes can be detected both in community and hospital environments. 
Although initial observation of infections caused by bacteria harbouring CTX-M enzymes was 
in hospitals, they rapidly spread to the community. Nursing homes may serve as reservoirs 
from which colonized and infected patients transfer these ESBL-producing strains to the 
community or back to the hospitals (Pitout et al., 2005; Wiener et al., 1999). Some of the 
identified risk factors for infection with bacteria producing CTX-M are recent hospitalisation, 
age, and exposure to cephalosporins and/or quinolones (Perez et al., 2007). The detection of 
CTX-M-producing bacteria in food-producing animals could indentify them as potential 
reservoirs of resistant bacteria that intersect with the community (Duan et al., 2006; Meunier 
et al., 2006). 
 CTX-M enzymes usually confer high-level resistance to aminopenicillins, 
carboxypenicillins, ureidopenicillins and narrow-spectrum cephalosporins, while retaining 
susceptibility to cefoxitin and carbapenems. Kinetic studies show that CTX-M enzymes are 
less effective against penicillins than TEM and SHV penicillinases, as for most class A 
ESBLs (Bonnet, 2004). 
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Figure 1.5 - Dominant and frequent CTX-M β-lactamase types in different European 
countries (adapted from Livermore et al., 2007). 
 
The enzymes of the CTX-M family are more active against cefotaxime and 
ceftriaxone than against ceftazidime. In contrast with TEM and SHV cefotaximases (e.g. 
TEM-3, TEM-4, SHV-2, and SHV-3), CTX-M enzymes present weaker enzymatic efficiencies. 
However, some point mutations can increase activity against ceftazidime. For example, CTX-
M-15 and CTX-M-32 differ from CTX-M-3 and CTX-M-1, respectively, by an Asp240Gly 
substitution. Nevertheless, they present 100-fold more activity against ceftazidime than CTX-
M-3 and CTX-M-1 (Cartelle et al., 2004; Poirel et al., 2002b). CTX-M-27 and CTX-M-16, 
differing from CTX-M-9 and CTX-M-14, respectively, by means of the same mutation, also 
present higher catalytic efficiencies against ceftazidime (Bonnet et al., 2001; Bonnet et al., 
2003). Another substitution responsible for higher levels of resistance to ceftazidime, as 
compared to cefotaxime, is the Pro167Ser mutation, which differentiates CTX-M-19 from 
CTX-M-14 (Poirel et al., 2001b). The same mutation has been observed in other β-
lactamases, such as PSE-4 (Psedomonas-specific enzyme), with similar results (Therrien et 
al., 1998). Overall, CTX-M enzymes show a great degree of susceptibility to β-lactamase 
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inhibitors, although a low level of resistance to the combination of clavulanic acid with 
amoxicillin and ticarcillin could be observed (Bonnet, 2004). 
 
3.3.7. OXA β-lactamases 
 Classified in group 2d, OXA (active on oxacillin) enzymes are class D β-lactamases 
capable of hydrolysing isoxazolilpenicillins, such as oxacillin, and other penicillins (Bush et 
al., 1995). Currently, over than 127 different variants of OXA enzymes have been identified 
on the protein level (http://lahey.org/studies). 
Overall, there is a generally weak sequence identity between the various OXA-family 
members and even weaker homologies between them and Class A and C enzymes. 
However, all three classes share the same topological fold and hydrolyze substrates by a 
similar serine nucleophile-mediated acylation/deacylation mechanism (Massova & 
Mobashery, 1998). OXA-1, the most common type in enterobacteria (Liu et al., 1992), 
generally confers low level resistance to penicillins but not to broad-spectrum β-lactams, and 
some producers of this enzyme are resistant to clavulanic acid, but not to piperacillin-
tazobactam combination (Wu et al., 1992). Although the blaOXA-1 gene shows more than 50% 
divergence when compared with blaOXA-2, there is a functional similarity at the peptide level 
(Ouellette et al., 1987). When comparing OXA-2 with OXA-3, it is possible to detect 95% 
homology between them, which confers similar proprieties (Sanschagrin et al., 1995). Similar 
phenotypes are produced by OXA-1 and OXA-4, the latter differing from OXA-1 in two 
aminoacids (Asp48Val and Asp207Glu) (Philippon et al., 1986). 
 Most OXA-type β-lactamases are not regarded as ESBLs, because they do not 
hydrolyse the extended-spectrum cephalosporins. However, OXA-10, first called PSE-2 in 
Pseudomonas aeruginosa (Huovinen et al., 1988), can weakly hydrolyse cefotaxime, 
ceftriaxone and aztreonam (Hall et al., 1993). Other OXA ESBL enzymes that confer 
resistance to cefotaxime, and sometimes to ceftazidime and aztreonam, are already 
identified, as OXA-11, OXA-14 to OXA-19, OXA-28, OXA-31, OXA-32, OXA-45 (Aubert et 
al., 2001; Danel et al., 1995; Danel et al., 1997; Danel et al., 1998; Danel et al., 1999; Hall et 
al., 1993; Mugnier et al., 1998; Philippon et al., 1997; Poirel et al., 2001a; Poirel et al., 2002a; 
Toleman et al., 2003). Mostly detected in Europe, there are very few epidemiological data on 
the geographical spread of OXA-type ESBLs. An aminoacid substitution at position 167 
(Gly167Asp) increases resistance to ceftazidime, as detected for OXA-11, OXA-14, OXA-16 
and OXA-19 (Hall et al., 1993; Danel et al., 1995; Danel et al., 1998; Mugnier, 1998) (Table 
1.9). Another aminoacid substitution associated with the increase of resistance to ceftazidime 
was detected in position 164 (Trp164Gly) at OXA-28 (Poirel et al., 2001a). 
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Table 1.9 - Extended-Spectrum β-Lactamases closely related with 
OXA-10 (according to http://lahey.org/studies) 
Amino acid at position 
β-lactamase 10 20 58 76 110 127 144 164 167 184 240 258 272 pI
a 
OXA-10  Ile Gly Asp Asn Thr Ala Tyr Trp Gly Tyr Glu Ser Glu 6.1 
OXA-11         Ser  Asp     6.4 
OXA-14           Asp     6.2 
OXA-16        Thr   Asp     6.2 
OXA-17      Ser          6.1 
OXA-19 Thr Ser Asn  Ser    Asp Phe Gly Asn Ala 7.5 
OXA-28 Thr Ser Asn  Ser   Gly  Phe Gly Asn Ala 8.1 
a Isoelectric point. 
 
OXA-15, which is derived from OXA-2, presents an aminoacid substitution also 
capable of conferring resistance to ceftazidime (Asp149Gly) (Danel et al., 1997) (Table 1.10). 
OXA-32, also derived from OXA-2, presents a Leu169Ile substitution capable of conferring 
resistance to ceftazidime, but not to cefotaxime (Poirel et al., 2002a). 
OXA-31 is related to OXA-1, also called OXA-30, and to its derivative OXA-4 (Boyd & 
Mulvey, 2006; Siu et al., 2000); OXA-31 differs from them in four and three aminoacid 
substitutions, respectively (Ouellette et al., 1987; Sanshagrin et al., 1995). All of these three 
enzymes confer similar phenotypes, as resistance to cefepime and susceptibility to 
ceftazidime. They may selectively hydrolyze some 2-amino-5-thiazolyl cephalosporins 
(cefpirome, cefepime, and cefclidin) but not others (ceftazidime, cefotaxime), these drugs 
mostly differing by substitutions at the C-3 of the cephem core (Aubert et al., 2001). 
 
Table 1.10 - Extended-Spectrum β-Lactamases closely 
related with OXA-2 (according to http://lahey.org/studies) 
Amino acid at position 
β-lactamase 149 169 pI
a 
OXA-2  Asp Leu 7.7 
OXA-15 Gly  8.0 
OXA-32  Ile 7.7 
a Isoelectric point. 
 
OXA-18 and OXA-45 are members of the novel subgroup 2d’, related to other group 
2d β-lactamases, but with extended-spectrum hydrolytic properties and full inhibition by 
clavulanic acid (Philippon et al., 1997; Toleman et al., 2003). 
From the 127 enzymes identified, at least 45 exhibit carbapenem-hydrolysing activity, 
and they can be subclassified into eight subgroups (Walther-Rasmussen & Høiby, 2006) 
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(Table 1.11). The majority of carbapenem-hydrolysing OXA enzymes are detected in the 
Acinetobacter baumannii chromosome (Table 1.11). 
 
Table 1.11 - Compilation of the OXA-type carbapenemase-producing bacteria and 
geographicaly distribution (adapted from Walther-Rasmussen & Høiby, 2006) 
Subgroup Enzyme Genetic 
locationa 
Host Country 
I OXA-23 C/(C)/P Mainly Acinetobacter 
baumannii 
Countries from 
different regions 
 OXA-27 (C) A. baumannii Singapore 
 OXA-49  A. baumannii China 
II OXA-24 (C) A. baumannii Spain 
 OXA-25 (C) A. baumannii Spain 
 OXA-26 (C) A. baumannii Belgium 
 OXA-40 (C) A. baumannii France 
 OXA-72  A. baumannii Thailand 
III OXA-51 C A. baumannii Argentina 
 OXA-64 C A. baumannii Rep. of South Africa 
 OXA-65 C A. baumannii Argentina 
 OXA-66 C A. baumannii Spain 
 OXA-68 C A. baumannii Spain 
 OXA-69 C A. baumannii Turkey 
 OXA-70 C A. baumannii Hong Kong 
 OXA-71 C A. baumannii Rep. of South Africa 
 OXA-75 C A. baumannii France 
 OXA-76 C A. baumannii France 
 OXA-77 C A. baumannii na 
 OXA-78 (C) A. baumannii Turkey? 
IV OXA-58 C A. baumannii France 
V OXA-55 C Shewanella algae France 
 OXA-SHE C S. algae na 
VI OXA-48 P K. pneumoniae Turkey 
 OXA-54 C Shewanella oneidensis na 
VII OXA-50 C P. aeruginosas Countries from 
different regions 
VIII OXA-60 C Raistonia pickettii France 
a C, chromosome; ©, probably a chromosome; P, plasmid. 
na, not available. 
 
The sequence identities between members of each subgroup are more than 92.5%, 
while it ranges from 40 to 70% between enzymes from different subgroups. OXA-type 
carbapenemases present a diverse substrate range, but generally these enzymes hydrolyse 
penicillins and narrow-spectrum cephalosporins efficiently, while extended-spectrum 
cephalosporins are only very poorly hydrolysed, if at all (Walther-Rasmussen & Høiby, 2006). 
While in the late 1990s, carbapenems were the only remaining useful agent against severe 
Acinetobacter infections, natural selection or insertion into the chromosome by 
recombination, co-integration or transposition of the carbapenems resistance genes, has 
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now transformed this genus into one of the major producers of class D enzymes (Livermore 
& Woodford, 2006; Walther-Rasmussen & Høiby, 2006). 
A study conducted in 2002 (Barlow & Hall, 2002) concluded that the class D OXA 
enzymes were limited to Gram-negative bacteria, but some homologes of the OXA genes 
were found in the chromosome of Gram-positive bacteria, suggesting a horizontal transfer 
into these type of bacteria occurring between 575 and 520 million years ago. Additional 
horizontal transfer events within the Gram-negative bacteria were also apparent. The 
phylogeny shows that the OXA genes have been mobilized to plasmids about 116 ± 25 
million years ago and again 42 ± 9 million years ago, with a third mobilization occurring too 
recently to estimate accurately (Barlow & Hall, 2002). This is an indication that mobilization to 
plasmids and horizontal transfer is a phenomenon that predates the use of antibiotics (Hall & 
Barlow, 2004). 
Regarding OXA-type carbapenemases, a possible origin for these enzymes can be 
found on the soil. Imipenem is a derivative of thienamycin, which is a natural product of the 
soil organism Streptomyces cattleya (Kahan et al., 1979). Thus, possession of carbapenem-
hydrolysing enzymes would be beneficial for other soil bacteria. Other organisms may have 
developed enzymes with carbapenemase activity or acquired carbapenemase-encoding 
genes by means of conjugative plasmids (Walther-Rasmussen & Høiby, 2006). 
 
3.3.8. Metallo-β-lactamases 
Class B β-lactamases, or metallo-β-lactamases, required one or two zinc ions for their 
activity. This type of enzymes can degrade all classes of β-lactams except monobactams, but 
they are of particular interest because of their high capacity to hydrolyse carbapenems. 
Metallo-β-lactamases, like all β-lactamases, can be divided into those that are normally 
chromosomally mediated and those that are encoded by transferable genes (Walsh et al., 
2005) (Table 1.12).  
 Class B β-lactamases can be subdivided into three subclasses, B1 to B3, according 
to sequence alignments (Garau et al., 2004). Subclass B1 β-lactamases share more than 
23% identity, while members of subclass B2 present 11% identity with subclass B1 
members. Subclasses B1 and B3 hydrolyze most β-lactam antibiotics including 
carbapenems. Aztreonam is not hydrolysed by these enzymes, which are not inhibited by β-
lactamase inhibitors. Enzymes belonging to subclass B2 efficiently hydrolyze only 
carbapenems (Bebrone, 2007). Phylogenetic studies suggest that B1 and B2 descend from a 
common ancestor and subclass B3 shares only structural similarities with these subclasses 
(Garau et al., 2005). 
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Table 1.12 - Metallo-β-lactamases divided into three subclasses and classified by year of 
discovery. Not all variants are included in this table (adapted from Bebrone, 2007) 
Subclass Enzyme Strain  Year of 
Discovery 
Structure 
B1 BcII  Bacillus cereus 1966 Mono-zinc, Di-zinc Apo-
form 
 Bce 170 Alkalophilic 
Bacillus spp. 
1985  
 CcrA Bacillus fragilis 1990 Di-zinc 
 BlaB Elizabethkingia meningoseptica 1998 Di-zinc 
 IND-1 Chryseobacterium indologenes 1999  
 CGB-1 Chryseobacterium gleum 2002  
 EBR-1 Elizabethkingia brevis 2002  
 MUS-1 Myroides odoratimimus 2002  
 TUS-1 Myroides odoratus 2002  
 Bla2 Bacillus anthracis 2003  
 JOHN-1 Flavobacterium johnsoniae 2003  
 SFB-1 Shewanella frigidimarina 2005  
 SLB-1 Shewanella livingstonensis 2005  
Acquired B1 IMP-1 Serratia marcescens, 
P. aeruginosa 
1994 Di-zinc 
 VIM-1 P. aeruginosa, 
A. baumannii 
1999  
 VIM-2 P. aeruginosa, 
A. baumannii 
2000 Mono-zinc 1KO2, Di-
zinc 1KO3 
 IMP-2 A. baumannii, 
S. marcescens 
2000  
 SPM-1 P. aeruginosa 2002 Mono-zinc 
 VIM-4 P. aeruginosa, 
K. pneumoniae, 
E. cloacae 
2003  
 GIM-1 P. aeruginosa 2004  
 SIM-1 A. baumannii 2005  
B2 CphA Aeromonas hydrophila 1991 Mono-zinc 
 ImiS A. veronii 1996  
 Sfh-1 S. fonticola 2003  
B3 L1 Stenotrophomonas maltophilia 1991 Di-zinc, Mono-zinc 
2H6A, Apo-form 2FU6  
 GOB-1 E. meningoseptica 2000  
 FEZ-1 Legionella gormanii 2000 Di-zinc 
 THIN-B Janthinobacterium lividum 2001  
 Mbl1b Chryseobacterium crescentus 2001  
 CAU-1 Caulobacter vibrioides 2002  
 BJP-1 Bacillus japonicum 2006 Di-zinc 2GMN 
1 – Metallo-b-lactamases 
 
 Among the transferable B1 metallo-β-lactamases, IMP- (active on Imipenem) and 
VIM-types (Verona integron-encoded metallo-β-lactamase) occur most frequently and the 
majority of genes encoding IMP- and VIM-type, as well as GIM-1(German imipenemase), are 
found as gene cassettes in class 1 or class 3 integrons (Walsh et al., 2005). Another metallo-
β-lactamase gene, blaSPM-1 is associated with the ISCR variant, ISCR4 (Bebrone, 2007). 
These enzymes have now spread worldwide (Figure 1.6). 
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 IMP-1 was discovered in 1998 in Japan and constitutes, the most common metallo-β-
lactamase in this country, having been discovered in several types of Gram-negative bacteria 
(Walsh et al., 2005). 
Overall, more than 18 IMP-type enzymes have now been described, mostly in Japan, 
China and Taiwan, among other countries. The increasing use of carbapenems in these 
countries may have led to the emergence of IMP metallo-β-lactamases (Helfand & Bonomo, 
2003). 
 Among the VIM enzymes, the second most dominant group of transferable metallo-β-
lactamases, the great majority of variants have been detected in Europe. First discovered in 
France in 2000, VIM-2 is currently the most widespread transferable metallo-β-lactamase 
(Poirel et al., 2000) (Figure 1.6). 
 
Figure 1.6 - Current spread of acquired metallo-β-lactamases (adapted from Bebrone, 2007). 
 
 A panoply of structurally different coumponds has been tested in vitro for their 
potential inhibition of metallo-β-lactamases. However, there are obstacles to the use of 
carbapenems combined with β-lactamase inhibitors: (1) metallo-β-lactamases present slight 
but important variations in their active site that difficult the design of a unique inhibitor; (2) 
contrasting with clavulanic acid, metallo-β-lactamases do not form stable intermediates; (3) 
there is a lack of studies about strains containing metallo-β-lactamase genes, in order to 
understand if the presence of an inhibitor has a decreased effect in MIC values; (4) metallo-
β-lactamases have active site motifs similar to those for mammalian enzymes (e. g. human 
glyoxalase II), thus the use of inhibitors could represent a high level of toxicity to the patient 
(Walsh et al., 2005). 
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3.3.9. Other β-lactamases 
There are other unusual enzymes that also confer an ESBL phenotype and have been 
identified individually worldwide (e.g. BES-1, VEB-1, PER, SFO-1, GES, TLA-1) (Table 1.13). 
Enzymes like PER-1, PER-2, VEB-1, CME-1 and TLA-1 are related to each other, but 
present only 40 to 50% of homology and all of them confer resistance to oxyimino-
cephalosporins (Bradford, 2001). 
ESBL enzymes like PER-type share about 25 to 27% homology with TEM- and SHV-
type enzymes (Paterson & Bonomo, 2005). First detected in P. aeruginosas in 1991, PER-1 
efficiently hydrolyzes penicillins and cephalosporins and is susceptible to β-lactamase 
inhibitors. PER-2, which shares 86% homology with PER-1, has been found in Argentina in 
1996. While PER-1 is reported mostly in Turkey and Korea, reports of PER-2 are so far 
restricted to South America (Naas et al., 2008). 
Another rare ESBL enzyme, the plamid-mediated VEB-1, which shares 38% homology 
with PER-1 and PER-2, confers high-level resistance to third generation cephalosporins and 
aztreonam, but is susceptible to clavulanic acid. VEB-1 β-lactamase was first reported in 
1996 in an E. coli isolate from a Vietnamese patient. Other VEB enzymes have been 
identified in Kuwait and China (Paterson & Bonomo, 2005). 
 
Table 1.13 - Plasmid-encoded extended-spectrum β-lactamases not belonging 
to the TEM, SHV, CTX-M and OXA families (adapted from Naas et al., 2008) 
β-Lactamase 
name 
Yeara No. of 
variants 
Origin of the name 
‘Minor ESBL’    
SFO-1 1988 1 Serratia fonticola 
TLA-1 1991 1 Tlahuicas (Indian tribe) 
PER 1991 3 Pseudomonas extended resistance 
VEB 1996 5 Vietnam ESBLs 
BES-1 1996 1 Brazilian ESBLs 
GES 1998 9 Guyana ESBLs 
BEL-1 2005 1 Belgium ESBLs 
TLA-2 2005 1 51% amino-acid identity with TLA-1 
a Year first recorded. 
 
Enzymes of the GES type, also called IBC (integron-borne cephalosporinase), have 
been reported in widely separated countries (Poirel et al., 2006). First described in France, 
GES-1 presents activity against penicillins and extended-spectrum cephalosporins, but is 
inhibited by β-lactamase inhibitors. This enzyme does not hydrolyse aztreonam, 
cephamycins and carbapenems. The GES-2 variant also hydrolyzes carbapenems and is 
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less inhibited by clavulanic acid, just like GES-4, GES-5 and GES-6. Several outbreaks of 
bacteria producing GES-enzymes have been reported in Korea, Greece, The Netherlands 
and South Africa (Naas et al., 2008). 
Others ESBL, like SFO, TLA, BES and BEL, are unique enzymes. SFO-1 was detected 
in 1988 in Japan and efficiently hydrolyses cefotaxime, but not ceftazidime, and is inhibited 
by clavulanic acid. The plasmid-mediated BES-1 enzyme was detected in 1996 in a patient 
from Brazil, and presents 48% amino acid identity with the CTX-M group 1 enzymes. It 
confers high-level resistance to cefotaxime but low-level resistance to ceftazidime (Bonnet et 
al., 2000a). Identified in a P. aeruginosa strain, BEL-1 was reported in Belgium in 2004 and 
hydrolyses narrow- and extended-spectrum cephalosporins and aztreonam, but is inhibitied 
by clavulanic acid. The blaBEL-1 gene is associated with a class 1 integron located in the 
chromossome (Naas et al., 2008). Reported in Mexico in 1993, TLA-1 hydrolyses extended-
spectrum cephalosporins, aztreonam and cefepime, and is well inhibited by tazobactam and 
less by clavulanic acid. Sharing 51% amino acid identity with TLA-1, TLA-2, detected in 2002 
in Germany, presents an increased catalytic efficiency against most cephalosporins but not 
against penicillins. Weak or no inhibition by β-lactamase inhibitors was detected in vitro, 
although MICs of cephalosporins were significantly lowered by their addition (Girlich et al., 
2005). 
 
3.4. Detection of β-lactamases 
The detection of β-lactamase production can be performed by different methods, such 
as chromogenic reactions or detection of the destruction of antibiotic activity. Nitrocefin, an 
example of a chromogenic method, is fast, more convenient and highly sensitive to most β-
lactamases. Methods such as acidimetric and iodometric tests, in which the color changes 
are on a linked reaction, are cheaper than nitrocefin, but they are more prone to false-
positive results (Livermore, 1995). However, chromogenic tests do not identify the type of β-
lactamase present. 
Other methods for detection of β-lactamase production, based on detection of the 
destruction of antibiotic activity, include methods like broth dilution and disk diffusion. 
Although these tests are slower than chromogenic methods, they present extreme sensitivity. 
With the constant emergence of new ESBLs or variations of already known ESBLs, the 
establishment of rapid and reliable laboratory methods for screening and confirmation of 
ESBL production is of great importance (Table 1.14).  
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Table 1.14 - Laboratory tests for detection of extended-spectrum β-lactamases (adapted 
from Samaha-Kfoury & Araj, 2003) 
Tests Method and interpretation 
Screening tests  
Double disk approximation or 
double disk synergy  
Disk of third generation cephalosporins placed at 30 
mm distance from amoxicillin-clavulanic acid. 
Enhanced inhibition indicates ESBL 
Microdilution test  Growth in a broth containing 1 µg/mL third generation cephalosporins indicates ESBL  
Confirmatory tests   
MIC broth dilution  
MIC of third generation cephalosporins alone or 
combined with clavulanic acid. A decrease in the MIC 
of the combination of ≥3 two-fold dilutions indicates 
ESBL 
Combination disk  
Uses two discs of third generation cephalosporins 
alone and combined with clavulanic acid. An increase 
in the zone inhibition of >5 mm with the combination 
disk indicates ESBL 
Commercial tests  
Etest for ESBLs 
Two sided strip containing ceftazidime on one side 
and ceftazidime-clavulanic acid on the other. The 
ratio of the MIC of the combination to that of 
ceftazidime alone of >8, or the presence of a 
phantom zone (or both) indicates ESBL 
Vitek ESBL cards 
Measures MICs and compares growth of bacteria in 
presence of cefotaxime and ceftazidime, alone, and 
in combination with clavulanic acid 
MicroScan panels 
Dehydrated panels for MIC evaluation by 
microdilution testing, which contain combinations of 
ceftazidime or cefotaxime plus β-lactamase inhibitors. 
An isolate is considered positive by the ESBL 
confirmation test if there is a ≥3 two-fold dilution drop 
in a MIC value the antibiotic tested alone as 
compared to the MIC value of the antibiotic tested 
with clavulanic acid. 
BD Phoenix Automated Microbiology 
System 
Shorth-incubation system that uses growth response 
to cefpodoxime, ceftazidime, ceftriaxone and 
cefotaxime, with or without clavulanic acid 
Molecular tests  
DNA probes, PCR, RFLP 
Targets specific nucleotide sequences to detect 
different variants of differents β-lactamase family of 
genes 
 
Studies comparing commercial methods with double disk tests showed that the 
highest sensitivity (99%) was obtained with BD Phoenix and the lower with MicroScan (84%). 
On the other hand, specificity was more variable, ranging from 52% (BD Phoenix) to 85% 
(Etest strips) (Wiegand et al., 2007). However, manually performed double-disk tests 
presented the highest positive predictive value (98%) and one of the highest specificitie 
(97%) of all test methods. 
Different levels of resistance against extended-spectrum cephalosporins can be 
detected among strains producing different ESBL enzymes. While some clearly confer high-
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level resistance to these antibiotics, others can confer only intermediate-level resistance or 
even no resistance at all, to one or more third generation cephalosporins. Although a 
possible explanation for these differences could involve the inoculum effect (Katsanis et al., 
1994), routine clinical microbiology laboratories require ESBL detection methods and 
guidelines which are sensitive enough to recognize the level of resistance.  
 As such, ESBL-producing organisms may appear susceptible or resistant according 
to which breakpoints are used. With susceptibility defined by the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) as ‘a level of antimicrobial activity associated 
with a high likelihood of therapeutic success’ (http://www.EUCAST.org), and resistance as ‘a 
level of antimicrobial activity associated with a high likelihood of therapeutic failure’, it is 
suprising that breakpoint differences are quite considerable between different countries 
(Table 1.15). The breakpoins of the Clinical and Laboratory Standards Institute (CLSI), 
formely National Committee for Clinical Laboratory Standards, are the most commonly used 
guidelines worldwide. However, other countries like France and the United Kingdom, present 
their own breakpoints, from the Comité de L’Antibiogramme de la Société Française de 
Microbiologie (SFM) and the British Society for Antimicrobial Chemotherapy (BSAC), 
respectively. 
 
Table 1.15 - Comparision of MIC breakpoints for Enterobacteriaceae according 
to national guidelines (adapted from Paterson & Bonomo, 2005) 
MIC breakpointa (µg/ml) 
Cefotaxime  Ceftazidime Country 
S(≤) R (≥)  S(≤) R (≥) 
United States of America (CLSI) 8 64  8 32 
United Kingdom (BSAC) 1 2  2 4 
France (SFM) 4 32  4 32 
The Netherlands (CRG) 4 16  4 16 
Germany (DIN) 2 8  4 32 
Norway (NWGA) 2 16  2 16 
Sweden (SRGA) 4 32  4 16 
a S, susceptible; R, resistant. 
 
 Studies performed in the United States and Europe reported that errors in the 
detection of ESBL-mediated resistance are frequently encountered with both automated and 
disk diffusion methods (Perez et al., 2007). In Italy, some studies showed that only 42% of 
independent clinical microbiology laboratories correctly detected all of the ESBL-producing 
enterobacteria presented for analysis, while in the United States of America, only 32% of 
clinical microbiology laboratories reportedly perform tests to detect ESBL production by 
Enterobacteriaceae (Paterson & Bonomo, 2005; Perez et al., 2007). 
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 Broth dilution and disk diffusion methods can be used for screening of ESBL 
producers and the use of more than one of the tested antibiotics would improve the sensivity 
of ESBL detection. After screening, ESBL confirmatory testing should be based in the use of 
both ceftazidime and cefotaxime alone and in combination with clavulanic acid (CLSI, 2007).  
 In Enterobacteriaceae producing inducible AmpC chromosomal enzymes, ESBLs are 
more difficult to detect by CLSI guidelines, because AmpC enzymes may be induced by 
clavulanic acid, which may increase resistance to cephalosporins, overcoming the synergy 
arising from inhibition of the ESBL (Hanson, 2003). However, BSAC and SFM suggest the 
use of cefepime and cefpirome with clavulanic acid to compensate this problem (Perez et al., 
2007). 
 Other methods like IEF could be useful for narrowing down the possible identification 
of the ESBL enzyme. However, with the constant emergence of new ESBL and the growing 
number of enzymes sharing the same isoelectric points, such as it happens, for example, in 
the SHV, OXA and CTX-M families, discourages the exclusive use of this method. The most 
common molecular method of detecting and identifying the β-lactamases present, is PCR 
and sequencing with oligonucleotide primers specific for β-lactamase encoding genes. 
Several different PCR methods have been tested for different families of β-lactamase 
encoding genes, including restriction fragment length polymorphism of amplified products 
(PCR-RFLP), multiplex PCR, single strand conformation polymorphism of PCR products 
(PCR-SSCP), real-time PCR and microarrays (Bradford, 2001; Chia et al., 2005; Randegger 
and Hächler, 2001b; Zhu et al., 2007).  
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ABSTRACT 
Fifty-five isolates of K. pneumoniae were evaluated for ESBL detection and 
confirmation, using MIC testing by agar dilution, broth microdilution, and the ESBL Etest (AB 
biodisk, Solna, Sweden), according to reference laboratory criteria (RLC) and CLSI 
guidelines. The RLC classify as ESBL producers those strains for which any MIC of 
cephalosporins is 3-fold lower in the presence of 2 µg/mL of clavulanate. The Etest was the 
only to show 100% sensitivity and specificity to detect ESBL-producer strains with either set 
of guidelines. MIC determination by agar dilution or broth microdilution, using NCCLS 
guidelines showed sensitivity of 92.9%. Nucleotide sequencing allowed to the identification of 
a new ESBL (SHV-55). Overall, this gold standard method confirmed the production of 18 
ESBL-producers, 36 non-ESBL-producers, from which nine were false ESBL producers 
(suggesting hyperproduction) and one a presumptive ESBL TEM-derived. New guidelines for 
ESBL detection and reliable methods of ESBL identification are required. 
 
INTRODUCTION 
Antimicrobial resistance based on hydrolysis of the antibiotic by β-lactamases is 
currently a worldwide problem (Bradford, 2001). The overuse of new extended-spectrum 
cephalosporins and monobactams has allowed to the emergence of new resistant K. 
pneumoniae strains, some producing ESBL (http://www.lahey.org/studies). These ESBLs are 
variants of parental enzymes, carrying one or more amino acid substitutions that modify the 
substrate specificity of the enzyme. 
Resistance due to ESBL production can be difficult to detect because K. pneumoniae 
can hyperproduce non-ESBL β-lactamases (e.g., SHV-1) or possess modifications in outer 
membrane proteins, which also confer an ESBL similar phenotype causing false positive 
results (Rice et al., 2000; Schwaber et al., 2004; Wu et al., 2001). Inhibitor-resistant TEM 
enzymes and AmpC-type β-lactamase coexisting with ESBL enzymes can also compromise 
the inhibition of the ESBL enzyme by clavulanate, as the synergistic effect of the β-lactamase 
inhibitor and cephalosporins against ESBL is more difficult to visualize or is not detectable 
(Tzouvelekis et al., 1999). Indeed, inhibition by β-lactamase inhibitors, such as clavulanate or 
sulbactam, is the common property of ESBL enzymes and is used for the phenotypic 
confirmation of ESBL production by an isolate. There are various methods for confirming 
ESBL production. Evaluations of these methods have been published (Florijn et al., 2002; 
Komatsu et al., 2003; Leverstein-van Hall et al., 2002; Linscott & Brown 2005, MacKenzie et 
al., 2002). 
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Here, we compared phenotypic methods and guidelines used for the confirmation of 
clinical K. pneumoniae ESBL-producing strains of Portuguese origin. Our RLC was 
compared with the CLSI guidelines for interpreting confirmatory tests. Nucleotide sequencing 
was used as the gold standard method to distinguish between ESBL and non-ESBL isolates 
and to identify which ESBL type is present. 
 
MATERIALS AND METHODS 
Setting and bacterial isolates. Fifty-five K. pneumoniae strains isolated from clinical 
specimens were randomly selected from the strain collection of the Antibiotic Resistance Unit 
at the National Institute of Health (NIH) in Lisbon, ensuring that all isolates were from 
different patients. Each isolate was identified with the API 20E System (bioMérieux, Marcy 
l’Étoile, France). Control strains used in antimicrobial susceptibility determination were the 
non-ESBL-producing E. coli ATCC 25922, K. pneumoniae INSRA558, and the ESBL-
producer E. coli INSRA1248 (TEM-24). Control strains used for IEF of SHV-55 producers 
were E. coli INSRA99 (IRT-2, pI 5.2), E. coli RP4 (TEM-2, pI 5.6), K. pneumoniae INSRA558 
(SHV-28, pI 7.6), and E. coli SolRl 90 (AmpC, pI 9.2). E. coli R111 (TEM-1, pI 5.4; blaTEM-1 
plus ampC), S. enterica serovar Typhimurium (OXA-1, pI 7.4; blaOXA-1), E. coli C600 (SHV-1, 
pI 7.6; blaSHV-1) and E. coli UA1526 (CTX-M-15, pI 8.9; blaCTX-M-15) were used as control 
strains for both PCR and IEF. 
 
Antibiotic susceptibility determination and ESBLs detection. The MIC of various 
antibiotics was each determined by an agar dilution method, according to the SFM, which 
was considered as the reference method (Cavallo et al., 2005). The results obtained were 
interpreted using the same guidelines, except for cefoperazone for which the NCCLS (2004) 
guidelines were used. Our criteria – the RLC – classify as ESBL producers those strains for 
which any MIC of cephalosporins is three-fold lower in the presence of 2 µg/mL of 
clavulanate. 
 
Phenotypic confirmatory tests for ESBLs. ESBL production was confirmed by three 
phenotypic tests: 1) the Etest ESBL strips (AB Biodisk, Solna, Sweden), with ceftazidime, 
ceftazidime plus clavulanate, cefotaxime, and cefotaxime plus clavulanate; 2) MIC 
determination by a broth microdilution method (MicroScan ESBL Plus Confirmation Panel, 
Dade Behring, West Sacramento, CA) for ceftazidime, ceftazidime plus clavulanate, 
cefotaxime, and cefotaxime plus clavulanate; and 3) MIC determination by agar dilution 
method. Results from the three confirmatory methods were interpreted according to CLSI 
guidelines: an MIC value of at least one extended-spectrum cephalosporin (ceftazidime 
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and/or cefotaxime) was ≥ 2 µg/mL and was decreased by ≥ 3- to two-fold serial dilution by the 
presence of clavulanate. Tests 1 and 2 were also interpreted according to the RLC. The 
results of the different tests for ceftazidime, ceftazidime plus clavulanate, cefotaxime and 
cefotaxime plus clavulanate were compared. 
 
IEF. IEF tests of cell extracts from isolates producing SHV-55 enzymes were performed as 
previously described (Caniça et al., 1997a). 
 
Conjugation. Liquid mating experiments were conducted with streptomycin-, nalidixic acid- 
and rifampicin-resistant recipient strains of E. coli C600 to determine if the ESBL phenotype 
of the SHV-55 enzyme was transferable. Mueller-Hinton containing 1 mg of cefotaxime per 
liter and 300 mg of rifampicin or 50 mg of nalidixic acid or 20 mg of streptomycin per liter was 
used for selecting transconjugants. 
 
PCR and Sequencing. Total DNA was prepared as previously described (Féria et al., 2002). 
The genes blaTEM, blaSHV, blaOXA, blaCTX-M and ampC were detected by PCR at DNA Engine 
DyadTM (MJResearch, Waltham, MA, USA) in 25 µl reaction volume containing 0.5 mmol/L of 
each of the 4 deoxynucleotides (Roche Diagnostics GmbH, Mannhein, Germany), 0.2 µmol/L 
of each primer (Table 2.1), 3.0 mmol/L MgCl2, 1.25 U of Taq DNA polymerase (Qiagen, 
Izasa, Lisbon, Portugal), 1x Q-Solution (Qiagen) and 1x buffer (Qiagen). PCR conditions 
were: 7 minutes at 94ºC, followed by 30 cycles of 30 s at 94ºC, 1 minute at 56ºC (for blaTEM, 
blaSHV and blaCTX-M genes) or 61ºC (for blaOXA and ampC genes) and 30 s at 72ºC, and 
concluded by 10 minutes at 72ºC. PCR products were purified with ExoSAP IT (USB 
Corporation, Cleveland, OH), and all amplicons from phenotype-like-ESBL- and phenotypic-
like non-ESBL-producer strains were further sequenced directly on both strands using 
automatic sequencer ABI3100 (Applied Biosystems, Warrington, UK). Sequencing was used 
as the gold standard method for identifying enzymes according to the gene sequences. 
 
Table 2.1 - Primers used for PCR amplification and sequencing 
β-lactamase 
gene 
Primer
Name Primer Sequence 
Position 
(5’→3’) Reference  
FIN 5’-ATTCTTGAAGACGAAAGGGC-3’ 0/19 Belaaouaj et al., 1994blaTEM DEB 5’-ATGAGTAAACTTGGTCTGAC-3’ 1091/1072 Caniça et al., 1997b 
SHVsf 5’-CGCTTCTTTACTCGCCTTTA-3’ -50/-31 blaSHV SHVsr 5’-TTACGCTTGCCAGTGCTC-3’ 861/844 This study 
oxa1f 5’-TATCTACAGCAGCGCCAGTG-3’ 929/948 blaOXA oxa1r 5’-CGCATCAAATGCCATAAGTG-3’ 1127/1108 Féria et al., 2002 
ampCf 5’-CCCCGCTTATAGAGCAACAA-3’ 157/176 ampC ampCr 5’-TCAATGGTCGACTTCACACC-3’ 791/772 Féria et al., 2002 
CTXf 5’-TTTGCGATGTGCAGTACCAGTAA-3’ 205/227 blaCTX-M CTXr 5’-CGATATCGTTGGTGGTG CCATA-3’ 748/727 Edelstein et al., 2003 
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Statistic analysis. To evaluate ESBL detection and confirmatory methods, we calculated the 
sensitivity, specificity, and positive and negative predictive values for all strains using SFM 
method and RLC interpretative criteria. This method and criteria was considered as 
reference for comparisons. We used a 2-way table for calculation of efficiency values. 
 
Nucleotide sequence accession number. The blaSHV-55 nucleotide sequence was submitted 
to the EMBL Nucleotide Sequence Database under accession number AJ863560. 
 
RESULTS 
Evaluation of screening and phenotypic confirmatory tests for ESBLs. Among the 55 
isolates of K. pneumoniae, the reference method and criteria detected 28 strains as putative 
ESBL producers (Table 2.2) and 27 as non-ESBL producers (data no shown). Three 
phenotypic methods (MIC by agar dilution, MIC by broth microdilution and Etest ESBL strips) 
with both RLC and CLSI interpretations were used to confirm ESBL (Table 2.2). 
Using the CLSI guidelines to interpret the results we detected 92.9% of the 
phenotype-like ESBL-producing strains (Table 2.3). Broth microdilution and RLC 
interpretation identified a putative ESBL producer (strain 3330, data not shown) with MIC for 
ceftazidime of 1 µg/mL, for ceftazidime plus clavulanate of ≤ 0.12/4 µg/mL, for cefotaxime of 
≤ 0.5 µg/mL and for cefotaxime plus clavulanate of ≤ 0.12/4 µg/mL (specificity 96.2%). This 
strain was classified as a non-ESBL by all other tests including sequencing. ESBL detection 
by agar dilution or broth microdilution interpreted by CLSI guidelines gave three false 
negative ESBL producers (strains 3028, 3805 and 3807), all of which contained the ESBL 
enzyme SHV-2A (Table 2.2).  
The agar dilution method identified four strains (strains 251A, 1228, 1865A and 2613) 
with synergy only between ceftazidime and clavulanate and two strains (strains 3805 and 
3807) with synergy only between cefotaxime and clavulanate. The Etest detected all ESBL 
producers with either RLC or CLSI guidelines (sensitivity 100% and specificity 100%) (Table 
2.3). Broth microdilution and the Etest confirmed 27 strains as non-ESBL, as did the 
reference method. 
Values set in boldface shows CIM values by RLC with MIC decrease of ≥3 doubling dilutions between CAZ or CTX alone and 
in combination with clavulanate. AD = agar dilution method; BMD = broth microdilution method; AMX = amoxicillin; AMC = 
amoxicillin with clavulanate; CAZ = ceftazidime; CAZ/CLA = ceftazidime with clavulanate; CTX = cefotaxime; CTX/CLA = 
cefotaxime with clavulanate. 
a Also used as initial screen test for ESBL. 
b Identification by nucleotide sequencing. 
c Two micrograms of clavulanic acid per millilitre. 
e More than 1 blaSHV-1 genes with different frameworks present. 
f More than 1 blaTEM genes present. Putative ESBL TEM derived. 
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Table 2.3 - Comparison of the sensitivities, specificities, positive predictive value (PPV) and 
negative predictive value (NPV) of three methods, interpreted by CLSI guidelines or RLC, 
used as confirmatory test for 55 phenotype-like ESBL and non-ESBL K. pneumoniaea 
Test/Interpretation criteria Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
Broth Microdilution     
RLC 96.4 96.2 96.4 96.2 
CLSI  92.9 100 100 93.1 
Etest ESBL     
RLC 100 100 100 100 
CLSI 100 100 100 100 
Agar dilution     
CLSI 92.9 100 100 93.1 
a Reference method was agar dilution interpreted by RLC, used for ESBL detection and confirmation. 
  
Identification of genes coding for ESBLs. PCR detected the presence of genes coding for 
β-lactamases of the SHV and TEM families, but did not discriminate between different 
variants of TEM or SHV. No blaOXA, blaCTX-M or ampC gene was detected in our strains. 
However, sequencing was unable to identify one putative TEM-derived (strain 2613) enzyme, 
possibly responsible for an ESBL phenotype, due to the presence of more than one 
sequence of the blaTEM gene detected by gold standard method. We detected nine false 
ESBL producers (strains 251A, 371, 640, 674, 1205, 1228, 1242A, 1302 and 1865A), six of 
which presented more than one overlapping blaSHV-1 sequence. Sequencing of all 27 non-
ESBL isolates revealed parental blaSHV and blaTEM genes (data not shown). 
Sequencing also identified a blaSHV coding for the new ESBL enzyme, named SHV-55 
(Table 2.2). This enzyme presented three substitutions in the aminoacid sequence: Tyr7 
(TAT)→Phe (TTT), Gly238 (GGC) →Ser (AGC) and Glu240 (GAG) →Lys (AAG). The new 
blaSHV-55 gene was not self-transferable to E. coli receptor strains. Strains 3775 and 3972 
produced SHV-55 plus TEM-1 enzymes, which could be responsible for the high MICs of 
amoxicillin plus clavulanate, piperacillin, piperacillin plus tazobactam, and mecillinam (Table 
2.4). The MICs of ceftazidime for SHV-55 producers were 64 to 128 µg/mL, of cefotaxime 4 
µg/mL, of aztreonam 128 to 256 µg/mL and of ceftriaxone 4 to 16 µg/mL. The presence of 
clavulanate decreased the MIC of third-generation cephalosporins or monobactams by 
between 6- and 11-fold doubling dilutions (Table 2.4). 
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DISCUSSION 
 The emergence and rapid dissemination of ESBL-producing strains of K. pneumoniae 
are responsible for outbreaks of infection worldwide. Intensive care units are particularly 
sensitive in terms of clinical outcomes, and these organisms have been implicated in 
increased morbidity and mortality (Paterson & Bonomo, 2005). There are difficulties with the 
routine laboratory detection of ESBL which can be complex and misleading, and this restricts 
treatment options (Bradford, 2001; Paterson & Bonomo, 2005).  
The phenotypic methods gave nine false-positive classifications as ESBL producers, 
and the reasons include: modifications in outer membrane proteins (Rice et al., 2000), and 
hyperprodution of SHV-1 enzyme due to high gene copy number (Podbielski et al., 1991a), 
or a single base pair change in promoter sequence (Jacoby & Han, 1996; Rice et al., 2000). 
This can compensate for the low specific activity of the β-lactamase, allowing such isolates to 
cause diseases. Furthermore, it has been reported that a larger inoculum in vivo increases 
the success of infections of such strains (Jacoby & Han, 1996). Alternatively, these nine false 
ESBL producers may produce enzymes other than those studied, although the specific PCR 
for blaCTX-M and the MIC values for cefepime exclude enzymes of CTX-M family, because 
these enzymes efficiently hydrolyze cefepime (Sabaté et al., 2002). The reference method 
identified a false-positive ESBL producer (strain 3330), possibly due to hyperproduction of 
blaSHV-1 or outer membrane proteins changes. 
We found that the broth microdilution method with CLSI guidelines or RLC was less 
sensitive than the Etest with either criteria or agar dilution using RLC. The Etest was the only 
method, other than the reference method, to detect all the ESBL producers. However, it has 
some limitations, including reading and interpretation problems (Leverstein-van Hall et al., 
2002). Nevertheless, with either set of interpretative criteria, we and other obtained 100% 
sensitivity with the Etest (Leverstein-van Hall et al., 2002). Some authors have reported a 
lower sensitivity: Florijn et al. (2002), 93%; Linscott & Brown (2005), 97%; and MacKenzie et 
al. (2002), 77%. The broth microdilution method gave a sensitivity of 93% using CLSI 
guidelines, to be compared with results in other studies: Komatsu et al. (2003), 92%; Linscott 
& Brown (2005), 100%. 
Some of the ESBL producers had MIC values in the susceptible range according to 
CLSI criteria, suggesting that the synergy between the antibiotic and the inhibitor should be 
pointed out. Based only on the phenotype and with concentrations of ≥ 2 µg/mL, CLSI 
detection and confirmation methods may give false-positive and false-negative results for 
isolates with uncommon β-lactamases (Schwaber et al., 2004), besides SHV, TEM or CTX-
M. 
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However, increasing the breakpoint to ≥ 4 µg/mL for ceftazidime, as suggested by 
Moland et al. (1998), would decrease the apparent number of ESBL-like-phenotype isolates 
in our study by 17.9%, including two true positives with SHV-2A. Our study indicates that a 
screening test by agar dilution considering the susceptibility range under MIC of 2 µg/mL and 
synergy with clavulanate, or the Etest method, can be very reliable. The optimal laboratory 
method for ESBL detection has not yet been identified. Phenotypic methods are more 
reliable and less costly than genotypic methods for routine laboratory testing.  
However, the importance of genotypic methods is reflected here by sequencing all 
strains, which allowed us to identify a new ESBL encoding gene among other gene β-
lactamases. Thus, we report a new ESBL enzyme, SHV-55, that carries the variations of 
both SHV-5 (Gly238Ser and Glu240Lys) and SHV-28 (Tyr7Phe, in the signal peptide region) 
β-lactamases (http://www.lahey.org/studies/webt.htm). SHV-5 (with pI 8.2) was initially 
detected in a K. pneumoniae isolate from a patient attending a hospital in Santiago, Chile 
(Gutmann et al., 1989), and was subsequently widely found in other countries (Mulgrave & 
Attwood, 1993). Non-ESBL enzyme, SHV-28 (with pI 7.6), was first detected in a K. 
pneumoniae isolate in China in the year 2000 (accession number AF299299, unpublished) 
and again in China by another team in the year 2002 (accession number AF538324, 
unpublished). SHV-28, unlike ESBL, was not associated with the hydrolysis of broad-
spectrum cephalosporins or monobactams (Table 2.4). The positive charge on amino-
terminal region of the signal peptide plays an important role in protein secretion across the 
membrane (Inouye et al., 1982); however, the neutral charge resulting from the Tyr7Phe 
substitution appears not to have any functional significance for the expression of the 
resistance phenotype. SHV-55, like SHV-5, confers greater resistance to ceftazidime and 
aztreonam than to cefotaxime (Gutmann et al., 1989; Mulgrave & Attwood 1993). The 
coexpression of SHV-55 and TEM-1 enzymes in two strains (3775 and 3972) presumably 
explains their greater resistance to amoxicillin plus clavulanate, piperacillin, piperacillin plus 
tazobactam and mecillinam. 
Our study shows that the detection and confirmation of ESBL-producing strains is a 
problem and that K. pneumoniae producing ESBL enzymes are probably overlooked in some 
hospitals and private laboratories. This may constitute a real threat because 1) there is an 
inoculum effect in vivo, as well as in vitro, with a consequent rise in resistance to expanded-
spectrum cephalosporins; 2) K. pneumoniae is a major nosocomial pathogen; and 3) it is a 
frequent ESBL producer worldwide. Improved guidelines for ESBL testing with more 
appropriate cephalosporin breakpoints and improved automated methods for the detection of 
this β-lactamases are needed. 
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TEXT 
We biochemically characterized the K. pneumoniae extended-spectrum SHV-55 
enzyme carrying the aminoacid substitutions Tyr7Phe (as in SHV-28), Gly238Ser and 
Glu240Lys (both found in SHV-5) identified in a previous study (Mendonça et al., 2006a). 
SHV-55 ESBL differed from SHV-5 only in the signal peptide region (Gutmann et al., 1989). 
The blaSHV-55 gene was obtained as described by Mendonça et al (Mendonça et al., 2008), 
and transformants were selected on Luria Broth agar supplemented with 30 µg of 
kanamycin/ml and 16 µg of amoxicillin/ml. SHV-55 was extracted and purified according to 
the previously described protocol (Mendonça et al., 2008). The Michaelis constant (Km) and 
catalytic activity (kcat) of purified extracts of SHV-55 were obtained by using a computerized 
microacidimetric method and 702 SM Titrino pH-stat apparatus (Metrohm, Herisau, Swiss) 
(Labia et al., 1973). The complete hydrolysis time-courses were analyzed, and the kinetic 
progress curves were fitted by nonlinear least-squares regression. These kinetic parameters 
were determined and compared to those of SHV-1 enzyme for 10 β-lactams (Table 3.1). 
SHV-55 has a high affinity (Km, 5 to 10 µM) for penicillins, similar to that of SHV-5 
(Gutmann et al., 1989), and higher than that of SHV-1 (Km, 11 to 31 µM). SHV-55 presented 
higher affinity values (Km, 9 to 58 µM) than SHV-1 (Km, 40 to 257 µM) for narrow-, extended-, 
and broad-spectrum cephalosporins and monobactams. This finding may be a consequence 
of the Gly238Ser substitution present in the active site of both SHV-55 and SHV-5, which 
pushes the β-strand out and away from the reactive Ser70 (Huletsky et al., 1993). This 
results in a slightly expanded active site that may improve binding and accommodate 
cephalosporins with bulky side-chains (Matagne et al., 1998). 
SHV-55 presented a higher affinity for cefotaxime than for ceftazidime (Km, 21 and 58 
µM, respectively), as did SHV-5 (Gutmann et al., 1989; Mulgrave & Attwood, 1993). This 
finding is surprising because both enzymes possesses the Glu240Lys substitution, which 
increases hydrolytic activity against ceftazidime due to the change in the electrostatic charge 
of the exposed group at position 240 (Huletsky et al., 1993; Randegger et al., 2000). The 
enzymatic activity (kcats) of SHV-55 for penicillin G and amoxicillin were 84- and 45-fold 
lower, respectively, than those of SHV-1, and the catalytic efficiency (kcat/Km ratio) against 
penicillins was more than 10-fold higher for SHV-1 (kcat /Km ratio, 20 to 84 µM-1.s-1) than for 
SHV-55 (kcat /Km ratio, 2 to 5 µM-1.s-1). However, the enzyme activity and catalytic efficiency 
against extended- and broad-spectrum cephalosporins were higher for SHV-55 (kcat, 7 to 24 
s-1 and kcat /Km ratio, 0.2 to 1 µM-1.s-1) than for SHV-1 (note, however, that the values for 
monobactam were undeterminable), although the catalytic efficiency of the two enzymes 
against cephalothin were similar (kcat /Km ratio, 3.2 and 4.4 µM-1.s-1). This result may be due 
to the amino acid substitutions in SHV-55 causing conformational modifications in the active 
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site. Fifty percent inhibitory concentrations (IC50s) indicated that SHV-55 was nine-fold more 
susceptible to the inhibitor activity of clavulanate than SHV-1 (IC50s of clavulanate, 0.02 
versus 0.17 µM). 
 
Table 3.1 - Kinetic constants of SHV-55 and SHV-1 β-lactamasesa 
SHV-1b SHV-55 
Antibiotic Km 
(µM) 
kcat 
(s-1) 
kcat/Km 
(µM-1.s-1) 
IC50
(µM)
Km 
(µM) 
kcat 
(s-1) 
kcat/Km 
(µM-1.s-1) 
IC50 
(µM) 
Clavulanic Acid    0.17    0.02 
Penicillin G 23 ± 0.42 1,937 ± 82 84.3 ± 2.0  5 ± 0.51 23 ± 0.76 5.3 ± 0.42  
Amoxicillin 31 ± 1.29 1,044 ± 10 33.3 ± 1.1  10 ± 0.14 23 ± 0.17 2.5 ± 0.02  
Ticarcillin 11 ± 3.40 220 ± 49 20.4 ± 1.7  6 ± 0.02 8 ± 0.00 1.5 ± 0.00  
Piperacillin 24 ± 0.53 1,490 ± 96 62.5 ±  2.7  8 ± 0.37 27 ± 1.53 3.7 ± 0.03  
Cephalothin 40 ± 1.46 128 ± 33 3.2 ± 0.8  9 ± 0.68 38 ± 3.94 4.4 ± 0.78  
Cefuroxime 80 ± 0.59 <0.1 NDc  23 ± 0.53 7 ± 0.19 0.3 ± 0.00  
Ceftazidime 142 ± 3.18 <0.1 ND  58 ± 7.40 9 ± 0.21 0.2 ± 0.02  
Cefotaxime 257 ± 20.65 <0.1 ND  21 ± 0.13 24 ± 0.34 1.1 ± 0.01  
Aztreoname ND <0.1 ND  5 ± 0.62 <0.1 ND  
Cefepime 149 ± 7.30 <0.1 ND  149 ± 2.61 30 ± 3.10 0.2 ± 0.02  
a Values (except IC50s) are means ± standard deviations. 
b Data are from reference Mendonça et al. (Mendonça et al., 2008). 
c ND, Not determinable. 
 
In conclusion, these results confirmed the extended-spectrum activity of SHV-55 
enzyme, which is important due to the magnitude of extended- and broad-spectrum SHV β-
lactamases described to date and not biochemically characterized, in spite to the ease of 
sequencing genes (http://www.lahey.org/studies). 
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The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to 
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ABSTRACT 
The new β-lactamase SHV-72 was isolated from clinical K. pneumoniae INSRA1229, 
which exhibited the unusual association of resistance to amoxicillin-clavulanic acid 
combination (MIC, 64 μg/ml) and susceptibility to cephalosporins, aztreonam, and imipenem. 
SHV-72 (pI 7.6) harbored the three amino acid substitutions Ile8Phe, Ala146Val and 
Lys234Arg. SHV-72 had high catalytic efficiency against penicillins (kcat/Km, 35 to 287 µM-1.s-
1) and no activity against oxyimino β-lactams. The concentration of clavulanic acid necessary 
to inhibit the enzyme by 50% was 10-fold higher for SHV-72 than for SHV-1. Molecular 
dynamics simulation suggested that the Lys234Arg substitution in SHV-72 stabilized an 
atypical conformation of Ser130 side chain, which moved the Oγ atom of Ser130 around 3.5 
Å away from the key Oγ atom of the reactive serine (Ser70). This movement may therefore 
decrease the susceptibility to clavulanic acid by preventing cross-linking between Ser130 
and Ser70. 
 
INTRODUCTION 
The most common resistance mechanism in bacteria against β-lactam antibiotics is 
the production of β-lactamases (EC 3.5.2.6), which hydrolyze and inactivate β-lactams. β-
Lactamases are divided into four major classes (A to D) on the basis of their primary 
sequence (Ambler, 1980). While class B is composed of metalloenzymes that necessitate 
the presence of zinc cations for activity, classes A, C and D are serine hydrolases (Ambler, 
1980; Bush et al., 1995). Class A enzymes comprise several enzyme families, including the 
clinically relevant enzymes TEM and SHV (Livermore, 1995).  
TEM and SHV enzymes initially had preferential activity against penicillins, as in the 
case of enzymes SHV-1 and TEM-1. Oxyimino β-lactams that are resistant to their hydrolytic 
activity and β-lactam inhibitors, such as clavulanic acid and tazobactam, have been 
developed to get around the activities of these enzymes (Bradford, 2001; Chaïbi et al., 1999; 
Livermore, 1995). Nevertheless, the presence of point mutations in TEM and SHV enzymes 
has expanded the substrate spectrum to include oxyimino β-lactams and/or has conferred 
resistance to the inhibitors (Babic et al., 2006; Bradford, 2001; Chaïbi et al., 1999; Livermore, 
1995).  
More than 28 inhibitor-resistant TEM enzymes have been detected. They harbor 
amino acid substitutions at positions 69, 130, 165, 182, 244, 275 and/or 276 that confer 
resistance to inhibitors (Chaïbi et al., 1999; Helfand et al., 2003). Only three natural IRSs 
have been reported (http://www.lahey.org/studies). It has been proposed that substitutions at 
positions 69, 130 and 187 are involved in their resistance to inhibitors (Chang et al., 2001; 
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Dubois et al., 2004, Prinarakis et al., 1997). IRS enzymes have also been constructed in vitro 
by site saturation mutagenesis in position 244 (Thomson et al., 2006). 
In this study, we performed a phenotypic, molecular and biochemical characterization 
of the new IRS-type β-lactamase SHV-72 from a clinical K. pneumoniae strain and 
investigated by molecular dynamic simulations (MDSs) the role of the Lys234Arg substitution 
in its resistance to clavulanic acid. 
 
MATERIALS AND METHODS  
Bacterial strains and plasmid. K. pneumoniae INSRA1229 was isolated from sputum of an 
80 year old male in an internal medicine service of a general hospital in Lisbon, in 1999. E. 
coli DH5α ∆ampC and plasmid pBK-CMV (Stratagene, Amsterdam, The Netherlands) were 
used for the cloning experiments (Table 4.1) (Delmas et al., 2006). blaSHV-1-encoding E. coli 
C600 was used as control strain for PCR. 
 
Table 4.1 - Strains and plasmids used in this study 
Strain or plasmid Genotype or description Source or reference 
Strains   
K. pneumoniae Clinical strain harbouring the natural plasmid 
pINSRA1229 
This study 
E. coli C600 Strain harbouring the natural plasmid pINSRASHV-1 This study 
E. coli DH5α supE44 ΔlacU169 (φ80lacZΔM15) hsdR17 recA1 
endA1 gyrA96 thi-1 relA1 ΔampC 
Delmas et al., 2006 
Plasmid   
pINSRASHV-1 Plasmid from E. coli C600 containing blaSHV-1 gene; 
resistance phenotype: amoxicillin  
This study 
pINSRA1229 Natural plasmid from K. pneumoniae INSRA1229 
containing blaSHV-72 gene; resistance phenotype: IRS 
This study 
pBK-SHV-72 Recombinant plasmid containing 891-bp fragment 
with blaSHV-72 gene; resistance phenotype: IRS, 
kanamycin 
This study 
pBK-SHV-1  Recombinant plasmid containing 891-bp fragment 
with blaSHV-1 gene; resistance  phenotype: amoxicillin, 
kanamycin 
This study 
pBK-CMV Phagemid vector; resistance phenotype: kanamycin Stratagene 
 
Susceptibility testing. MICs were determined by agar dilution method, according to the 
recommendations of the SFM (Cavallo et al., 2007). Strains were tested against cefotaxime 
(Sanofi Aventis), ceftriaxone and trimethoprim (Roche Pharmaceuticals), aztreonam and 
cefepime (Bristol-Myers Squibb), amoxicillin, cefuroxime, ceftazidime, clavulanic acid and 
ticarcillin (GlaxoSmithKline), cefoxitin (Labesfal), mecillinam (Leo Pharma), cephalothin 
(Sigma), cefoperazone (Pfizer), piperacillin and tazobactam (Wyeth Pharmaceuticals), 
imipenem (Merck Sharp & Dohme, Lda), ciprofloxacin (Bayer HealthCare), gentamicin 
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(Schering-Plough) and penicillin (Laboratórios Atral, S.A.). MICs of β-lactam antibiotics were 
determined alone and combined at a fixed concentration of clavulanic acid (2 µg/ml) 
(amoxicillin, ceftriaxone, cefotaxime, ceftazidime and aztreonam) or tazobactam (4 µg/ml) 
(piperacillin). 
 
IEF. Cell extracts were obtained by ultrasonic treatment, and isoelectric focusing was 
performed with polyacrylamide gels containing ampholines with a pH range of 3.5 to 9.5, as 
previously described (Bonnet et al., 2001), with IRT-2 (pI 5.2), TEM-1 (5.4), TEM-2 (pI 5.6), 
OXA-1 (pI 7.4), SHV-1 (pI 7.6), CTX-M-15 (pI 8.9) and AmpC (pI 9.2) as standards.  
 
Amplification, sequencing and cloning of β-lactamase genes. The β-lactamase-encoding 
genes were detected and sequenced, as described elsewhere (Mendonça et al., 2006a). The 
complete SHV-encoding open reading frame of the blaSHV-1 and blaSHV-72 genes was amplified 
with the specific primers SHVsf and SHVsr (Mendonça et al., 2006a). The blaSHV-1 and blaSHV-
72 genes were cloned as follows: proofreading Isis DNA polymerase (Qbiogene, Irvine, CA) 
was used for blaSHV-72 and proofreading iProofTM high-fidelity DNA polymerase (Bio-Rad 
Laboratories Inc., Hercules, CA) was used for blaSHV-1. PCR products were ligated in the 
SmaI site of the plasmid pBK-CMV, and the recombinant plasmids were electroporated in E. 
coli DH5α ∆ampC. The transformants harboring the recombinant SHV-encoding plasmids 
(pBK-SHV-72 and pBK-SHV-1) were selected on Mueller-Hinton agar supplemented with 30 
µg/ml kanamycin and 16 µg/ml ticarcillin. The sequence and the orientation of the inserted 
open reading frames were determined from PCR experiments, which were performed with 
different combinations of primers pBK-CMV1’ (5’-CTAGTGGATCCAAAGAATTCAAAAAGC-
3’), pBK-CMV2’ (5’-AATTGGGTACACTTACCTGGTACCC-3’), SHVsf and SHVsr.  
 
β-Lactamase preparation. The SHV-producing clones were grown for 18 h at 37ºC in 6 
liters of Luria-Bertani broth complemented with yeast extract, 30 µg/ml of kanamycin and 16 
µg/ml of ticarcillin. After centrifugation, bacterial pellets were suspended with MES-NaOH 
20mM (pH 6) and disrupted by ultrasonic treatment as previously described (Bonnet et al., 
2000a). The extract was then clarified by centrifugation and treated with DNase I (Roche 
Applied Science, Meylan, France). Purification was carried out by ion-exchange 
chromatography with an SP Sepharose column or HiPrep 16/10 SP HF column (Amersham 
Pharmacia Biotech) and gel filtration chromatography with a Superose 12 or HiPrep 16/60 
Sephacryl S-100 HR column (Amersham Pharmacia Biotech), using a fast-protein liquid 
chromatography system as previously described (Bonnet et al., 2001). The protein 
concentration was estimated by the BCA protein assay kit (Pierce, Rockford, IL,). The purity 
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of enzymes was estimated by using sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis as previously described (Bonnet et al., 2001). 
 
Determination of β-lactamase kinetic constants. The Km and kcat of the SHV-1 and SHV-
72 enzymes were obtained with purified extracts by a computerized microacidimetric method, 
using 702 SM Titrino pHstat apparatus (Labia et al., 1973). These kinetic parameters were 
determined by the analysis of the complete hydrolysis time-courses and the kinetic progress 
curves were fitted by nonlinear least-squares regression (Labia et al., 1973). The IC50s 
(clavulanate and tazobactam) were determined as described elsewhere (Bonnet et al., 
2001), with 200 µM ticarcillin as reporter substrate. The kinetic constants were determined 
three times for each subtract tested. 
 
MDS. The model of the mutant enzyme (SHV-72) was constructed on the basis of SHV-1 
crystal structure (Kuzin et al., 1999). SHV-72 and SHV-1 enzymes were solvated with water 
in a periodic cubic box that was large enough to contain the system and 1 nm of solvent on 
all sides. Version 1.8.2 of the VMD package was used to manipulate the two systems 
(Humphrey et al., 1996). The GROMACS software package, version 3.2 (Lim et al., 2001), 
and the geometric and charge parameters of the OPLSAA (optimized potentials for liquid 
simulations in all-atom) force field (Jorgensen et al., 1996) were used to carry out all energy 
minimizations and MDSs. TIP3P parameters were used for the water molecules (Jorgensen 
et al., 1983). The particle-mesh Ewald method was used to treat long-range electrostatics 
(Darden et al., 1993). All covalent bond lengths were constrained by the SHAKE algorithm 
(Ryckaert et al., 1977) with a relative tolerance of 10−4. The systems were equilibrated as 
reported previously (Maveyraud et al., 2002) and MDSs of 400 ps were then made with a 
time step of 1.5 fs and coordinates collected every 0.0015 ps. The velocities of all atoms 
were generated from a Maxwellian distribution. The temperature was kept constant at 300 K, 
while the pressure was kept constant by the weak coupling constant of 1 bar using 
Berendsen’s algorithms (Lindahl et al., 2001).  
 
Nucleotide sequence accession number. The new blaSHV nucleotide sequence was 
submitted to the EMBL Nucleotide Sequence Database as blaSHV-72 with accession number 
AM176547. 
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RESULTS 
Phenotypic characterization. The clinical K. pneumoniae INSRA1229 strain exhibited 
resistance to amoxicillin (2,048 µg/ml), ticarcillin (512 µg/ml) and piperacillin (32 µg/ml) 
(Table 4.2). The strain was susceptible to cephalosporins, monobactams, imipenem, 
ciprofloxacin, gentamicin and trimethoprim. K. pneumoniae INSRA1229 was also resistant  to 
amoxicillin combined with clavulanic acid (64 µg/ml). MIC for piperacillin-tazobactam was 
much lower than that for amoxicillin-clavulanic acid combination (Table 4.2).  
 
Table 4.2 - MICs of β-lactam antibiotics for the clinical K. pneumoniae strain INSRA1229, 
SHV-72 and SHV-1-producing transformants and the recipient E. coli DH5α ∆ampC 
MIC (μg/mL) for strains: 
Antimicrobial drug E. coli 
DH5α ∆ampC
E. coli 
DH5α-SHV-1a
E. coli 
DH5α-URA1229b 
K. pneumoniae 
INSRA1229 
Amoxicillin   8 2,048 512 2,048 
Amoxicillin + CLAc   8        8   64      64 
Ticarcillin   4 1,024     8    512 
Piperacillin   2      64     4      32 
Piperacillin + TAZd   1        2     2        2 
Mecillinam   0.125        0.5     0.25        0.25 
Cephalothin   8      16     4        8 
Cefuroxime   4        4     8        2 
Cefoperazone ≤0.25        4   ≤0.25        2 
Ceftriaxone   0.03        0.03     0.03        0.03 
Ceftriaxone+ CLA   0.06      0.03     0.03      ≤0.015 
Cefotaxime   0.06      0.06     0.06        0.125 
Cefotaxime + CLA   0.06      0.06     0.06        0.06 
Ceftazidime   0.25      0.5     0.25        0.06 
Ceftazidime + CLA   0.125      0.25     0.25        0.06 
Aztreonam   0.06      0.125     0.125      ≤0.015 
Aztreonam + CLA   0.06      0.125     0.125      ≤0.015 
Cefepime   0.03      0.03     0.03        0.03 
Cefoxitin   4      8     8        4 
Imipenem   0.25      0.25     0.125        0.125 
Ciprofloxacin ≤0.125    ≤0.125   ≤0.125      ≤0.125 
Gentamicin ≤0.125      0.25     0.25        0.5 
Trimethoprim ≤0.125    ≤0.125   ≤0.125        0.5 
a E. coli DH5α-SHV-1 was the transformant producing SHV-1. 
b SHV-72-producing E. coli DH5α-URA1229 was the transformant corresponding to K. 
pneumoniae INSRA1229. 
c CLA, clavulanic acid at a fixed concentration of 2 μg/ml. 
d TAZ, tazobactam at a fixed concentration of 4 μg/ml. 
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Molecular characterization of blaSHV-72 gene. The blaSHV gene of INSRA1229 was amplified 
and sequenced. The sequence showed the nonsynonymous nucleotide mutations A10T, 
C425T and A689G compared to blaSHV-1. According to Ambler numbering (Ambler, 1980), 
these mutations lead to the two previously described amino acid substitutions Ile8Phe and 
Ala146Val, and to the new substitution Lys234Arg. The corresponding enzyme was 
designated SHV-72 and its gene was cloned downstream of promoter LacZ of the plasmid 
pBK-CMV, as well as blaSHV-1. The SHV-72-producing clone, designated E. coli DH5α-
URA1229, exhibited a β-lactam resistance phenotype similar to that of the clinical strain 
(Table 4.2). 
 
Biochemical proprieties of β-lactamase SHV-72. The clinical strain and the corresponding 
clone produced only β-lactamases of pI 7.6, which is compatible with the amino acid 
sequence of SHV-72. SHV-72 and SHV-1 were purified from the E. coli clones by ion 
exchange and gel filtration. The rate of purity was estimated to be ≥ 96% for SHV-72 and ≥ 
95% for SHV-1 on SDS-PAGE gel as a band of 28kDa, which corresponded to the molecular 
mass deduced from the amino acid sequence (data not shown). 
 The kinetic parameters for SHV-72 were determined for seven β-lactams and 
compared with those of SHV-1 (Table 4.3). kcat values of SHV-72 against penicillins were 
higher than those of SHV-1, and Km values were comparable or slightly higher (19 to 43 µM 
versus 11 to 31 µM). Overall, catalytic efficiency against penicillins was slightly higher for 
SHV-72 (kcat /Km, 36 to 286 µM-1.s-1) than for SHV-1 (kcat /Km, 20 to 84 µM-1.s-1), except for 
piperacillin (kcat /Km, 45 µM-1.s-1 versus 62 µM-1.s-1). In contrast with penicillins, SHV-72 had 
lower catalytic efficiency against cephalothin (11-fold) than SHV-1. Neither SHV-1 nor SHV-
72 exhibited catalytic activity against oxyimino β-lactams. 
 
Table 4.3 - Kinetic parameters of SHV-72 and SHV-1 
SHV-1 SHV-72 
Antibiotic Km 
(µM) 
kcat 
(s-1) 
kcat/Km 
(µM-1.s-1) 
Km 
(µM) 
kcat 
(s-1) 
kcat/Km 
(µM-1.s-1) 
Penicillin G 23 ± 0.42 1,937 ± 82 84.2 ± 2.0 19 ± 0.92 5,438 ± 176 286.2 ± 23.5 
Amoxicillin 31 ± 1.29 1,044 ± 10 33.7 ± 1.1 26 ± 6.97 5,876 ± 79 226.0 ± 66.4 
Ticarcillin 11 ± 3.40 220 ± 49 20.0 ± 1.7 36 ± 3.45 1,279 ± 24 35.5 ± 2.8 
Piperacillin 24 ± 0.53 1,490 ± 96 62.1 ± 2.7 43 ± 5.45 1,918 ± 33 44.6 ± 6.5 
Cephalothin 40 ± 1.46 128 ± 33 3.2 ± 0.8 141 ± 12.5 38 ± 7 0.3 ± 0.1 
Ceftazidime NDa <0.1 ND ND <0.1 ND 
Cefotaxime ND <0.1 ND ND <0.1 ND 
a ND, Not determinable.  
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The IC50 for SHV-1 and SHV-72 are as follows: for clavulanic acid, the IC50 was 0.17 
µM for SHV-1 and 1.72 µM for SHV-72; for tazobactam, the IC50 was 0.11 µM for SHV-1 and 
0.08 µM for SHV-72. The IC50 of clavulanic acid was 10-fold higher for SHV-72 than for SHV-
1, and IC50 of tazobactam was similar for both enzymes. Tazobactam was 22-fold more 
active than clavulanic acid against SHV-72 enzyme.  
 
 
MDS. The enzyme SHV-72 was modeled from the crystallographic structure of SHV-1 (Kuzin 
et al., 1999). The behaviors of SHV-72 and SHV-1 were compared during MDSs of 400 ps at 
a temperature of 300 K. The MDS for each model were checked for stability by monitoring 
several overall properties such as the radius of gyration, the secondary structure, root mean 
squared deviation (RMSD) from the initial structure, and the kinetic and potential energies 
(data not shown). These parameters were found to stabilize after about 100 ps, and hence, 
data from 300 ps were used for all subsequent analyses. The radius of gyration and the 
RMSDs of Cα atoms were similar to those for the crystallographic structure of SHV-1 (Table 
4.4). The secondary structure was also preserved during the simulation (Table 4.4). The 
relatively small deviations were further evidence of the inherent stability of the model and 
indicated that the dynamic structures of the models remained in the realm of the crystal SHV-
1 geometry during the course of the simulation. The largest fluctuations were localized in 
loops connecting the secondary structure elements, as is usual in MDSs of proteins (data not 
shown). The introduction of Ala146Val and Lys234Arg substitutions caused no overall or 
large-scale deviation of the dynamic properties. 
 
Table 4.4 - Summary of statistical data for 300ps MDSs 
Secondary structure analysis (%) Enzyme and use Radius of 
gyration (Å)a
Cα  
RMSD (Å) Helix β-sheet Coil Turn  
Molecular modeling: 
  - SHV-72 
  - SHV-1 
 
1.81 ± 0.01 
1.80 ± 0.00 
 
0.88 ± 0.12b 
0.90 ± 0.16b 
 
41.5 ± 2.7
42.8 ± 2.6
 
16.7 ± 0.8 
17.2 ± 0.4 
 
18.2 ± 0.8 
18.2 ± 0.6 
 
14.6 ± 1.8
12.7 ± 1.4
Crystal structure: 
   - SHV-1c 
 
1.79 
 
1.20 ± 0.11d 
 
44.5 
 
17.0 
 
17.3 
 
13.2 
a Average radius of gyration of nonhydrogen atoms. 
b RMSD of α-carbon atoms with respect to the minimized starting structures. 
c Crystal structure of β-lactamase SHV-1 (PDB identification code 1SHV) (Kuzin et al., 1999). 
d RMSD of α-carbon atoms with respect to the molecular dynamics structures. 
 
Position 146, which is located at the surface of the protein and at distance from the 
catalytic site (distance between Cα of positions 70 and 140 : 16.7 Å), did not modify the 
positioning of surrounding residues. Residue Arg234 is located in the catalytic site and 
adopted the conformation observed in the crystallographic structure of the class A β-
lactamase PSE-4 (Figure 4.1A) (Lim et al., 2001). Overall, the architecture of the active site 
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was identical for both enzymes SHV-72 and SHV-1. All residues of the active site except 
residue Ser130 had similar positioning in SHV-1 and SHV-72.  
The behavior of Ser130 side chain was different in the two enzymes. In the initial set 
of MDSs, χ1 angle of Ser130 was around -145° in the starting models (Figure 4.1A, Figure 
4.2A and C), as observed in the crystal structure of class A enzymes such as the TEM-, 
SHV- and CTX-M-type enzymes (Chen et al., 2005; Kuzin et al., 1999; Minasov et al., 2002). 
After 130 ps of MDS, Ser130 χ1 angle of SHV-72 increased to -61 ± 11° and thereafter 
remained stable until the end of the simulation (Figure 4.2A). In SHV-1, χ1 angle kept the 
value of -145 ± 12° during almost all the simulation (Figure 4.2C).  
 
A                                               B 
 
Figure 4.1 - The two conformations of Ser130 side chain. (A) SHV-72 exhibiting Ser130 χ1 
angle value of -145°. (B) SHV-1 exhibiting Ser130 χ1 angle value of -60°. χ1 is the angle 
between the plane containing the atoms N, CA, CB and the plane containing the atoms CA, 
CB and Oγ. 
 
In a second set of MDS, χ1 angle of Ser130 was set at -61° in the starting models by 
manual modeling (Figure 4.1B, Figure 4.2B and D). For SHV-72, χ1 angle value of Ser130 
was -67 ± 10° and stable (Figure 4.2B). In contrast, the Ser130 χ1 angle of SHV-1 decreased 
after 160 ps from -58 ± 10° to -153 ± 20° and remained stable until the end of the MDS 
(Figure 4.2D). The Lys234Arg substitution thus stabilized an atypical conformation of the 
Ser130 side chain. This conformation was characterized by an χ1 angle between -50° and -
77°, which moved the Oγ atom of Ser130 around 3.5 Å away from the key Oγ atom of the 
reactive serine (Ser70).  
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DISCUSSION 
The study of β-lactamases that are resistant to inhibitors is of great importance owing 
to the restricted number of drugs capable of eluding bacterial resistance. In this work we 
characterized a new enzyme, SHV-72, from a K. pneumoniae isolated in a Portuguese 
hospital, that exhibits unusual resistance to amoxicillin and the amoxicillin-clavulanic acid 
combination. SHV-72 harbored three substitutions: Ile8Phe in the leader peptide, Ala146Val 
at distance from the catalytic pocket (distance between Cα atoms 146 and 70: ≈17 Å) and 
the substitution Lys234Arg in the catalytic pocket. To our knowledge, this last substitution is 
observed for the first time in a natural SHV/TEM-type β-lactamase (Lenfant et al., 1991). 
The resulting new enzyme induced resistance phenotype compatible with that of an 
inhibitor-resistant penicillinase. No effect was observed on imipenem MIC, beside the 
presence of the substitution Ala146Val (Poirel et al., 2003). The kinetic constant confirmed a 
high catalytic efficiency against penicillins, no significant activity against oxyimino β-lactams, 
and decreased susceptibility to clavulanate in comparison with results for SHV-1.  
Only the three SHV-type enzymes SHV-10, SHV-26 and SVH-49 have been 
previously described as resistant to inhibitors. In contrast to SHV-72, these enzymes have an 
increase in Km values and/or a decrease in kcat values against penicillins (Chang et al., 2001; 
Dubois et al., 2004; Prinarakis et al., 1997). In SHV-10 and SHV-49, the amino acid 
substitutions Ser130Gly and Met69Ile reduced activity against β-lactam substrates (Dubois et 
al., 2004; Prinarakis et al., 1997). The introduction of Lys234Arg in TEM-1 by site-directed 
mutagenesis experiments induce a 10-fold decrease of the affinity against penicillins (Lenfant 
et al., 1991). The mutations observed in SHV-72 did not significantly affect Km values and did 
not decrease catalytic activity against penicillins. 
Among IRSs, SHV-10 is the most resistant (with an IC50 41-fold higher than that for 
SHV-1) to inhibitors and SHV-26 the least (with an IC50 3-fold higher than that for SHV-1) 
(Chang et al., 2001; Prinarakis et al., 1997). SHV-72 like SHV-49 (Dubois et al., 2004), was 
10-fold more resistant to clavulanic acid than SHV-1. The Ser130Gly substitution in SHV-10 
also induces resistance to inhibitors in TEM-, OXY- and CTX-M-type enzymes (Aumeran et 
al., 2003; Leflon-Guibout et al., 2000b; Prinarakis et al., 1997; Sirot et al., 1998). The 
mechanism of inhibition by clavulanic acid is based on the formation of a covalent cross-link 
between Oγ atoms of Ser70 and Ser130 by residual atoms of the inhibitor. In enzymes 
harboring Gly130, this residue, which is deprived of the side chain, prevents cross-linking 
with position 70 (Sulton et al., 2005; Sun et al., 2004; Thomas et al., 2005). In SHV-49, the 
substitution Met69Ile is responsible for resistance to inhibitors (Dubois et al., 2004).  
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By analogy with inhibitor-resistant TEMs (Wang et al., 2002), substitution in position 
69 may decrease the susceptibility to inhibitors because of the modification of Ser130 side-
chain positioning. In SHV-72, the Lys234Arg substitution is probably responsible for 
resistance to inhibitors owing to its location in the catalytic pocket and in the vicinity of 
residue 130.  
 To understand the role of Arg234 in the resistance to clavulanic acid, SHV-72 was 
modeled from SHV-1 crystal structure (Kuzin et al., 1999) and analyzed during MDSs. SHV-
72 and SHV-1 models exhibited different behavior only in the local region of residue 234. In 
Lys234-harboring class A β-lactamases, the conformation of the Ser130 side chain is such 
that its χ1 values are in the range of -120.5°to -163.5°, as for SHV-1 (-140°). In SHV-72 
MDSs, an alternative conformation of the Ser130 side chain (χ1 ≈ -64°) appeared because of 
a hydrogen bond with Arg234, as previously observed in the crystal structure of the Arg234-
harboring enzyme PSE-4 (Lim et al., 2001). This alternative conformation is probably 
stabilized because of the restricted ability of Arg234 to move and establish hydrogen bond, 
since hydrogen bonds are favorable only in the plane of the rigid arginine guanidium group. 
This conformation is probably involved in the weak susceptibility to inhibitors of SHV-72. 
The change of χ1 angle by around -64° moved the Ser130 Oγ atom away from the 
reactive Ser70 Oγ atom. This movement of the Oγ of Ser130, which is the ultimate covalent 
attachment point for the inhibitors, may therefore prevent the cross-link. Such a resistance 
mechanism has been previously proposed for TEM-32, for which the substitution Met69Ile 
induces, by another mechanism, the same movement of Ser130 side chain (χ1 angle -64°) 
(Wang et al., 2002). The effects of substitutions Met69Ile, Ser130Gly and Lys234Arg 
therefore share a common logic for inhibitor resistance. 
The Oγ atom of Ser130 plays a role in the hydrolysis of β-lactams (Lamotte-Brasseur 
et al., 1994). In SHV-72, this role could presumably be disrupted. However, the enzyme did 
not lose its catalytic efficiency. This behavior may be explained by the coexistence of the two 
Ser130 conformers and/or the replacement of Ser130 Oγ atom by a water molecule, as 
observed in the crystal structures of the enzymes deprived of Ser130 such as SHV-10 and 
TEM-76 (Sun et al., 2004; Thomas et al., 2005). 
In conclusion, we report a new SHV-type penicillinase resistant to clavulanic acid. 
The resistance to clavulanic acid is induced by substitution Lys234Arg, which probably 
affects the positioning of Ser130 side chain, a key element of the inhibition reaction mediated 
by clavulanic acid. 
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ABSTRACT 
All 187 K. pneumoniae strains isolated over six consecutive months of 1999 in 17 
Portuguese health institutions were studied: 89% were resistant to ampicillin, 31% to 
trimethoprim-sulphametoxazole, 17% to aminoglycosides and 3% to fluoroquinolones; 16% 
were multidrugresistant and 14% expressed an ESBL phenotype confirmed by genotyping. 
Molecular methods identified 11 strains possessing blaESBL-SHV genes (blaSHV-2A, blaSHV-5, 
blaSHV-12 and blaSHV-55), nine with blaESBL-TEM (blaTEM-3, blaTEM-10 and blaTEM-24) and seven with 
blaGES-1, encoding ESBL enzymes; 160 with blaSHV-1 and blaSHV-type encoding non-ESBL 
enzymes. Overall, we detected 15 new β-lactamases: SHV-60 to SHV-62, SHV-71 and SHV-
73 to SHV-83. The genetic relatedness of 108 isolates was studied by pulsed-field gel 
electrophoresis (PFGE) analysis. The strains were diverse, and 18 clusters were defined, the 
largest including 12 strains of different biological origins, and six of which expressed GES-1 
enzymes. Twenty additional strains isolated during a second period, between March and 
November 2006, in three of the participating hospitals, contained ESBL-encoding genes 
whereas none of the strains isolated in the same hospitals in 1999 carried such genes: 
blaSHV-5, blaSHV-12, blaTEM-10, blaTEM-52, blaCTX-M-15, blaCTX-M-32 and blaCTX-M-61 (firstly described in 
the country). In this period we detected three new enzymes: SHV-106 to SHV-108. We 
provide evidence that the genotypes of K. pneumoniae strains is changing toward the 
emergence of ESBL enzymes. 
 
INTRODUCTION 
SHV β-lactamases are classified in groups 2b and 2be of Bush-Jacoby-Medeiros 
classification scheme and in Ambler class A (Ambler et al., 1991; Bush et al., 1995). These 
enzymes are constitutive of the majority of K. pneumoniae strains. The chromosomal blaSHV-1 
gene encodes resistance to amoxicillin and was believed to be ubiquitous in K. pneumoniae 
(Babini & Livermore, 2000); these genes can be associated with plasmid-borne β-lactamases 
(Paterson & Bonomo, 2005), and if plasmid-mediated the possibility of development of an 
ESBL phenotype increases (Hammond et al., 2008). Co-expression of SHV enzymes and 
ESBL, from TEM, CTX, or other SHV enzyme families is common (Romero et al., 2005). 
ESBLs have a high clinical and epidemiological importance since they lead to therapeutic 
failure and increase hospital costs (Lee et al., 2006a; Peterson, 2008). 
Little is known about the antimicrobial resistance mechanisms of K. pneumoniae in 
Portugal. K. pneumoniae strains are found worldwide associated to pneumonia and urinary 
tract infections in nosocomial and community environments (Bell et al., 2007; Caccamo et al., 
2006; Zhanel et al., 2005). We report phenotypic and genotypic analysis of clinical isolates of 
Chapter V  
 80 
K. pneumoniae of both community and nosocomial origin recovered in various hospitals and 
public health institutions in the country. 
 
MATERIALS AND METHODS 
Setting and bacterial isolates. A total of 187 unduplicated K. pneumoniae strains collected 
consecutively in 17 Portuguese public health institutions (from which 14 were hospitals) in 
three different regions of Portugal (North, Centre and Lisbon and Tagus Valley), over a six-
month period from the first of January of 1999, were sent to the Antibiotic Resistance Unit at 
the NIH in Lisbon. The bacteriology laboratories of these public health institutions are 
participating in a surveillance program with NIH, as contributors to the Antibiotic Resistance 
Surveillance Program in Portugal (ARSIP): one K. pneumoniae isolate and the corresponding 
laboratory records from each patient were sent to NIH. Origin of infection (nosocomial or 
community acquired) was identified according to Centers of Disease Control and Prevention 
criteria (Garner et al., 1996). 
 Twenty K. pneumoniae strains, also collected consecutively, but in a second period, 
between March and November of 2006, in three of the hospitals (North, Centre, and Lisbon 
and Tagus Valley regions), were included as a prospective laboratory surveillance for 
comparison regarding ESBL production.  
Each isolate was identified with the API 20E System. Strains used as control for both 
PCR and IEF were the same as previously (Mendonça et al., 2007). 
 
Antibiotic susceptibility testing. MICs of 23 antibiotics were determined by microdilution 
broth method (MicroScan Panel Sólo 1S, Dade Behring, West Sacramento, California, USA) 
against strains of both periods (187 from 1999 and 20 from 2006). Results were interpreted 
according to CLSI guidelines (2007). An isolate was considered multidrug-resistant if it had 
reduced susceptibility to three or more structurally unrelated antibiotics. For strains producing 
new enzymes and their respective transconjugants, MICs were also determined by an agar 
dilution method, according to the SFM (Cavallo et al., 2007); MICs of amoxicillin, ceftriaxone, 
cefotaxime, ceftazidime and aztreonam were determined alone and combined with a given 
concentration of clavulanic acid (2 µg/ml). The 187 strains were tested by the Etest ESBL 
method using strips with cefotaxime and ceftazidime both alone and associated with 
clavulanate. 
 
IEF. Cell extracts from the 187 isolates were obtained by ultrasound treatment and IEF was 
used to determine the pIs of all β-lactamases as previously (Caniça et al., 1997a). The pI of 
each β-lactamase was compared with those of enzymes produced by control strains. 
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PCR, gene sequencing and transfer of resistance. PCR amplification and sequencing 
was performed for all strains with specific primers to search for and to identify blaTEM, blaOXA, 
blaSHV, blaCTX-M and ampC β-lactamase genes, as previously described (Mendonça et al., 
2007). The primer SHVi (5’-GCT GGT TTA TCG CCG ATA AGA C-3’) was used allowing the 
complete sequence of the blaSHV gene to be determined. Specific primers were design for 
PCR amplification and sequencing of the blaGES gene (GESf, 5’-TTC CAT CTC AAG GGA 
TCA CC-3’ and GESr, 5’-GCG TCA ACT ATT TGT CCG TG-3’). Transference of ESBL 
encoding genes and of new blaSHV resistance genes was tested, as previously (Mendonça et 
al., 2006a). 
 
PFGE. DNA preparation, PFGE and gel analysis for 108 strains from the first period of the 
study were performed as previously (Mendonça et al., 2007). We selected strains for PFGE 
analysis according to the genotype: nine strains expressing ESBL enzymes of the SHV 
family, eight with ESBL enzymes of the TEM family, seven expressing ESBL enzymes of the 
GES family and 84 expressing SHV non-ESBL. The Dice band-based similarity coefficient, 
with a band position tolerance of 1.0% and an optimization of 1.0%, was used for clustering. 
A cutoff value of 80% similarity was determined by the cluster cutoff method according to 
Bionumerics software (Version 3.5; Applied Maths, Sint-Martens-Latem, Belgium). Isolates 
with a Dice band-based similarity coefficient value of >80% were considered to belong to the 
same cluster. 
 
Statistical analysis. Analysis of variance was used to assess the significance of differences 
between various factors (sex, age group, specimen, region, multidrugresistance and local of 
acquired infection) and antibiotics, mostly from different classes (ampicillin, cephalothin, 
ceftazidime, gentamicin, ciprofloxacin and trimethoprim-sulphamethoxazole). Data were 
compared using χ2 or Fisher’s exact tests (SPSS software, version 14). For all tests, P < 0.05 
was considered significant. 
 
Nucleotide sequence accession numbers. The new blaSHV sequences were submitted to 
the EMBL Nucleotide Sequence Database under the accession numbers AJ866283 (blaSHV-
60), AJ866284 (blaSHV-61), AJ866285 (blaSHV-62), AM176546 (blaSHV-71), AM176548 (blaSHV-73), 
AM176549 (blaSHV-74), AM176550 (blaSHV-75), AM176551 (blaSHV-76), AM176552 (blaSHV-77), 
AM176553 (blaSHV-78), AM176554 (blaSHV-79), AM176555 (blaSHV-80), AM176556 (blaSHV-81), 
AM176557 (blaSHV-82), AM176558 (blaSHV-83), AM941847 (blaSHV-106), AM941848 (blaSHV-107) 
and AM941849 (blaSHV-108). 
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RESULTS 
Clinical isolates and patient characteristics. Fifty-six of the 187 strains (from first period of 
the study) (30%) were identified as nosocomial, 57 (30%) were community acquired, and 74 
(40%) were of unknown origin. One-hundred-and-twenty-six strains were isolated from urine 
(67%), 12 from wounds (6%), 18 from blood (10%), seven from sputum (4%), two from 
bronchoalveolar lavage (1%) and five from secretions (3%). Thirteen were from other 
biological samples, and four were of unknown origin. Of the 101 strains isolated from women, 
33 were from patients over 60 years old, while of the 81 strains from men, 27 were from 
patients over 60 years old. 
 
Identification of bla genes. PCR with blaSHV primers identified 187 (100%) isolates carrying 
blaSHV genes among the total strains collected in the first semester of 1999. All of these 
genes were sequenced: 11 possessed blaESBL-SHV genes frequently associated with non-
ESBL genes (including five blaSHV-2A of which four were associated with blaTEM genes, one 
blaSHV-5 plus blaSHV-12 and five blaSHV-55 of which one was associated with blaTEM), nine blaESBL-
TEM (blaTEM-3, blaTEM-10, blaTEM-24 all associated with non-ESBL bla genes), seven blaGES-1 
(associated with non-ESBL bla genes) and 160 non-ESBL blaSHV genes associated or not 
with blaTEM or blaOXA genes (Table 5.1).  
Strains isolated in a hospital (North region) in 2006 possessed genes encoding ESBL 
enzymes including blaSHV-12, blaTEM-52 and blaCTX-M-32; isolates from another hospital (Centre 
region) had blaSHV-5, blaTEM-10 and blaCTX-M-15; and isolates from a third hospital (Lisbon and 
the Tagus Valley) carried blaSHV-12, blaCTX-M-15 and blaCTX-M-61 genes (Table 5.2). 
 
Antibiotic susceptibility. Twenty-seven strains were ESBL producers (14%). All ESBL-
producing strains were resistant to ampicillin, ticarcillin, piperacillin and cefazolin; 30% had 
intermediate resistance to amoxicillin-clavulanate and 48% to piperacillin-tazobactam 
combinations; 7% were resistant to cefotaxime and 78% to ceftazidime. For other antibiotic 
families, 74% of the ESBL-producing strains were resistant to gentamicin and 89% to 
trimethoprim-sulphametoxazole (Table 5.3). For the β-lactam family, 88% of non-ESBL 
producers were resistant to ampicillin and 0.6% to amoxicillin-clavulanate (Table 5.3). All 
non-ESBL producers were susceptible to third generation cephalosporins. 
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Twenty-one % of the strains were resistant to trimethoprim-sulphametoxazole, 7% to 
gentamicin and 3% to the fluoroquinolones tested (Table 5.3). The only class of β-lactams to 
which all strains were susceptible was to carbapenems. Overall, 30 strains (16%) were 
multidrug resistant.  
The percentage of isolates susceptible to different antibiotics (ampicillin, cephalothin, 
ceftazidime, gentamicin, trimethoprim-sulphametoxazole and ciprofloxacin) did not differ 
according to sex, age, specimen from which strains were isolated, region, or type of infection 
(community- or hospital-acquired) (data not shown). 
 
Table 5.2 - Phenotypes and genotypes identified in 20 strains isolated in three hospitals (C, G, L), 
during a second period of the study (for comparison of ESBL production) 
Hospital code 
(region)a,b 
β-Lactamase Antimicrobial resistance patternc No. of 
strains 
Total
C SHV-11 + TEM-52 AMP AZT CTX CPD CAZ CXM CFZ PIP 
TIC CIP GEN TOB SXT 
1 10 
(Nr) SHV-106 + CTX-M-
32 
AMP AZT CTX CPD CAZ CXM CFZ CPE 
PIP TIC GEN TOB SXT 
1  
 SHV-106 + TEM-1 AMP CTX CPD CXM CFZ PIP TIC GEN 
TOB SXT 
1  
 SHV-1 + CTX-M-32 AMP AZT CTX CPD CXM CFZ CPE PIP 
TIC 
1  
 SHV-12 AMP AZT (CTX) CPD (CAZ) (CXM) CFZ 
(CPE) PIP TIC CIP (GEN) (TOB) SXT 
5  
 SHV-106 AMP CPD CFZ PIP TIC GEN TOB SXT 1  
     
G SHV-108 + TEM-10 
+ CTX-M-15 
AMP AZT CPD CAZ CFZ CPE PIP TIC 
GEN TOB 
1 5 
(Cn) SHV-5 AMP AZT CPD CAZ CFZ PIP TIC GEN 
TOB SXT 
1  
 SHV-5 + TEM-1 + 
CTX-M-15 
AMP AZT CPD CAZ CFZ PIP TIC TOB SXT 1  
 SHV-1 + TEM-10 + 
CTX-M-15 
AMP AZT CPD CAZ PIP TIC GEN TOB 1  
 SHV-107 AMP CPD CAZ CXM CFZ PIP TIC 1  
     
L SHV-1 + TEM-1 + 
CTX-M-15 + OXAd 
AMP AZT CTX CPD CXM CFZ CPE PIP 
TIC GEN TOB SXT 
1 5 
(LTv) SHV-1 + CTX-M-15 
+ OXAd 
AMP AZT CTX CPD CAZ CXM CFZ 
CPE PIP TIC GEN TOB SXT 
1  
 SHV-11 + CTX-M-
61 
AMP AZT CTX CPD CXM CFZ CPE PIP 
TIC CIP GEN TOB SXT 
2  
 SHV-12 + TEM-1 AMP AZT CPD CAZ CXM CFZ PIP 
TIC CIP GEN TOB SXT 
1   
a All hospitals were general hospitals (same hospital codes of Table 5.1). 
b Cn, Centre region; LTv, Lisbon and Tagus Valley region; Nr, North region. 
c AMP, ampicillin; AZT, aztreonam; CTX, cefotaxime; CPD, cefpodoxime; CAZ, ceftazidime; CXM, cefuroxime; CFZ, cefazolin; 
CPE, cefepime; PIP, piperacillin; TIC, ticarcillin; CIP, ciprofloxacin; GEN, gentamicin; TOB, tobramycin; SXT, trimethoprim-
sulfamethoxazole. 
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Strains producing new SHV β-lactamases. Fifteen strains expressing new β-lactamases 
identified during the first period of the study presented resistance to amoxicillin, and some 
presented resistance to the combination amoxicillin plus clavulanic acid (INSRA1234, 
INSRA1677 and INSRA2500) (Table 5.4). Only two of these strains (INSRA3530 and 
INSRA1234) expressed another β-lactamase (TEM), which was detected either by PCR or 
IEF. None of the new β-lactamases were classified as ESBL either by agar dilution or Etest 
analysis. Three strains of the second period of the study expressed new enzymes: SHV-106 
and SHV-107, both identified as probable ESBL, and SHV-108, which was not possible to 
clarify the corresponding phenotype (because it was associated to TEM-10 and CTX-M-15 
enzymes). The non-synonymous nucleotide mutations and aminoacid substitutions in the 
new blaSHV genes are reported in Table 5.5. 
 
Transfer of antibiotic resistance. Overall, it was possible to transfer ESBL encoding genes 
in 59% of all ESBL K. pneumoniae-producing strains (Table 5.1). Only one of the 18 clinical 
isolates producing new SHV enzymes gave a transconjugant. This transconjugant (E. coli 
C600-INSRA577) carried the blaSHV-60 gene, which presented antibiotic susceptibility 
phenotype similar to that of the clinical strain (K. pneumoniae INSRA577) (Table 5.4).  
 
Clonality of K. pneumoniae strains. PFGE analysis was used to establish the genetic 
relatedness of 108 of the K. pneumoniae strains producing four different types of β-
lactamases (see material and methods). Sixty-five PFGE profile types were identified; 47 
included only a single isolate (non-clustered) genetically unrelated to other isolates in the 
study. The remaining 18 profile types, defined clusters I to XVIII, included two or more 
isolates that were genetically related (with >80% similarity) or indistinguishable (with 100% 
identity) (Table 5.1). The largest cluster XIV (include profile type 0053) consisted of 12 
strains producing mainly SHV β-lactamases, co-expressed with GES-1 in six cases; these 
strains were of different biological origins, isolated in two hospitals in Lisbon and the Tagus 
Valley region and one in the North region. The second largest cluster XV (include profile type 
0054) consisted of only strains collected from urine (n=7); all expressed SHV-28 and most 
(n=4) co-expressed TEM-10 enzymes; six were isolated in one hospital in the Centre region. 
(Table 5.1). Strains with multidrugresistance were detected in eight clusters (II, III, VIII, IX, 
XII, XIII, XIV XV) and in two unique profiles types with a single clone (profile type 0055, 
0058). 
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DISCUSSION 
We conducted this study because there was little available information about 
antimicrobial susceptibility and resistance mechanisms of K. pneumoniae isolates in Portugal 
and this pathogen remain one of the major ESBL producing strains worldwide (Pitout & 
Laupland, 2008). In addition, an increase of hospital costs is associated to ESBL-producing 
K. pneumoniae (Lee et al., 2006a). We studied the phenotype and genotype of 187 clinical K. 
pneumoniae strains responsible for community and hospital-acquired infections and isolated 
between January and June of 1999 in 14 Portuguese hospitals and three other public health 
institutions (representing three of the five regions of mainland Portugal).  
K. pneumoniae isolates are expected to present an intrinsic resistance to ampicillin 
(Heritage et al., 1999), but only 95% (178/187) of all our strains showed reduced 
susceptibility and 89% resistance to this antibiotic. Indeed, similar resistance have been 
reported for the same year elsewhere in Europe (84%) (Kahlmeter, 2003). 
ESBL production was detected in 14% of the strains: this is a lower prevalence than 
reported for 1999 in paediatrics centres in France (32%) (Raymond et al., 2007), in an Italian 
survey (20%) and in the Asia-Western Pacific region (18%) (Luzzaro et al., 2006; Turnidge et 
al., 2002); it is however higher than the 9% observed for North America (Sader et al., 2005); 
13% of our isolates from patients with urinary tract infections were ESBL-producing strains 
(data not shown), and the corresponding figures are 27%, 2% and 19% for Latin America, 
United States and Italy, respectively (Caccamo et al., 2006; Turnidge et al., 2002). None of 
our isolates from blood expressed ESBL, and this is contrary to findings in other countries 
(Tumbarello et al., 2006). The differences in the prevalence of ESBL production between 
isolates in Portugal and elsewhere may be due to the more extensive use of other antibiotic 
families (penicillins, quinolones and macrolides) rather than third generation cephalosporins 
in Portugal (Goossens et al., 2005). 
Only 3% of the strains presented resistance to fluoroquinolones, but resistance to 
aminoglycosides and trimethoprim-sulphametoxazole was more widespread (19% and 30%, 
respectively). K. pneumoniae isolates resistant to these antibiotics are less common (1%, 0% 
and 12%, respectively) elsewhere in Europe (Kahlmeter, 2003). A multi-continental study 
reported similar resistance to aminoglycosides (13%) and to fluoroquinolones (8%) 
(Deshpande et al., 2006). 
 Overall, of the 187 strains studied in six months of 1999, 27 possessed blaESBL genes. 
We identified nine strains which had blaESBL-TEM genes including the blaTEM-10 gene, the most 
prevalent within this group (five strains, 56%). In our survey, the blaTEM-10 gene was present 
in two of 17 public health institutions in the Centre and Lisbon and Tagus Valley regions, one 
of which was previously associated to an endemic TEM-10 enzyme produced by K. 
pneumoniae strains, identified during a survey in 1995 and 1996 (Barroso et al., 2000).
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The blaGES-1 gene, encoding an ESBL enzyme, was detected in three hospitals in two 
different regions (North and Lisbon and Tagus Valley); the blaGES-1 gene has already been 
found in one hospital in the Lisbon and Tagus Valley region (Duarte et al., 2003).  
We document substantial genetic heterogeneity among K. pneumoniae strains 
collected in different regions in the same period of 1999. No epidemic strains could be 
defined, and this contrasts with the situation for E. coli for which a survey after 2004 including 
the same regions identified the presence of a CTX-M-15, OXA-30 and TEM-1 producing 
clone (Mendonça et al., 2007). In the major profile type (0053) in our collection 12 of the 108 
(11%) strains shared 80% similarity, and all 12 were isolated in three hospitals. 
Of the strains isolated in three hospitals in the second period of the study (year 2006), 
45% expressed CTX-M enzymes in contrast with only non-ESBL present in 1999 isolates; 
this confirms the emergence of this family of β-lactamases in K. pneumoniae in Portugal as 
in other countries (Cantón & Coque, 2006; Livermore et al., 2007). Romero et al (2005) also 
did not detect any CTX-M enzymes in 1999, but 33% of strains isolated in 2002 carried these 
genes. In Italy, in 2003, only 12% of K. pneumoniae strains presented CTX-M enzymes 
(Mugnaioli et al., 2006), and between 1998 and 2003, the SENTRY program in the Asia-
Pacific region, reported that 25% of strains possessed CTX-M enzymes (Bell et al., 2007). 
Emergence of this type has previously been observed in Portugal for E. coli and other 
Enterobacteriaceae strains (Machado et al., 2007; Mendonça et al., 2007). 
This work documents the substantial diversity of β-lactamases produced by K. 
pneumoniae and identified several new β-lactamases. Among the 160 strains producing SHV 
non-ESBL enzymes in the first period, we identified 15 new blaSHV genes. The importance of 
ESBL as a serious clinical problem for treat patients with K. pneumoniae expressing these 
resistance determinants is of concern; however, the clinical importance of the non-ESBL 
enzymes is yet to be revealed (Paterson & Bonomo, 2005; Heritage et al., 1999). A similar 
nationwide survey with a population based may elucidate the real emergence of other β-
lactamases produced nowadays by K. pneumoniae strains in this country, as we show that 
CTX-M β-lactamases added to the list look to predominate. 
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ABSTRACT 
Of the 308 clinical K. pneumoniae strains collected in 21 Portuguese health 
institutions, eleven encoded for LEN and nine for OKP enzymes; of these, fifteen were new 
enzymes. Ninety-one % of LEN and all OKP producer strains were resistant to amoxicillin. 
We demonstrate that these β-lactamase producers were highly diverse. 
 
TEXT 
K. pneumoniae strains are responsible for pneumonia and urinary tract infections, 
both in community and hospital environments (Gonzalez-Vertiz et al., 2001; Goossens et al., 
2005; Karlowsky et al., 2001), and can be classified into three clusters according to the 
intrinsic beta-lactamases they express. More than 80% of strains belong to group KpI, which 
express SHV enzymes, while groups KpII and KpIII each account for 10% of the population 
and express OKP and LEN enzymes, respectively (Brisse & Verhoef, 2001; Hæggman et al., 
2004). Until now co-expression of LEN and OKP enzymes and ESBLs, from the TEM, CTX 
and SHV families, is rarely described (Romero et al., 2005). The aim of this study was to 
identify and characterize strains expressing OKP and LEN enzymes among clinical K. 
pneumoniae isolates and to understand their distribution in Portugal. 
A total of 308 K. pneumoniae strains isolated from patients, were collected in 21 
health institutions in three different regions of Portugal (North, Centre and Lisbon and Tagus 
Valley), between August 1998 and October 1999 and between May 2004 and May 2005, and 
sent to the Antibiotic Resistance Unit at the NIH in Lisbon. The bacteriology laboratories of 
these hospitals are participating in a surveillance program with the NIH, as contributors to the 
ARSIP: they send one K. pneumoniae isolate from each patient and corresponding 
laboratory records. 
The detection and identification of LEN and OKP enzymes produced by 20 of 308 K. 
pneumoniae strains were performed by PCR and sequencing. E. coli R111 (TEM-1, pI 5.4; 
blaTEM-1 plus ampC), S. enterica serovar Typhimurium (OXA-1, pI 7.4; blaOXA-1), E. coli C600 
(SHV-1, pI 7.6; blaSHV-1) and E. coli UA1526 (CTX-M-15, pI 8.9; blaCTX-M-15) were used as 
control strains for PCR. The blaLEN and blaOKP genes were identified and sequenced with 
blaSHV primers, as previously described (Mendonça et al., 2007). The primer SHVi (5’-
GCTGGTTTATCGCCGATAAGAC-3’) was used allowing the complete sequence of the 
blaLEN and blaOKP genes to be determined. Transference of β-lactam resistance genes was 
tested for all strains presenting new blaOKP and blaLEN genes, as previously described 
(Mendonça et al., 2006a). 
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MICs of non-β-lactam antibiotics (ciprofloxacin, norfloxacin, ofloxacin, amikacin, 
gentamycin, tobramycin, trimethoprim-sulphamethoxazole) were evaluated by a microdilution 
broth method (MicroScan Panel Sólo 1S) against LEN and OKP producer strains. Results of 
the susceptibility testing were interpreted according to CLSI guidelines (2007). MICs of β-
lactam antibiotics (amoxicillin, piperacillin, cephalothin, cefuroxime, cefotaxime, ceftazidime 
and cefoxitin) were determined by an agar dilution method, according to the SFM (Cavallo et 
al., 2007). MICs of amoxicillin, cefotaxime and ceftazidime were also determined in 
combination with 2 µg/mL of clavulanic acid. All strains were tested by the Etest ESBL 
method using strips with cefotaxime and ceftazidime both alone and associated with 
clavulanate. 
Cell extracts from the 20 isolates were obtained by ultrasound treatment and IEF was 
used to determine the pIs of β-lactamases as previously described (Caniça et al., 1997a). 
The pIs were compared with those of enzymes produced by the following control strains: E. 
coli R57b (OXA-3, pI 7.1), E. coli pMG48 (OXA-2, pI 7.7), E. coli INSRA5776 (CTX-M-14, pI 
8.1); and those strains also used as control for PCR. PFGE was used to establish the genetic 
relatedness of all K. pneumoniae strains, as previously described (Mendonça et al., 2007).  
The majority of the 20 K. pneumoniae isolates were from women (60%), patients over 
60 years-old (40%) and from urinary tract (70%). Overall, OKP producing strains (n=9) were 
resistant to amoxicillin, while only 11% were resistant to amoxicillin plus clavulanic acid 
combination and 11% were non-susceptible to both piperacillin and cephalothin (Table 6.1). 
Intermediate level of resistance for cefuroxime and cefoxitin was detected in 22% of the 
OKP-producing strains. LEN-producing strains presented lower resistance values to 
amoxicillin and piperacillin (91% and 9%, respectively), but showed 9% resistance to 
amoxicillin plus clavulanic acid combination (Table 6.1). No synergy with ceftazidime and the 
β-lactamase inhibitor was detected for either group, indicating that all strains were non-ESBL 
producers (Table 6.1); the Etest was negative confirming those results. All strains were 
susceptible to trimethoprim-sulphametoxazole, aminoglycosides and fluoroquinolones. The 
phenotypes of strains producing OKP and LEN enzymes were similar to the previously 
described for these types of β-lactamases (Fèvre et al., 2005; Hæggman et al., 2004). 
IEF method identified that LEN β-lactamases had pIs between 7.3 and 7.6, and OKP β-
lactamases between 7.0 and 7.8 (Table 6.1). PCR and sequencing identified 11 blaLEN 
genes, seven of which were firstly describe here (LEN-18 to LEN-24) (Table 6.2); eight new 
blaOKP genes were also identified: two coding to OKP-A enzymes (OKP-A-11 and OKP-A-12) 
and six coding to OKP-B enzymes (OKP-B-15 to OKP-B-20), according to the classification 
established by Fèvre et al. (Fèvre et al., 2005) (Table 6.3). 
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The substitutions Asp88Val in LEN-21, Ile115Val in LEN-18, LEN-19 and LEN-20, 
Ala264Val in LEN-20 and Thr14Asn in LEN-24 were firstly described in this study. As in 
previous studies, we did not observe co-expression of SHV and LEN or OKP enzymes 
(Hæggman et al., 2004; Remeli et al., 2007; Siebor, et al., 2005). Transfer experiments failed 
to produce transconjugants containing LEN or OKP enzymes, which may imply that the 
genes encoding for these β-lactamases are present in the chromosome or in non-
transferable plasmids. 
 According to the PFGE analysis, all K. pneumoniae isolates were genetically diverse, 
presenting 18 different profile types. Only two clusters grouped isolates from the same 
hospital: cluster I included two strains from the North region producing LEN-20 enzymes and 
cluster II included two strains from the Center region, one producing an OKP-B-17 enzyme 
and another producing an OKP-B-18 enzyme (Table 6.1).  
 
Table 6.2 - Amino acid substitutions in the seven new LEN enzymes identified by 
sequencing in K. pneumoniae strains of Portuguese origin 
Nucleotide a (aminoacid)b at position no. 
Gene 41 
(14) 
58 
(20)
250 
(84) 
263 
(88) 
328
(110)
329
(110)
343
(115)
589
(197)
667
(223)
769
(257)
791
(264)
Accession 
no. 
blaLEN-2 
C 
(Thr) 
G 
(Asp)
S 
(Val) 
A 
(Asp) 
G 
(Val)
T 
(Val)
A 
(Ile)
G 
(Ala)
C 
(Pro)
C 
(Ile)
C 
(Ala)
AY037780 
blaLEN-18   
G 
(Leu) 
 
A 
(Thr)
C 
(Thr)
G 
(Val)
  
A 
(Leu)
 AM850908 
blaLEN-19  
T 
(Tyr)
G 
(Leu) 
 
A 
(Thr)
C 
(Thr)
G 
(Val)
    AM850909 
blaLEN-20   
G 
(Leu) 
 
A 
(Thr)
C 
(Thr)
G 
(Val)
   
T 
(Val)
AM850910 
blaLEN-21    
T 
(Val) 
    
G 
(Ala)
  AM850911 
blaLEN-22        
C 
(Pro)
G 
(Ala)
  AM850912 
blaLEN-23  
T 
(Tyr)
G 
(Leu) 
 
A 
(Thr)
C 
(Thr)
   
A 
(Leu)
 AM850913 
blaLEN-24 
A 
(Asn) 
 
G 
(Leu) 
        AM850914 
a Numbering is according to Sutcliffe (Sutcliffe, 1978). 
b Numbering is according to Ambler (Ambler et al., 1991). 
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There are few studies about LEN and OKP enzymes. This work describes the 
phenotypic and genetic characterization of strains expressing OKP and LEN enzymes 
produced by clinical K. pneumoniae isolated in Portugal, among which 15 were new β-
lactamases.  
 
Nucleotide sequence accession number. The new blaLEN and blaOKP sequences were 
submitted to the EMBL Nucleotide Sequence Database under the accession numbers 
AM850908 (blaLEN-18), AM850909 (blaLEN-19), AM850910 (blaLEN-20), AM850911 (blaLEN-21), 
AM850912 (blaLEN-22), AM850913 (blaLEN-23), AM850914 (blaLEN-24), AM850915 (blaOKP-A-11), 
AM850916 (blaOKP-A-12), AM850917 (blaOKP-B-15), AM850918 (blaOKP-B-16), AM850919 (blaOKP-B-
17), AM850920 (blaOKP-B-18), AM850921 (blaOKP-B-19), and AM850922 (blaOKP-B-20). 
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ABSTRACT 
The diversity of blaSHV genes based on nucleotide synonymous mutations and the 
presence or absence of the nonsynonymous mutation T92A was investigated; these 
mutations may result in different nucleotide sequences, designated here as sequence 
frameworks. We considered blaSHV gene sequences determined at the National Institute of 
Health in Lisbon and others from various bacterial species in the Genbank database. The 
totality of the gene coding region was used to align all the sequences. Eighty-three different 
blaSHV gene sequence frameworks were detected based on the combination of synonymous 
nucleotide mutations at 39 different positions and the non-synonymous mutation T92A, which 
results in amino acid substitution Leu35Gln and allows to differentiate SHV-11 from SHV-1. 
Synonymous nucleotide mutations A402G, G705A and C786G, were the most frequent. 
Among the 297 blaSHV genes studied, 61 were identified as blaSHV-11 presenting 20 different 
nucleotide sequence frameworks and 59 were blaSHV-1 with 18 nucleotide sequence 
frameworks. The complex molecular diversity of blaSHV genes impelled us to propose a 
classification, based on the name of the blaSHV gene, the parental origin (blaSHV-1 or blaSHV-11) 
and the number of the variant (the last being v83). 
 
INTRODUCTION 
β-Lactamases are an important cause of resistance to β-lactam antibiotics. The SHV 
enzymes are distributed worldwide (Livermore, 1995; Bradford, 2001). SHV-1 is the most 
prevalent β-lactamase in K. pneumoniae, but it is also present as a plasmid-borne gene in 
various other species (Livermore, 1995). Non-synonymous nucleotide substitutions of the 
parental blaSHV-1 gene led to the emergence of ESBL enzymes, which are responsible for 
higher levels of resistance to extended-spectrum cephalosporins (Paterson & Bonomo, 
2005). Until now, 112 SHV enzymes have been identified but several of them do not code for 
ESBL enzymes (http://www.lahey.org/studies/). In addition, synonymous nucleotide 
substitutions and the presence or absence of the synonymous mutation T92A are found in 
blaSHV genes, resulting in different nucleotide sequences, which we designated here as 
sequence frameworks, even for genes coding for the same enzyme. Like the parental blaTEM-
1 and blaTEM-2 genes, which differ by one point mutation responsible for the Gln39Lys amino 
acid substitution, the blaSHV-1 and blaSHV-11 genes differ by one non-synonymous mutation 
corresponding to the Leu35Gln substitution (Nüesch-Inderbinen et al., 1997). 
The aim of this study was to analyse the diversity of nucleotide sequences of 297 
SHV-encoding genes. The analysis of this diversity allowed us to develop and propose a 
classification to differentiate the various blaSHV gene sequence frameworks. 
Chapter VII  
 104 
 
MATERIAL AND METHODS 
Computer analysis of DNA and amino acid sequences. The sequences of 215 blaSHV 
genes, previously determined in the Antibiotic Resistance Unit at the NIH, were investigated 
(unpublished results) (Mendonça et al., 2006a); 82 other blaSHV gene sequences, not 
detected in that collection, were downloaded manually from the NCBI GenBank database 
(Table 7.1) or retrieved from scientific publications. BioNumerics software was used for 
sequence entry and manipulation for all sequences. The blaSHV-1 gene sequence, as found in 
the Genbank database (accession number AF148850), was used as reference for the 
development of the framework classification. A nucleotide sequence of 861 bp from each 
blaSHV gene analysed in this study (beginning at nucleotide 1 of the coding region, according 
to numbering of Sutcliffe), was used for sequence alignments (Sutcliffe, 1978). Numbering 
system of Ambler was also used with regards to amino acid positions (Ambler et al., 1991). 
 
RESULTS AND DISCUSSION 
Using the sequence of the blaSHV-1 gene submitted in 1999 to GenBank (accession 
number AF148850) as reference, the characterization of the diversity of the 297 blaSHV genes 
studied, permitted the identification of 83 different blaSHV gene sequence frameworks (Table 
7.2). These frameworks resulted from the combination of both synonymous nucleotide 
mutations at 39 different nucleotide positions and the T92A non-synonymous mutation. 
Among the synonymous variations, three appeared to be more frequent: A402G (90%), 
G705A (60%) and C786G (66%) (Table 7.2). Ten years ago, other authors reported that 59% 
of 34 blaSHV genes had synonymous mutation A402G and 9% G705A (Nüesch-Inderbinen et 
al., 1997). Among the 83 blaSHV gene sequence frameworks that we identified, 45 were based 
on the parental gene blaSHV-1, characterized by a T residue at position 92 resulting in amino 
acid Leu at position 35, while 38 were based on the blaSHV-11 gene with the non-synonymous 
mutation T92A encoding amino acid substitution Leu35Gln. 
The high diversity of the blaSHV gene family compelled us to define a classification 
based on the following principle: for gene blaSHV-X-1v or -11v (1 to 83), X is the gene number that 
has already been attributed to the blaSHV gene and corresponding enzyme 
(http://www.lahey.org/studies); 1 or 11 indicates that this gene derived from either blaSHV-1 or 
blaSHV-11 parental genes; the number attributed to “v” indicates the framework variant 
according to the order of appearance in GenBank and literature (from 1 to 83, until now).  
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Table 7.1 - blaSHV genes used in this study (n=101) as described in the NCBI databasea 
blaSHV genes Accession No. (year) ESBLb Organism blaSHV genes Accession No. (year) ESBLb Organism 
blaSHV-1 AF148850 (1999) - E. coli blaSHV-46 AY210887 (2003) + K. oxytoca 
blaSHV-1 X98100 (1997) - K. pneumoniae blaSHV-48 AY263404 (2003) - K. pneumoniae 
blaSHV-1 X98099 (1997) - K. pneumoniae blaSHV-49 AY528718 (2004) - K. pneumoniae 
blaSHV-1 X98098 (1997) - K. pneumoniae blaSHV-50 AY288915 (2003) - K. pneumoniae 
blaSHV-1 AF462396 (2002) - Acinetobacter spp blaSHV-51 AY289548 (2003) - K. pneumoniae 
blaSHV-2 AF282921 (2001) + Shigella flexneri blaSHV-53 AY590467 (2004) - K. pneumoniae 
blaSHV-2a AF462393 (2002) + K. pneumoniae blaSHV-55 AJ863560 (2004) + K. pneumoniae 
blaSHV-2a L47119 (1990) + Salmonella spp blaSHV-56 AY352599 (2003) - A.baumannii 
blaSHV-2a X98102 (1997) + K. pneumoniae blaSHV-57 AY223863 (2003) - E. coli 
blaSHV-5 AF550679 (2007) + E. coli blaSHV-59 AY790341 (2004) - K. pneumoniae 
blaSHV-5 AF462394 (2002) + E. coli blaSHV-60 AJ866283 (2004) - K. pneumoniae 
blaSHV-5 X98103 (1997) + K. pneumoniae blaSHV-61 AJ866284 (2004) - K. pneumoniae 
blaSHV-6 Y11069 (1997) - K. pneumoniae blaSHV-62 AJ866285 (2004) - K. pneumoniae 
blaSHV-7 U20270 (1995) + E. coli blaSHV-63 EU342351 (2007) - K. pneumoniae 
blaSHV-8 U92041 (1997) + E. coli blaSHV-64 DQ174304 (2005) + K. pneumoniae 
blaSHV-9 S82452 (1996) + K. pneumoniae blaSHV-65 DQ174305 (2005) + K. pneumoniae 
blaSHV-11 Y18299 (1999) - Shigella dysenteriae blaSHV-66 DQ174306 (2005) + K. pneumoniae 
blaSHV-11 X98101 (1997) - K. pneumoniae blaSHV-67 DQ174307 (2005) + K. pneumoniae 
blaSHV-11 AY293069 (2003) - E. coli blaSHV-69 DQ166779 (2005) + K. pneumoniae 
blaSHV-12 AY293070 (2003) + E. coli blaSHV-69 DQ174308 (2005) + K. pneumoniae 
blaSHV-13 AF164577 (2000) + K. pneumoniae blaSHV-70 DQ013287 (2005) + E. cloacae 
blaSHV-14 AF226622 (2001) - K. pneumoniae blaSHV-71 AM176546 (2005) - K. pneumoniae 
blaSHV-15 AJ011428 (2001) + E. coli blaSHV-72 AM176547 (2005) - K. pneumoniae 
blaSHV-16 AF072684 (2001) - K. pneumoniae blaSHV-73 AM176548 (2005) - K. pneumoniae 
blaSHV-18 AF132290 (2000) + K. pneumoniae blaSHV-74 AM176549 (2005) - K. pneumoniae 
blaSHV-19 AF117743 (2001) - K. pneumoniae blaSHV-75 AM176550 (2005) - K. pneumoniae 
blaSHV-20 AF117744 (2001) + K. pneumoniae blaSHV-76 AM176551 (2005) - K. pneumoniae 
blaSHV-21 AF117745 (2001) + K. pneumoniae blaSHV-77 AM176552 (2005) - K. pneumoniae 
blaSHV-22 AF117746 (2001) + K. pneumoniae blaSHV-78 AM176553 (2005) - K. pneumoniae 
blaSHV-24 AB023477 (1999) + E. coli blaSHV-79 AM176554 (2005) - K. pneumoniae 
blaSHV-25 AF208796 (2001) - K. pneumoniae blaSHV-80 AM176555 (2005) - K. pneumoniae 
blaSHV-26 AF227204 (2001) - K. pneumoniae blaSHV-81 AM176556 (2005) - K. pneumoniae 
blaSHV-27 AF293345 (2001) - K. pneumoniae blaSHV-82 AM176557 (2005) - K. pneumoniae 
blaSHV-28 AF299299 (2000) - K. pneumoniae blaSHV-83 AM176558 (2005) - K. pneumoniae 
blaSHV-28 AF538324 (2002) - K. pneumoniae blaSHV-85 DQ322460 (2005) - K. pneumoniae 
blaSHV-29 AF301532 (2000) - K. pneumoniae blaSHV-86 DQ328802 (2005) + K. pneumoniae 
blaSHV-30 AY661885 (2004) + E. cloacae blaSHV-89 DQ193536 (2005) + K. pneumoniae 
blaSHV-31 AY277255 (2003) - K. pneumoniae blaSHV-92 DQ836922 (2006) - K. pneumoniae 
blaSHV-32 AY037778 (2001) - K. pneumoniae blaSHV-93 EF373969 (2007) - K. pneumoniae 
blaSHV-33 AY037779 (2001) - K. pneumoniae blaSHV-94 EF373970 (2007) - K. pneumoniae 
blaSHV-34 AY036620 (2001) + E. coli blaSHV-95 EF373972 (2007) - Citrobacter freundii
blaSHV-35 AY070258 (2002) - K. pneumoniae blaSHV-96 EF373971 (2007) - A. baumannii 
blaSHV-36 AF467947 (2002) - K. pneumoniae blaSHV-97 EF373973 (2007) + 
Enterococcus 
faecalis 
blaSHV-37 AF467948  (2002) - K. pneumoniae blaSHV-101 EU155018 (2007) - K. pneumoniae 
blaSHV-38 AY079099 (2003) - K. pneumoniae blaSHV-102 EU024485 (2007) + E. coli 
blaSHV-40 AF535128 (2002) - K. pneumoniae blaSHV-103 EU032604 (2007) - K. pneumoniae 
blaSHV-41 AF535129 (2002) - K. pneumoniae blaSHV-104 EU274581 (2007) + K. pneumoniae 
blaSHV-42 AF535130 (2002) - K. pneumoniae blaSHV-106 AM941847 (2008) + K. pneumoniae 
blaSHV-43 AY065991 (2003) - K. pneumoniae blaSHV-107 AM941848 (2008) - K. pneumoniae 
blaSHV-44 AY259119 (2003) - K. pneumoniae blaSHV-108 AM941849 (2008) - K. pneumoniae 
blaSHV-45 AF547625 (2002) - K. pneumoniae     
aGene sequences unpublished and unsubmitted to GenBank database (and consequently, not included in this study): blaSHV-4, 
blaSHV-10, blaSHV-23, blaSHV-39, blaSHV-47, blaSHV-52, blaSHV-54, blaSHV-58, blaSHV-68, blaSHV-84, blaSHV-87, blaSHV-88, blaSHV-90, blaSHV-91, blaSHV-
98, blaSHV-99, blaSHV-100, blaSHV-105; the blaSHV-17 gene was not included because it was withdrawn from the site 
http://www.lahey.org/studies/webt.htm. Despite being unsubmitted the blaSHV-3 gene sequence was included in the study as it 
has been published (Nicolas et al., 1989). 
bESBL genotype based on the presence of non-synonymous mutations at nucleotide positions 700 and 703 and/or based on 
previous descriptions 
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This codification is both flexible and open-ended, and allows naming of all 
frameworks of the blaSHV genes. The proposed classification may appear in the SHV enzyme 
designation (ex: blaSHV-76-11v46 which encodes SHV-76-11v46). 
A comparable system, based on blaTEM genes, proposed by Leflon-Guidout et al. 
(Leflon-Guibout et al., 2000a) after that of Caniça et al. (Caniça et al., 1997b), and currently 
used, as far as we are aware has no more than seven different gene sequence frameworks 
(from “a” to “g”), due to variants of nucleotides at seven positions (Leflon-Guibout et al., 
2000a; Pomba-Féria & Caniça, 2003). In a previous study Ford & Avison (2004), named 
different gene sequence frameworks “v1” to “v4” following the name of the blaSHV gene (ex: 
blaSHV-1v4). We believe that our classification tends to be more complete. 
 When the gene sequence frameworks and the non-synonymous mutations other than 
T92A were considered, we observed that among the 297 blaSHV gene sequences 61% 
derived from blaSHV-1 and 39% derived from blaSHV-11 gene; the two most represented genes 
were blaSHV-11 and blaSHV-1 (each with 20%), with 20 and 18 gene sequence frameworks, 
respectively. Lee et al studied 142 blaSHV genes and reported 62% blaSHV-11 genes and 35% 
blaSHV-1 (Lee et al., 2006b). The 297 blaSHV gene sequences comprised 135 different blaSHV 
genes encoding 36 ESBL and 99 non-ESBL enzymes. Among the ESBL encoding genes, we 
identified 22 (61%) with the blaSHV-1 gene sequence framework and 14 (39%) with the blaSHV-
11 gene sequence framework. Among the non-ESBL encoding genes, 56 (57%) presented 
the blaSHV-1 gene sequence framework and 43 (43%) the blaSHV-11 gene sequence framework. 
Here, we established a classification for the blaSHV gene family by taking into 
consideration the great variety of the gene sequence frameworks displayed by the available 
blaSHV genes. This study helps document the diversity of blaSHV genes, thereby contributing to 
a future understanding of the evolution of blaSHV family, and especially bla genes encoding 
ESBL enzymes. 
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TEXT 
Currently, CTX-M-type enzymes are the most common group of extended-spectrum 
beta-lactamases (ESBLs) not belonging to the TEM and SHV families (Livermore & Hawkey, 
2005). 
Here, we report the first phenotypic and molecular characterization of Portuguese E. 
coli strains harbouring CTX-M-15. Both strains were isolated in 2004. One strain 
(INSRA5753), isolated at Hospital Garcia de Orta in Lisbon, was from the urine of a 78-year-
old woman who was living in a residential care home, using a catheter. The other strain 
(INSRA5754) was isolated from the blood of a 90-year-old woman 1 day after of 
hospitalization in Vila Real. These two hospitals are about 400 km apart. The strains were 
detected as ESBL-producers in the hospitals, using the VITEK 1 system and ATB G-5, 
respectively. 
In the Antibiotic Resistance Unit, at the NIH in Lisbon, β-lactamase production was 
confirmed using the Etest ESBL screen method. Using PCR, fragments indicating the 
presence of blaTEM gene, the blaOXA gene, the blaCTX gene and the ubiquitous ampC gene 
were amplified from both strains (Casin et al., 1999; Edelstein et al., 2003; Féria et al., 2002). 
The amplification products from blaTEM, blaOXA and blaCTX genes from both strains were 
purified and sequenced. For sequencing of the blaCTX-M-15 gene, we used the primers specific 
for the consensus of CTX-M group I: CTX-M-15F, 5’-AGAATAAGGAATCCCATGGTT-3’ and 
CTX-M-15R, 5’-ACCGTCGGTGACGA TTTTAG-3’. 
Sequencing confirmed three resistance genes in both strains: the blaTEM-1B, blaOXA-30 
and blaCTX-M-15 genes. Sequence analysis using CTX-M-15 primers and ISEcp1, IS26 or 
IS903r primers (Eckert et al., 2004) indicated the presence of an ISEcp1-like element in both 
strains although neither had IS903, thus differing from mobile elements of blaCTX-M-15 gene 
detected previously in K. pneumoniae (Conceição et al., 2005). The IS26 element was not 
also present in our strains. These findings suggest that CTX-M-15 enzymes in these two 
species in Portugal might have emerged in multiple places by plasmid acquisition of blaCTX-M-
15 genes, with different elements implicated in the dissemination of these β-lactamase genes 
(Conceição et al., 2005). This was corroborated by the PFGE analysis, which showed 
different clonal origins for each isolate (data not shown). 
The transconjugant C600-URA5753 was a CTX-M-15-positive-transconjugant from E. 
coli INSRA5753 derived using C600 as the recipient. The transconjugant C600-URA5754 co-
expressed CTX-M-15, OXA-30 and TEM-1 enzymes; indeed, none of these enzymes were 
transferable alone from E. coli INSRA5754 strain to E. coli C600 (Table 8.1), suggesting that 
blaCTX-M-15 gene was carried in only one transferable plasmid with blaTEM-1B and blaOXA-30. 
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MICs of various β-lactams, alone or in combination with β-lactamase inhibitors (Table 
8.1) were determined by an agar dilution method (Féria et al., 2002), and MICs of other 
antimicrobial agents were determined by broth microdilution method. The clinical isolates and 
the transconjugants showed a higher level of resistance to cefotaxime, ceftriaxone, and 
aztreonam than to ceftazidime, which is characteristic of CTX-M producers. Isoelectric 
focusing revealed for both clinical strain and transconjugant C600-URA5754 produced β-
lactamases with pIs of 5.4 (TEM-1), 7.5 (OXA-30) and 8.9 (CTX-M-15). Transconjugant 
C600-URA5753 produced a β-lactamase with a pI of 8.9. 
 
Table 8.1 - MICs of β-lactam antibiotics for E. coli strains isolated in two hospitals, 
transconjugants, and recipientsa 
 MIC (mg/L) for E. coli strains: 
Antimicrobial drug C600 K12-J53 C600-URA5753 INSRA5753 C600-URA5754 INSRA5754 
Amoxicillin  4 >4,096   4,096 >4,096   4,096 >4,096 
Amoxicillin + CLAb ≤2       64        16      128        32      256 
Ticarcillin  8 >4,096 >4,096 >4,096 >4,096 >4,096 
Piperacillin  0.5     256    >512    >512      512    >512 
Piperacillin + TAZc  0.5         2        32          8          2        32 
Mecillinam  0.25         4          4          2          1          1 
Cephalothin  4       32 >1,024 >1,024 >1,024 >1,024 
Cefuroxime  2         4    >256    >256    >256    >256 
Cefoxitin  2       16          4          8          2        16 
Cefepime  0.125         0.06        64        32          8        64 
Cefoperazone ≤0.25         4    >512    >512      256    >512 
Ceftriaxone  0.03         0.06    >512      512      128      512 
Ceftriaxone+ CLA  0.03         0.06          0.03          0.125        ≤0.015          0.25 
Cefotaxime  0.06         0.25      512      512      128    >512 
Cefotaxime + CLA  0.03         0.06          0.03          0.125        ≤0.015          0.25 
Ceftazidime  0.125         0.125      128        64        32        64 
Ceftazidime + CLA  0.06         0.125          0.25          0.5          0.125          0.5 
Aztreonam  0.125         0.125    >256      128      128      256 
Aztreonam + CLA  0.06         0.125          0.125          0.25          0.125          0.25 
Imipenem  0.125         0.125        ≤0.06          0.125        ≤0.06          0.125 
Ciprofloxacin ≤0.5       ≤0.5        ≤0.5        >2        ≤0.5        >2 
Tobramicin ≤2       ≤2        ≤2        >8          4        >8 
Trimethoprim- 
Sulfamethoxazole 
≤1/19       ≤1/19        ≤1/19        ≤1/19        ≤1/19        ≤1/19 
aE. coli C600-URA5753 (harbouring CTX-M-15 enzyme) and E. coli C600-URA5754 (harbouring TEM-1B, OXA-30 and CTX-M-
15 enzymes) were transconjugants of E. coli INSRA5753 (harbouring TEM-1B, OXA-30, CTX-M-15 enzymes) and INSRA5754 
(harbouring TEM-1B, OXA-30, CTX-M-15 enzymes), respectively; E. coli C600 was the recipient; E. coli K12 J53 R111 
(harbouring TEM-1 enzyme) was used as the control. 
bCLA, clavulanic acid at a fixed concentration of 2 mg/L. 
cTAZ, tazobactam at a fixed concentration of 4 mg/L. 
 
To our knowledge the combination of CTX-M-15, TEM-1 and OXA-30 β-lactamases, 
here reported, was previously described only in strains from Senegal (Weill et al., 2004). 
However, the combination of CTX-M-15 and OXA-1 (similar to OXA-30) as been described in 
the UK, Canada and India (Livermore & Hawkey, 2005; Boyd et al., 2004). The spread of 
resistance to extended-spectrum cephalosporins, their extensive use, and the coexistence of 
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strains co-expressing the same TEM, OXA and CTX-M enzymes in distant regions of 
Portugal may impede the use of β-lactams in other regions of the country. These cases 
involving hospital and community environments are consistent with dissemination either from 
or to the community, which is of high concern. 
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ABSTRACT 
Of the 181 unduplicated E. coli strains isolated in nine different hospitals in three 
Portuguese regions, 119 were ESBL-CTX-M producers and were selected for phenotype and 
genotype characterization. CTX-M producer strains were prevalent among community-
acquired infections (56%), urinary tract infections (76%), and patients ≥ 60 years old (76%). 
In MIC tests, all strains were resistant to cefotaxime, 92% were resistant to ceftazidime, 93% 
were resistant to quinolones, 89% were resistant to aminoglycosides and 26% were resistant 
to trimethoprim-sulfamethoxazole; all strains were sensitive to carbapenems, and 92% had a 
multidrug resistance phenotype. Molecular methods identified 109 isolates harbouring a 
blaCTX-M-15 gene, one harbouring the blaCTX-M-32 gene (first identification in the country), and 
nine the blaCTX-M-14 gene. All isolates presented the ISEcp1 element upstream from the blaCTX-
M genes; one presented the IS903 element (downstream of blaCTX-M-14 gene) and none the 
IS26 element; 85% carried blaTEM-1B, and 84% also carried a blaOXA-30. Genetic relatedness 
analysis based of pulsed-field gel electrophoresis defined five clusters, and indicated that 
76% of all isolates (from cluster IV) corresponded to a single epidemic strain. Of the 47 
strains from one hospital, 41 belonged to cluster IV, and were disseminated in three main 
wards. CTX-M-producing E. coli strains are currently a problem in Portugal, with CTX-M-15 
particularly common. This study suggests that the horizontal transfer of blaCTX-M genes, 
mediated by plasmids and/or mobile elements, contributes to the dissemination of CTX-M 
enzymes to community and hospital environments. The use of extended-spectrum 
cephalosporins, quinolones and aminoglycosides is compromised, leaving carbapenems as 
the therapeutic option for severe infections caused by ESBL producers. 
 
INTRODUCTION 
Production of ESBLs is a major mechanism of resistance to β-lactam antibiotics. First 
detected in 1986 (Matsumoto et al., 1988), CTX-M is an ESBL family including more than 60 
different enzymes in five phylogenetic groups (http://www.lahey.org/studies/webt.htm). CTX-
M β-lactamases of group 2be (Bush et al., 1995), unlike other ESBL, are more active against 
cefotaxime than against ceftazidime (Bonnet, 2004). The rapid emergence and worldwide 
spread of this plasmid-mediated family is associated with mobile elements and particularly 
insertion sequences (Baraniak et al., 2002a; Boyd et al., 2004; Eckert et al., 2006; Karim et 
al., 2001; Munday et al., 2004; Poirel et al., 2005; Walther-Rasmussen & Høiby, 2004). This 
high mobility associated with inefficient antibiotic policies has led to community-acquired and 
nosocomial infections (Livermore & Hawkey, 2005; Woodford et al., 2004). 
Many strains that express CTX-M β-lactamases are multidrug resistant (Eisner et al., 
2006; Karim et al., 2001; Livermore, 2005; Woodford et al., 2004). Genes conferring 
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resistance to aminoglycosides and tetracycline and other bla genes have been found on the 
same plasmids as the blaCTX-M genes (Boyd et al., 2004). Genes conferring plasmid-mediated 
quinolone resistance has also been associated to blaCTX-M genes (Jacoby et al., 2006). 
CTX-M-15 appears to have the best dissemination capacity of all the CTX-M family, 
probably due to successful genetic rearrangements (Walsh, 2006). The corresponding gene 
is normally associated with an upstream ISEcp1 element. The gene has been detected in 
Europe (Baraniak et al., 2002a; Conceição et al., 2005; Eckert et al., 2004; Livermore and 
Hawkey, 2005), Africa (Moubareck et al., 2005; Ndugulile et al., 2005; Ramdani-Bouguessa 
et al., 2006; Soge et al., 2005), North and South America (Boyd et al., 2004; Pallecchi et al., 
2004) and Asia (Karim et al., 2001; Kim et al., 2005), and has been associated with many 
community and hospital outbreaks. To our knowledge, only dispersed cases have been 
reported in Portugal (Conceição et al., 2005; Costa et al., 2004; Machado et al., 2006; 
Machado et al., 2004; Mendonça et al., 2006b). 
We investigate the dissemination of CTX-M enzymes among clinical isolates of E. coli 
recovered in various Portuguese hospitals from cases of community-acquired and 
nosocomial infections. We describe the phenotypes and genetic characteristics of these 
isolates. 
 
MATERIALS AND METHODS 
Bacterial strains. A total of 181 unduplicated E. coli strains isolated from patients, were 
collected in nine hospitals in three different regions of Portugal, between March 2004 and 
March 2006, and sent to the Antibiotic Resistance Unit at the NIH Dr. Ricardo Jorge in 
Lisbon. The bacteriology laboratories of these hospitals collaborate with the NIH as 
contributors to the ARSIP; they sent all E. coli strains identified as ESBL producers by 
different systems (ATB G-5, VITEK 1, VITEK 2 and Phoenix). Of the 181 strains received, 
119 were detected as ESBL-(CTX-M)-producers by phenotypic and genotypic 
characterization at NIH, as stated below. The NIH conducted the main study using those 119 
out of 126 CTX-M producer strains because only the first bacterial isolate from the three 
patients with multiple isolates was considered (among a total of 181 ESBL producers) (Table 
9.1). The other ESBL producers were not investigated in present study. Of the 119 strains, 
47 were nosocomial, and 66 were community acquired, according to Centers for Disease 
Control and Prevention criteria (Garner et al., 1996), and six were of unknown origin (Table 
9.1).  
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Strains were isolated from urine (n= 90), wounds (n= 13), blood (n= 4), ascitic fluid (n= 
3), sputum (n=3), bronchoalveolar lavage (n=2) and secretions (n=3) and gastric fluid (n=1). 
E. coli INSRA99 (IRT-2, pI 5.2), E. coli RP4 (TEM-2, pI 5.6) and E. coli SolRl 90 (AmpC, pI 
9.2) were used only as control strains for IEF. E. coli R111 (TEM-1, pI 5.4; blaTEM-1 plus 
ampC), S. enterica serovar Typhimurium (OXA-1, pI 7.4; blaOXA-1), E. coli C600 (SHV-1, pI 
7.6; blaSHV-1) and E. coli UA1526 (CTX-M-15, pI 8.9; blaCTX-M-15) were used as control strains 
for both PCR and IEF. The control strains used for PCR with insertion sequence primers 
were: INSRA5753 (ISEcp1), INSRA5776 (IS903) and Kp125 (IS26). 
 
Susceptibility testing and ESBL confirmation. The MICs of 23 antibiotics were determined 
by a broth microdilution method (MicroScan Panel Sólo 1S) for all strains. The MICs of 
antibiotics were determined by the agar dilution method for all transformants obtained as 
previously (Mendonça et al., 2006a). The results were interpreted using CLSI (formerly 
National Committee for Clinical Laboratory Standards) criteria (CLSI, 2007). Isolates were 
considered multidrug resistant if they had reduced susceptibility to three or more structurally 
unrelated antibiotics. ESBL production was confirmed by a broth microdilution method: 
strains with synergy between ceftazidime and ceftazidime-clavulanic acid were suspected of 
producing ESBL. To confirm ESBL producers, 52 of 119 strains were randomly chosen for 
further testing by the Etest ESBL method using strips with cefotaxime and ceftazidime both 
alone and associated with clavulanate; findings were interpreted according to the 
manufacturer’s instructions. 
 
Transfer of resistance. We tested whether the ESBL phenotypes of strains producing CTX-
M-14, CTX-M-15 and CTX-M-32 enzymes were transferable. Plasmid DNA was extracted 
from six producer strains, representative of the different CTX-M-type enzymes detected, and 
used to transform E. coli DH5α by electroporation. Transformants were selected on Luria 
Broth medium containing 1 μg of cefotaxime/ml. PCR was used to test for the bla gene in 
transformants as described below for clinical isolates. 
 
IEF. Cell extracts from all isolates were obtained by ultrasonic treatment and IEF was used to 
characterise pI of ESBLs as previously described (Caniça et al., 1997a). The pIs of each β-
lactamase were compared with those produced by control strains.  
 
PCR amplification and gene sequencing. PCR amplification was used to test for the 
blaCTX-M gene and ISEcp1, IS26 and IS903 elements, and multiplex-PCR was used to test for 
the blaTEM, blaOXA, blaSHV, and ampC genes in all 119 ESBL producer strains as previously 
(Machado et al., 2004; Mendonça et al., 2006a; Pomba et al., 2006). Specific primers were 
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used for PCR and sequencing (Table 9.2). A particular specific primer (CTX15i) was used to 
determine the nucleotides of codon 288, which distinguish blaCTX-M-15 from blaCTX-M-28. PCR 
products were purified and further sequenced as previously described (Mendonça et al., 
2006a). 
 
Table 9.2 - Primers used for PCR amplification and sequencing 
Gene Primera Primer Sequence (5’ → 3’) PCR product size (bp) 
Reference 
or source 
blaTEM P1 5’-TACGATACGGGAGGGCTTAC-3’ 
 P2 5’-TTCCTGTTTTTGCTCACCCA-3’ 
716 Belaaouaj 
et al., 1994 
 FIN 5’-ATTCTTGAAGACGAAAGGGC-3’ 
 DEB 5’-ATGAGTAAACTTGGTCTGAC-3’ 
1091 Caniça et 
al., 1997b 
 P3b 5’-TGGGTGAGCAAAAACAGGAA-3’  Caniça et 
al., 1997b 
 CLBb 5’-AATGAAGCCATACCAAACGA-3’  Belaaouaj 
et al., 1994 
blaSHV SHVf1 5’-TCAGCGAAAAACACCTTG-3’ 
 SHVr2 5’-TCCCGCAGATAAATCACCA-3’ 
471 M’Zali et al., 
1996 
blaOXA oxa1f 5’-TATCTACAGCAGCGCCAGTG-3’ 
 oxa1r 5’-CGCATCAAATGCCATAAGTG-3’ 
199 Féria et al., 
2002 
 oxa1sf 5’-ATGAAAAACACAATACATATC-3’ 
 oxa1sr 5’-AATTTAGTGTGTTTAGAATGG-3’ 
816 Casin et al., 
1999 
ampC ampCf 5’-CCCCGCTTATAGAGCAACAA-3’ 
 ampCr 5’-TCAATGGTCGACTTCACACC-3’ 
634 Féria et al., 
2002 
blaCTX-
M 
CTXfc 5’-TTTGCGATGTGCAGTACCAGTAA-3’
 CTXrd 5’-CGATATCGTTGGTGGTGCCATA-3’ 
543 Edelstein et 
al., 2003 
blaCTX-
M-15 
CTX15f 5’-AGAATAAGGAATCCCATGGTT-3’ 
 CTX15r 5’-ACCGTCGGTGACGATTTTAG-3’ 
875 This study 
 CTX15ib 5’-GGAATCTGACGCTGGGTAAA-3’  This study 
blaCTX-
M-14 
CTXg3f 5’-CTGATGTAACACGGATTGACC-3’ 
 CTX14r 5’-CGATTTATTCAACAAAACCAG-3’ 
871 This study 
ISEcp1 ISEcp1 5’-AAAAATGATTGAAAGGTGGT-3’ Variable Eckert et al., 2004
IS26 IS26 5’-AGCGGTAAATCGTGGAGTGA-3’ Variable Eckert et al., 2004
IS903 IS903 5’-CGGTTGTAATCTGTTGTCCA-3’ Variable Eckert et al., 2004
a For PCR amplification and sequencing (except those in used only for internal sequencing). 
b Only for internal sequencing. 
c When used with primer ISEcp1, IS26, IS903, this also amplifies the downstream region of the blaCTX-M gene. 
Various sized PCR products expected. 
d When used with primer ISEcp1, IS26, IS903, this also amplifies the upstream region of the blaCTX-M gene. Various 
sized PCR products expected. 
 
PFGE. Of the 119 isolates, 116 were analysed by PFGE. Seven other strains from three 
patients with multiple isolates in different hospitals were also subjected to PFGE analysis 
(Table 9.1). Plugs were prepared from bacterial suspensions (300 µl) with an optical density 
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at 650 nm of 1.2 to 1.4 in phosphate buffer (50 mM). SeaPlaque GTG (Cambrex Bio Science 
Rockland, Rockland, ME) agarose was added (1.5% in 300 µl of TF buffer); the mixture was 
immediately taken up in a 1-ml syringe, and placed for exactly 4 min at -20ºC. The syringe 
was then incubated at room temperature for 10 min, and its end was cut off. The plugs were 
sliced into 1-mm-thick sections and incubated in EC buffer (6 mM Tris, 1 M NaCl, 0.1 M 
EDTA, 0.2% deoxycholic acid, 0.5% N-lauroylsarcosine and 0.5% Brij 58) for 3 hours at 
37ºC. The EC buffer was replaced with ES lysis buffer (0.5 M EDTA and 1% N-
lauroylsarcosine) plus proteinase K (1 mg/strain) and the samples incubated for 16 h at 55ºC. 
The plugs were then washed with distilled water for 5 min and with TE buffer (100 mM Tris 
and 10 mM EDTA) four times for 30 min each time. The DNA in the plugs was digested with 
30 U of XbaI for 16 hours at 37ºC. PFGE was performed on a CHEF MAPPER PFGE 
apparatus (Bio-Rad, Hercules, CA) with 1.2% Seakem Gold agarose (Cambrex) in 0.5x Tris-
borate-EDTA at 11ºC and 6 V/cm. The duration of the run was 24 h, with initial and final 
switch times of 0.1 s and 36 s, respectively. The gels were stained with ethidium bromide 
and photographed with Gel Doc 2000 (Bio-Rad). Banding patterns were analyzed by using 
BioNumerics software. The unweighted-pair-group method was used to construct a 
dendrogram based on PFGE XbaI restriction patterns of the 123 E. coli isolates. The Dice 
band-based similarity coefficient, with a band position tolerance of 1.0% and an optimization 
of 1.8%, was used for clustering. A cutoff value of 80% similarity was determined by the 
cluster cutoff method according to Bionumerics software. Isolates with a Dice band-based 
similarity coefficient value of >80% were considered to belong to the same cluster.  
 
RESULTS 
Clinical ESBL producer strains and antibiotic susceptibility. We confirmed that the 119 
isolates included in the study were ESBL producers. The CTX-M-32 producer strain was 
from a wound in a 51 year-old man, and eight of the nine CTX-M-14 producers were isolated 
from urine, and one was from a wound. Most of CTX-M-15 producers (92%) were from urine 
from men or women ≥ 60 years old (data not shown). 
A total of 90% of the isolates were resistant to 11 of the 14 β-lactam antibiotics tested: 
more than 98% CTX-M group 1 enzyme producers were resistant to ceftazidime and 
cefotaxime; all CTX-M group 9 producers were resistant to cefotaxime, and 11% resistant to 
ceftazidime (Table 9.3). Only 26% CTX-M group 1 producers showed nonsusceptibility to 
amoxicillin-clavulanate and 12% showed nonsusceptibility to piperacillin-tazobactam. 
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Imipenem and meropenem were the only antibiotics effective against all isolates 
producing either group 1 or group 9 enzymes (Table 9.3). A total of 92% of the isolates were 
multidrug resistant: 50% were isolated in the community and 37% were isolated from 
hospitalized patients. 
 
Transfer of antibiotic resistance. We tested whether blaCTX-M genes in six selected isolates 
were transferable by transformation of E. coli strain DH5α. Only three transformants were 
obtained: two representative of CTX-M group 1 isolates (one carrying the blaCTX-M-15 plus 
blaTEM-1B genes and other carrying the blaCTX-M-32 gene) and one representative of CTX-M 
group 9 isolates (carrying the blaCTX-M-14 gene). Generally the transformants had antibiotic 
resistance profiles similar to those of their parental clinical isolates (Table 9.4). All clinical 
strains were resistant to ciprofloxacin, but none of the transformants maintained that 
condition. Transformants of E. coli strains harboring CTX-M-32 or CTX-M-14 enzymes, 
whose clinical strains were resistant to gentamicin and trimethoprim-sulfamethoxazole, 
presented susceptibility to those antibiotics. 
 
IEF. As determined by IEF, 82% of the CTX-M group 1 strains (n=110) contained enzymes 
with pIs 5.4, 7.4 and 8.9 (Table 9.5), 9% contained enzymes of pIs 5.4 and 8.9; and 9% 
contained enzymes with pIs of 7.4 and 8.9. All CTX-M group 9 strains (n=9) contained an 
enzyme of pI 8.1 and 44% contained an enzyme with a pI of 5.4. 
 
Identification of bla genes and IS elements. The PCR tests used detected a blaCTX-M gene 
and the ampC gene in all isolates. A total of 91 of the 119 strains (76%) contained also 
blaTEM and blaOXA genes, 13 (11%) contained blaCTX-M plus blaTEM but not blaOXA gene and 10 
(8%) had blaCTX-M and blaOXA genes (Table 9.5). Sequencing identified the blaCTX-M-15, blaCTX-M-
14 and blaCTX-M-32 genes in 109 (92%), nine (8%) and one (1%) strains, respectively; the 
blaTEM-1B gene in 101 (85%) strains, blaTEM-1C in one strain and blaTEM-1A in one strain (note 
that all these blaTEM genes had a P3 promoter region). One strain had more than one blaTEM 
gene sequence. A total of 101 (85%) strains harboured a blaOXA-30 gene. No strain carried the 
blaSHV gene. In all strains, the ISEcp1 element was found upstream from the blaCTX-M genes. 
One strain also carried an IS903 element downstream from its blaCTX-M-14 gene (Table 9.5). 
 
Clonality of CTX-M-producer strains. PFGE analysis was used to establish the genetic 
relatedness of the 116 CTX-M producer strains. We identified 19 PFGE profile types were 
identified: 14 included a single clone genetically unrelated to other isolates in the study 
(types 0001, 0002, 0004, 0005, 0007, 0008 and 0011 to 0018).  
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Table 9.5 - Phenotypic and genotypic characteristics of 119 E. coli CTX-M producer strains 
Genotype by PCR (Gene type by  sequencing): c 
Antimicrobial resistance patterna pI(s)b  
blaTEM blaCTX-M blaOXA ISEcp1 IS26 IS903 
PFGE Profiled 
(No. of strains) 
Hospital 
code 
Total No.
of 
Strains 
AM A/S AT CF CT FX TX TZ XM KZ 
PM PI P/T TI CI NX OF AK GM 
TO 
5.4;7.4;8.9 + (1b) + (15) + (30) + - - 0010 A 1 
AM A/S A/C AT CF CT TX TZ XM 
KZ PM PI P/T TI CI NX OF GM 
TO 
7.4;8.9 - + (15) + (30) + - - 0010 D 2 
AM A/S A/C AT CF CT TX TZ XM 
KZ PM PI P/T TI CI NX OF AK 
TO 
5.4;7.4;8.9 + (1b) + (15) + (30) + - - 0006 E 1 
AM A/S AT CF CT TX TZ XM KZ PM 
PI P/T TI CI NX OF AK GM TO 
5.4;7.4;8.9 + (1b) + (15) + (30) + - - 0010 C 1 
AM A/S AT CF CT TX TZ XM KZ PM 
PI P/T TI CI NX OF GM TO T/S 
5.4;7.4;8.9 + (1b) + (15) + (30) + - - 0010 C 1 
AM A/S AT CF CT TX TZ XM KZ PM 
PI TI CI NX OF AK GM TO T/S 
5.4;7.4;8.9 + (1b) + (15) + (30) + - - 0010 B 1 
AM A/S AT CF CT TX TZ XM KZ PM 
PI P/T TI CI NX OF GM TO 
5.4;7.4;8.9 + (1b) + (15) + (30) + - - 0010 C 1 
AM A/S AT CF CT TX TZ XM KZ PM 
PI TI CI NX OF GM TO T/S 
5.4;7.4;8.9 + (1b) + (15) + (30) + - - 0009(1), 0010(13), 
0012(1), 0013(1), 
0015(1), 0017 (1), 
nd(1) 
A, B, C, 
D, E, F, 
H 
19 
 5.4;7.4;8.9 + (1)e + (15) + (30) + - - 0010 C 1 
 5.4;8.9 + (1b) + (32) - + - - 0019 E 1 
 5.4;8.9 + (1b) + (15) - + - - 0019 E 1 
AM A/S AT CF CT TX TZ XM KZ PM 
PI TI CI NX OF GM TO 
8.1 - + (14) - + - - 0005 C 1 
 7.4;8.9 - + (15) + (30) + - - 0007(1), 0010(3) B, D, H 4 
 5.4;7.4;8.9 + (1b) + (15) + (30) + - - 0016(1), 0009(2), 
0010 (48), 0011(1) 
A, B, C, 
D, E, G, 
H, I 
52 
 5.4;7.4;8.9 + (1ª) + (15) + (30) + - - 0010 H 1 
AM A/S AT CF CT TX TZ XM KZ PM 
PI TI CI NX OF TO T/S 
5.4;7.4;8.9 + (1b) + (15) + (30) + - - 0010 I 1 
AM A/S AT CF CT TX TZ XM KZ PM 
PI TI CI NX OF GM 
5.4;8.9f + (1b) + (15) + (30) + - - 0010 A 1 
AM A/S AT CF CT TX TZ XM KZ PM 
PI TI CI NX OF TO 
7.4;8.9 - + (15) + (30) + - - 0010 D, E 3 
  5.4;8.9 + (1b) + (15) - + - - 0010 D 1 
 5.4;7.4;8.9 + (1b) + (15) + (30) + - - 0006(2), 0008(1), 
0010(7) 
C, D, E, 
I 
10 
AM A/S AT CF CT TX TZ XM KZ PM 
PI TI CI NX OF T/S 
5.4;8.9 + (1b) + (15) - + - - 0010 A 2 
AM AT CF CT TX TZ XM KZ 
  PM PI TI CI NX OF TO 
7.4;8.9 - + (15) + (30) + - - 0010 E 1 
AM A/S AT CF CT TX TZ XM KZ PM 
PI TI CI NX OFg 
5.4;8.9 + (1b) + (15) - + - - 0006(1), 0010(1) E 2 
AM A/S CF CT TX XM KZ PI 
  TI CI NX OF GM TO T/S 
5.4;8.1 + (1b) + (14) - + - + 0001 E 1 
AM A/S CF CT TX XM KZ PI 
  TI CI NX OF T/S 
5.4;8.1 + (1b) + (14) - + - - nd C 1 
AM A/S AT CF CT TX XM 
  KZ PM PI TI T/Sg 
5.4;8.9 + (1b) + (15) - + - - 0004 E 1 
AM A/S CF CT TX XM 
  KZ PM PI TI T/Sg 
5.4;8.1 + (1b) + (14) - + - - 0018 C 1 
AM A/S CF CT TX XM 
  KZ PM PI TIg 
8.1 - + (14) - + - - 0002(1), 0003(2), 
nd(1) 
C, D, I 4 
 5.4;8.1 + (1c) + (14) - + - - 0014 D 1 
AM AT CF TX XM KZ PI TIg 5.4;8.9 + (1b) + (15) - + - - 0010 E 1 
a AM, Ampicillin; A/S, ampicillin-sulbactam; A/C, amoxicillin-clavulanic acid; AT, aztreonam; CF, cephalothin; FX, cefoxitin; 
CT, cefotaxime; TX, ceftriaxone; TZ, ceftazidime; XM, cefuroxime; KZ. Cefazolin; PM, cefepime; PI, piperacillin; P/T, 
piperacillin-tazobactam; TI, ticarcillin; CI, ciprofloxacin; NX, norfloxacin; OF, ofloxacin; AK, amikacin; GM, gentamicin; TO, 
tobramycin; T/S, trimethoprim-sulfamethoxazole. 
b pIs were determined by IEF: 5.4 corresponds to TEM-1A, TEM-1B or TEM-1C enzyme production, 7.4 corresponds to 
OXA-30 production, 8.1 corresponds to CTX-M-14, and 8.9 corresponds to CTX-M-15 or CTX-M-32 enzyme production. 
c blaTEM genes amplified by PCR were identified by sequencing as blaTEM-1A, blaTEM-1B or blaTEM -1C; blaCTX-M genes by 
sequencing were identified as blaCTX-M-14, blaCTX-M-15 or blaCTX-M -32; and blaOXA genes were identified as blaOXA-30. +, 
Amplification by PCR; -, No amplification by PCR. 
d PFGE profile and number of strains with each profile, deduced from the dendrogram presented on Figure 9.1. ND, not 
determined. 
e More than one blaTEM-1 present. 
f β-Lactamase with pI 7.4, corresponding to OXA-30 enzyme production, was not detected by IEF. 
g Non-multidrug-resistant pattern. 
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The five other types, defined as clusters I to V, included numerous related (with >80% 
similarity) or indistinguishable (100% homology) isolates (Figure 9.1). Of the 102 (88%) 
strains in these five clusters, 91 (89%) had profile type 0010 (cluster IV). These 91 isolates 
included clones from all hospitals (isolated from 53 outpatients, 36 inpatients and two with no 
information) (Tables 9.1 and 9.5, and Figure 9.1). Hospital C provided more isolates than any 
other hospital, including four single-isolate profile types (0005, 0011 and 0018) and two 
profile types including numerous isolates (0003 and 0010) (Figure 9.1). 
All isolates from the internal medicine, attending, intensive care unit (ICU), and 
urology services of hospital C were profile type 0010. Only the nephrology, pediatric, and 
emergency services of hospital C presented clones belonging to other different profile types 
(Table 9.6). 
 Isolates of profile types 0006 to 0013, 0015 to 0017 and 0019, expressed a CTX-M 
enzyme of group 1, and were multidrug-resistant. Isolates of profile types 0001 and 0005 
were also multidrug resistant and expressed CTX-M enzyme of group 9. Isolates with profile 
types 0002, 0003, 0014 and 0018 also produced the CTX-M group 9 enzyme but were not 
multidrug resistant (Table 9.5). Three patients (from three different hospitals, C, D and E) 
gave multiple isolates; all provided isolates with PFGE profile type 00010, although the 
patient from hospital D also gave one isolate of PFGE profile type 0007 (Table 9.1). 
 
DISCUSSION 
 The prevalence of CTX-M-type β-lactamases has increased substantially since 1992 
(Bonnet, 2004): in Portugal, they have been found in isolates from animals, healthy humans 
and patients (Costa et al., 2004; Machado et al., 2006). Here, we investigated the 
dissemination of these enzymes among clinical strains responsible for community and 
hospital-acquired infections. 
In a survey conduced in 1999, no ESBL enzymes of the CTX-M family were detected 
in clinical E. coli isolates in Portugal (M. Caniça, unpublished data). 
We included only those strains resistant to extended-spectrum cephalosporins and 
monobactam-producing CTX-M β-lactamases collected in three different regions of Portugal 
between March 2004 and March 2006: 119 (66%) CTX-M producer strains out of 181 ESBL 
producers. The majority of the strains had CTX-M enzymes of group 1, CTX-M-15 (n=109) 
and CTX-M-32 (n=1), and nine strains had CTX-M-14, an enzyme of group 9. Most of CTX-
M-15 producers were isolated in urine from men or women ≥ 60 years old as in Spain (Oteo 
et al., 2006). 
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Figure 9.1 - Genetic relatedness among 123 E. coli strains by PFGE. PFGE profile types and clusters 
are shown from left to right. A total of 116 strains were the first isolate from each patient; seven 
additional isolates were collected from three of the patients. Strains INSRA5966, INSRA5979, 
INSRA5876, INSRA5879, INSRA5907, INSRA5863, INSRA5758 and INSRA5775 are multiple isolates 
of three patients. Strains with PFGE profile types 0003, 0006, 0009, 0010 and 0019 were defined as 
forming clusters I to V, respectively (indicated by vertical bands on the right).  
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Strains producing CTX-M of group 1 were more resistant to ceftazidime and 
aztreonam (100%) than those producing CTX-M of group 9 (11%). This is consistent with 
previous reports (Bonnet, 2004). CTX-M-14 differs from its parental enzyme CTX-M-9 by a 
single substitution (Ala231Val), which does not confer an extension of resistance (Pai et al., 
2001; Sabaté et al., 2000). CTX-M-32 differs from its parental enzyme CTX-M-1 by a single 
substitution (Asp240Gly), which confers high-level resistance to ceftazidime (Cartelle et al., 
2004). The same substitution is found in CTX-M-15 relative to its parental enzyme CTX-M-3, 
similarly conferring high-level resistance to ceftazidime (Poirel et al., 2002b).  
A total of 98% of strains producing CTX-M of group 1 were resistant to quinolones 
and 95% were resistant to aminoglycosides; only 33% and 22% of isolates producing CTX-M 
of group 9 were resistant, respectively. Resistance to quinolones (93%) was considerably 
more prevalent among our isolates than the 21% reported by Edelstein (Edelstein et al., 
2003); 89% of the isolates in both studies were resistant to aminoglycosides. Resistance to 
trimethoprim-sulfamethoxazole was more prevalent in isolates carrying CTX-M of group 9 
(33%) than CTX-M of group 1 (26%). 
 Combined production of CTX-M and OXA enzymes by E. coli improved resistance to 
β-lactamase inhibitors. Less than 24% of the isolates were nonsusceptible to clavulanate and 
tazobactam, and more than 98% were resistant to sulbactam (Table 9.3). The usefulness of 
β-lactams plus a β-lactamase inhibitor is uncertain for patients with treatment failure 
(Livermore & Hawkey, 2005). Ninety-two percent of our strains harboring blaCTX-M-15 gene 
(Table 9.5) also possessed a blaOXA-30 gene, presumably explaining the high percentage of 
nonsusceptibility to ampicillin-sulbactam. Strains carrying blaCTX-M of group I enzymes were 
the only strains not susceptible to amoxicillin-clavulanate and to piperacillin-tazobactam 
which may imply a low expression of β-lactamase OXA-30 or even another mechanism of 
resistance (Oliver et al., 1999). 
 The genes blaCTX-M-15 plus blaOXA-1 (blaOXA-30) have been found associated in the same 
strain in India (Karim et al., 2001), the UK (Livermore & Hawkey, 2005) and Canada (Boyd et 
al., 2004). Note that blaOXA-1 and blaOXA-30 have the same sequence, and thus code for the 
same enzyme, called OXA-1 or OXA-30 (Ouellette et al., 1987; Siu et al., 2000). The 
combination of blaCTX-M-15 plus blaOXA-30 (or blaOXA-1) plus blaTEM-1 has been reported in seven 
strains from Korea (Jacoby et al., 2006), in two strains from Senegal (Weill et al., 2004) and 
also in Spain (Oteo et al., 2006). An association between blaCTX-M-14 and blaTEM-1B has been 
described in Korea (Kim et al., 2005). However, our detection of blaCTX-M-32 in the same strain 
as blaTEM-1B is, to our knowledge, a first. 
There was an ISEcp1 element upstream from all blaCTX-M genes detected. Thus, we 
add the blaCTX-M-32 gene to the list of blaCTX-M genes associated with the ISEcp1 element 
(Baraniak et al., 2002a; Boyd et al., 2004; Eckert et al., 2006; Karim et al., 2001; Munday et 
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al., 2004; Poirel et al., 2005; Walther-Rasmussen & Høiby, 2004), which contributes to their 
mobilization (Poirel et al., 2005). The IS903 element was detected downstream from only the 
blaCTX-M-14 gene, a finding in agreement with other studies (Eckert et al., 2006; Machado et 
al., 2006). The IS26 element, characteristic of the epidemic strain A from the United 
Kingdom, was not detected among our strains, but was recently detected in clinical isolates 
from Spain that were collected in the same period as the strains of our study (Oteo et al., 
2006; Woodford et al., 2004). 
We tested for gene transfer from six isolates and genes were successfully transferred 
by electroporation to another E. coli strain from only three. This may suggest a major 
horizontal transfer by mobile elements. We obtained transformants containing CTX-14 alone, 
CTX-M-32 alone, and CTX-M-15 plus TEM-1B. The clinical strain containing CTX-M-14 
enzyme was the only one not susceptible to cefoxitin; however, the transformant was 
susceptible indicating another mechanism of resistance. None of the transformants 
presented the same resistance to quinolone, aminoglycosides and trimethoprim as the 
clinical strains. Nevertheless, plasmid-determined resistance to quinolones and 
aminoglycosides, recently described in Portugal (Machado et al., 2006), involving a variant of 
aminoglycoside acetyltransferase AAC(6’)-Ib (Robicsek et al., 2006), was not possible to 
identify in the three studied strains. 
Resistance to quinolones (93%), aminoglycosides (89%) and trimethoprim-
sulfamethoxazole (26%) explains why most CTX-M producers were multidrug resistant. 
Another study reported lower prevalences of non-susceptibility to quinolones (55%) and 
aminoglycosides (37%), but more frequent resistance to trimethoprim-sulfamethoxazole 
(34%) (Eisner et al., 2006), and yet another describes very different percentages of 
resistance for trimethoprim-sulfamethoxazole (78% resistance) and aminoglycosides (43%) 
(Moubareck et al., 2005). Eckert et al (2004) reported that 58% of isolates were resistant to 
trimethoprim-sulfamethoxazole, 74% to aminoglycosides, and 100% of CTX-M enzymes 
producers were multidrug resistant. In our study, the value was 92% for multidrug resistance, 
with a higher percentage of isolates from community (50%) than from hospital environments 
(37%), which was consistent with predominance of E. coli expression CTX-M enzyme in the 
community described by Pitout et al (Pitout et al., 2005). Indeed, the high-level consumption 
of antibiotics in outpatients in Portugal may be responsible for this resistance (Goossens et 
al., 2005). A wide diversity of resistance genes of numerous families coding for various 
antibiotic resistance mechanisms have now been described in CTX-M-15 producer strains.  
We used PFGE to classify the strains. Three quarters of the strains clustered together 
(>80% similarity) in cluster IV, indicating countrywide dissemination of this multidrug resistant 
clone. Various factors may have contributed to this dissemination: the small size of the 
country, the proximity of population areas, and/or an inadequate antibiotic use. Since all 
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strains were susceptibility to carbapenems, the use of these or other appropriate drugs could 
help reduce the prevalence of strains from cluster IV.  
Note that similar values for susceptibility to carbapenems were reported by others 
(Livermore, 2005; Soge et al., 2005; Weill et al., 2004). The spread of a single clone in 
hospital C suggested nosocomial dissemination, especially in internal medicine service. 
Nevertheless, the genetic similarity of clones in community services, in particular the 
attending and emergency rooms, also suggest dissemination within the community. The 
hospital-community and community-hospital dissemination of blaCTX-M-15 enzyme, mainly in 
hospital C (Table 9.1 and 9.6), suggest the presence of an epidemic strain. The analysis of 
the three patients with multiple isolates shows that nosocomial infections due to E. coli CTX-
M-15 producer strains are persistent (hospital D and E); that nosocomial infection is easily 
transferred among services (hospital D); and that nosocomial infection can become a 
community infection (hospital C and hospital D) (data not shown). 
Our study suggests that E. coli CTX-M-producers are widespread in at least three 
regions of Portugal, possibly a consequence of the dissemination of major clones between 
hospitals and community and between regions and of the horizontal transfer of plasmids or 
mobile elements. Our findings also illustrate the potential dangers that the misuse of 
antibiotic can cause and the importance of measures to control infection. Nevertheless, 
rational use of other drugs may improve the situation. As previously noted (Livermore & 
Hawkey, 2005), the use of extended-spectrum cephalosporins, quinolones and 
aminoglycosides could be replaced with carbapenems for in infections in which ESBL-
producing strains are likely to emerge. 
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ABSTRACT 
Sixteen strains of E. coli isolated between January and June 2005 in a hospital in 
Algiers carry the ISEcp1 element and TEM and either CTX-M-3 (n=3) or CTX-M-15 (n=13) β-
lactamases. Fourteen of the isolates are multidrug resistant. Five isolates from the neonatal 
ward were indistinguishable by pulsed-field gel electrophoresis. 
TEXT 
CTX-M-type enzymes are the ESBL most commonly produced by Enterobacteriaceae 
(Bonnet, 2004), and more than 55 CTX-M-type β-lactamases have been described 
(http://www.lahey.org/studies/webt.htm). Despite the prevalence of ESBL in 
Enterobacteriaceae, data from Algeria are scarce (although the prevalence has been 
reported to be 20 to 45%) (Ramdani-Bouguessa et al., 2001). We investigated the 
phenotypic and genetic profiles of clinical E. coli ESBL producers isolated in an Algerian 
hospital. (This work was presented at the 16th European Congress of Clinical Microbiology 
and Infectious Diseases, abstract P509, 2006). 
Between January and June 2005, 279 non-duplicate E. coli strains were recovered 
consecutively from patients at the Mustapha Pacha Hospital (1,800 beds) of Algiers, Algeria, 
and routinely analyzed in the hospital’s microbiology laboratory. All strains were identified 
with an API 20E System. Antimicrobial susceptibility was determined by disc diffusion 
according to the NCCLS guidelines (2004), and 22 (7.9%) of the strains were resistant to 
extended-spectrum cephalosporins. Only 16 of these 22 were available for this study; related 
specimens, patient age, and ward of hospitalization are specified in Table 10.1. A double 
disc diffusion test (Jarlier, 1988) and Etest ESBL strips, with cefotaxime and ceftazidime plus 
clavulanate, confirmed that all were ESBL producers. 
All 16 isolates were positive for blaTEM- and blaCTX-M-related genes, and negative for 
blaOXA and blaSHV genes as assessed by PCR using previously described specific primers 
(Mendonça et al., 2006a), and all isolates carried the ubiquitous ampC gene (Mendonça et 
al., 2006a). Isoelectric focusing confirmed that all strains expressed both TEM-derived (pI of 
5.4) and CTX-M-derived (pI of 8.0 and 8.9) enzymes (Table 10.1). The presence of an 
ISEcp1 element upstream from blaCTX-M genes and the absence of IS26 and IS903 elements 
were shown by PCR experiments (Eckert et al., 2004). ExoSAP IT was used for purification 
of PCR products, which were sequenced with an automatic sequencer ABI3100. Thirteen 
isolates carried the blaCTX-M-15 gene and three the blaCTX-M-3 gene; 16 isolates carried a blaTEM-
1B-type gene. 
MICs of antibiotics were determined by broth microdilution (MicroScan Panel Sólo 
1S): 100% of strains were resistant to gentamicin, 31% to amikacin, 88% to cotrimoxazole, 
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and 19% to ciprofloxacin; 88% were multidrug-resistant (Table 10.1). The 13 isolates 
carrying both TEM and CTX-M-15 enzymes were more resistant to ceftazidime (with MICs 
>16 µl/ml), than the 3 CTX-M-3 plus-TEM producers (with MIC ≤0.5 to 1 µg/ml). CTX-M-15, 
which harbors the Asp240Gly substitution, confers higher levels of resistance to ceftazidime 
than its parental enzyme CTX-M-3 (Poirel et al., 2002b). 
The diversity of the isolates was investigated by a protocol for PFGE modified from 
that previously described (Caniça et al., 2003), using XbaI-digested genomic DNA as 
suggested for E. coli (Davis et al., 2003) (Figure 10.1). PFGE was performed on a CHEF 
MAPPER PFGE apparatus using a run time of 24 h, with an initial and final switch time of 0.1 
s and 36 s, respectively. Strain INSRA5754 and the Lambda ladder (Biolabs, Beverly, MA) 
were used as markers for intragel normalization and intergel comparison. The PFGE profiles 
of five isolates producing CTX-M-15 β-lactamase from the neonatal ward were 
indistinguishable (100% similarity, cluster I). This suggests the spread of an epidemic clone. 
Two other clones producing CTX-M-3 β-lactamase were closely related (with >90% similarity, 
formed the cluster II). The PFGE profiles of the other isolates were heterogeneous. 
ESBL-positive Enterobacteriaceae are frequently isolated in hospitals in Algeria, and 
the overall frequency of ESBL producers at the Mustapha Pacha hospital from January to 
June 2005, was 20.4% (n=217 of the 1,066 Enterobacteriaceae isolates): 22 of 279 (7.9%) E. 
coli isolates, 131 of 259 (50.6%) Klebsiella sp isolates, eight of 131 (6.1%) Proteus sp 
isolates, 35 of 90 (38.9%) Enterobacter sp isolates, 13 of 48 (27.1%) Serratia sp isolates, two 
of 19 (10.5%) Morganella morganii isolates, four of 18 (22.2%) Citrobacter sp isolates, and 
two of 14 (14.3%) Salmonella sp. isolates CTX-M-15 has been described in Asia, Europe 
and recently in Africa (Baraniak et al., 2002a; Edelstein et al., 2003; Gangoue-Pieboji et al., 
2005; Karim et al., 2001; Soge et al., 2006), both in nosocomial and community-acquired E. 
coli isolates (Moubareck et al., 2005; Woodford et al., 2004). Several studies in African 
countries report a high prevalence of ESBL-producing Enterobacteriaceae (Blomberg et al., 
2005; Gangoue-Pieboji et al., 2005; Ramdani-Bouguessa et al., 2001; Soge et al., 2006). 
There have been reports of ESBL producers in North Africa: TEM-3 in S. enterica serovar 
typhymurium in Morocco (AitMhand et al., 2002), CTX-M-27 in S. enterica serovar livingstone 
in Tunisia (Bouallègue-Godet et al., 2005), and CTX-M-3 in S. enterica serovar senftenberg 
in Algeria (Naas et al., 2005).  
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Figure 10.1 - Genetic relatedness of the 16 E. coli strains as assessed by PFGE. A band position 
tolerance of 0.4% was used in PFGE pattern analysis with the Dice band-based similarity coefficient. 
Strain code numbers are shown on the right. Clones in clusters I and II (indicated by vertical bands on 
the right) contain isolates of >80% similarity. Clones in cluster I were 100% identical and those in 
cluster II had >90% similarity 
 
The frequency of Enterobacteriaceae producing ESBL in Algeria has not been 
reported. 
The production of similar TEM and CTX-M-type enzymes in various genetically 
related strains and in isolates from different wards of the hospital suggests horizontal transfer 
of the corresponding genes. Five CTX-M-15-producing isolates were genetically 
indistinguishable; they were isolated from patients in the neonatal ward, except for isolate 
108 which was from a patient hospitalized elsewhere for 20 days but who had previously 
been in this ward. Three of the patients in the neonatal ward were preterm (with 31 to 34 
weeks): the patient infected with strain 171 had nosocomial meningitis, and the patients with 
isolates 131 and 229 had probably acquired the infection by transmission from the mother. 
The two cases of meningitis were cured but the case of bacteremia was fatal. 
Invasive infections due to E. coli producing ESBL are a major problem in neonates, 
because the choice of drug is restricted. The widespread use of cefotaxime and ceftriaxone 
has been suggested to be have favored the emergence of CTX-M-enzymes (Wang et al., 
2003). However, treatment of infections with ESBL-producing strains in this hospital usually 
do not involves those antibiotics for meningitis. Therefore, this hospital may have 
experienced the spread of an epidemic clone not directly due to antibiotic selection pressure, 
but with ISEcp1 insertion sequences, involved in the mobilization of CTX-M-enzymes, 
  CTX-M-producing isolates in Algeria 
 141
contributing to the process. Dissemination of community clones in the hospital environment is 
also a possibility. 
To our knowledge this is the first report of CTX-M enzymes in E. coli from Algeria. We 
show that CTX-M-15 is widespread among E. coli isolates which are multidrug resistant, 
substantially restricting therapeutic alternatives. Implementation of a strict hospital infection 
control policy associated with efforts to promote judicious use of antibiotics is needed. 
Continuous monitoring of ESBL-producing Enterobacteriaceae in the community and the 
hospital setting is also required. 
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 Antimicrobial resistance to antibiotics is a growing problem worldwide. ESBL- 
producing organisms remain an important cause of cephalosporin therapy failure with serious 
consequences for infection control (Paterson & Bonomo, 2005). The results presented in this 
dissertation answer several important questions, such as how is the CTX-M family 
disseminated in clinical isolates of E. coli in community and nosocomial environments? Or 
which specific amino acid substitutions promote the resistance to β-lactamase inhibitors or 
improve the resistance to extended-spectrum cephalosporins and what is their function within 
the resistance mechanism? On the other hand, this work raised other as of yet unanswered 
questions. 
 In the end of chapters II to X, which consist of published or submitted publications 
(chapters II to VII on K. pneumoniae, chapters VIII to X on E. coli), the results presented in 
each one of the publications are discussed. However, an overall discussion of the different 
chapters is valuable. 
 By far the most important mechanism of resistance to β-lactam antibiotics, the β-
lactamases, could confer loss of susceptibility to several antibiotic classes like penicillins, 
narrow-, extended-, and broad-spectrum cephalosporins and also to β-lactam/β-lactamase 
inhibitor combinations. ESBL-producing Klebsiella spp and E. coli, have been reported as 
one of the six drug-resistant microbes to which new therapies are urgently needed (Talbot et 
al., 2006). 
 The rapidly evolving ESBL enzymes are inhibited by clavulanic acid, although the 
emergence of CMT compromises this inhibition. These enzymes are frequently encoded in 
plasmids that may simultaneously possess other genes responsible for resistance to different 
antibiotic classes, like quinolones and aminoglycosides, which is a further limiting factor to 
viable treatment options. Furthermore, ESBL-producing organisms may often present a non-
ESBL phenotype, by being susceptible to extended-spectrum cephalosporins, which could 
increase failure rates of treatment options (Lin et al., 2006). Thus, the presence of ESBLs 
carries tremendous clinical significance. It has long been documented that the 
cephalosporins breakpoints presently used fail to detect many of ESBLs in 
Enterobacteriaceae.  
Therefore, in Chapter II, CLSI guidelines were compared with reference laboratory 
criteria, that classify as ESBL producer strains for which any MIC of extended-spectrum 
cephalosporins is 3-fold lower in the presence of an established concentration of clavulanate. 
We obtained lower values of sensitivity for the agar dilution and broth microdilution methods 
when interpreted using CLSI guidelines in 2006, which proves that breakpoints should be 
lowered. In fact, recent breakpoint revision from CLSI guidelines, reduce the nonsusceptible 
MIC breakpoint to ≥ 2 mg/L for cefotaxime and ≥ 8 mg/L for ceftazidime instead of ≥ 16 mg/L 
previously established for both antibiotics (Kahlmeter, 2008). This revision agrees with the 
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MIC breakpoints of the newly established EUCAST guidelines, although for ceftazidime MIC 
breakpoint has been established even lower (≥ 2 mg/L). These new breakpoints would 
increase sensitivity for both techniques, thus improving results of susceptibility tests, and 
obviating the use of genotypic methods as ancillary tests. 
A major issue that concerned both EUCAST and CLSI committees was if the new 
Enterobacteriaceae MIC breakpoints would be able to predict clinical success or failure, by 
correctly identifying ESBL producers without the need of complementary methods. Based on 
the available data, and besides lowering the existing breakpoints, both committees 
concluded that detection and characterisation of new ESBLs would continue to be important 
for infection control and surveillance purposes (Kahlmeter, 2008). 
 The detection and identification of a new ESBL, SHV-55 (Chapter II), allowed for the 
biochemical characterization of this enzyme (Chapter III). Although when using MIC 
evaluation tests SHV-55 conferred a higher level of resistance to ceftazidime than to 
cefotaxime, kinetic studies showed higher affinity, enzymatic activity and catalytic efficiency 
towards cefotaxime than for ceftazidime. Similar results had been previously obtained for 
SHV-5 (Gutmann et al., 1989; Mulgrave & Attwood, 1993). Overall, only less than 30% of 
SHV enzymes which present amino acid substitutions related to extended-spectrum 
cephalosporin resistance (Chapter I, Table 1.7) have been biochemicaly characterized. 
However, these kinetic studies are of crucial importance. 
A new IRS enzyme conferring increased resistance to amoxicillin plus clavulanic acid, 
SHV-72, was also characterized and, furthermore, the role of Lys234Arg substitution was 
investigated (Chapter IV). With the identification of this IRS enzyme, the number of natural 
occuring SHV enzymes that could confer inhibitor resistance was increased. Recently, 
another IRS enzyme was described with the same amino acid substitution plus the Leu35Gln 
substitution, SHV-56 (Dubois et al., 2008). 
The emergence of IRS enzymes raises the question of the possible appearance of 
CMS (Complex Mutant SHV) capable of conferring ESBL plus IRS phenotype. In fact, an 
enzyme was described in 1997, SHV-10, which possessed the ESBL-related amino acid 
substitutions of SHV-5 plus the IRS substitution, Ser130Gly (Prinarakis et al., 1997). This 
enzyme could not be considered a CMS, because the cephalosporinase and penicillinase 
activities associated with SHV-5 were reduced in SHV-10. This confirms that Ser130 is 
important in the interaction with cephalosporins and β-lactamase inhibitors (Jacob et al., 
1990). 
 The emergence of CMS by mutational events might be associated with a selection 
process within specific sites of infection. As most IRT and CMT enzymes have been 
recovered from urinary isolates, where penicillin-β-lactamase inhibitors reach higher 
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concentrations, the same could happen with complex mutant enzymes from SHV or even 
CTX-M families. The massive use of β-lactam plus β-lactamase inhibitor combinations in 
patients from the community and hospital environments also facilitates the appearance of 
these type of enzymes (Cantón et al., 2008). 
In Chapter V, where there was an investigation of extended- and broad-spectrum β-
lactamase-producing K. pneumoniae isolated in 17 clinical health institutions, 18 new SHV 
enzymes were identified, of which 17 were non-ESBL. This study documents the substantial 
diversity detected among 207 K. pneumoniae strains collected in different regions of 
Portugal, where it was not possible to define an epidemic strain. Nevertheless, the genetic 
relatedness of 108 isolates studied by PFGE analysis identified a major profile type in our 
collection, 50% of which being GES-1 producers. Among the new SHV enzymes identified in 
the country, SHV-71, SHV-72, SHV-73 and SHV-80, all presenting an amino acid 
substitution, Ala146Val, described before in SHV-38 as contributing to an elevated 
carbapenem-hydrolytic activity (Poirel et al., 2003). Could the presence of this amino acid 
substitution produce carbapenem-hydrolytic activity in these new SHV enzymes? According 
to the authors that described the SHV-38, the Ala146Val substitution is located at the N 
terminus of an alpha helix, neither in the β-lactam binding site nor in the catalytic site. The 
alpha helix where is located the amino acid Ala146 is parallel to positions 161 to 164 of the Ω 
loop at a distance of 3.1 Å, and the side chain, although hydrophobic, is oriented toward the 
solvent (Poirel et al., 2003). However, the authors did not have data that explained how the 
amino acid substitution alters the behaviour of the SHV-38 enzyme towards imipenem. 
Nevertheless, the future characterization of this substitution in the four enzymes that we 
detected may increase the knowledge about carbapenem-hydrolysing SHV enzymes. 
 One of the other new blaSHV genes we detected, blaSHV-83, with a T2A mutation 
(Met5Lys), may be considered of particular interest, as one may wonder about a possible 
effect in the level of expression associated to this initiation codon. Under Ambler numbering, 
the Met at position 5 corresponds to the site of translation initiation (Ambler et al., 1991). 
Other codons besides ATG, which codes for a Met, can be used to initiate translation (for 
example, GTG, which codes for a Val; and TTG, which codes for a Leu) (Lewin, 1994). In 
SHV-83, despite the fact that the mature protein is identical to SHV-1, the deduced translated 
sequence has an initial Lys residue; thus, either an unusual starting codon is being used or 
another Met residue in a different position is responsible for the beginning of translation. In 
fact, blaOXA-20 translation initiates with a TTG (Leu) codon, which, according to the authors, 
implies a reduced level of expression (Naas et al., 1998), this being the least efficient 
initiation codon in E.coli (Lewin, 1994). Recently, a SHV enzyme (SHV-104) that presented a 
Met5Leu substitution was also reported (http://www.lahey.org/studies).  
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 Two other enzymes, SHV-106 and SHV-107, possess amino acid substitutions within 
the active site (Chapter V). The ESBL enzyme SHV-106 presents two amino acid 
substitutions, Tyr7Phe and Gly238Ser, the latter extensively studied and implicated in the 
increase of resistance to extended-spectrum cephalosporins (Huletsky et al., 1993). 
However, SHV-107 showed a new amino acid substitution, Thr235Ala. In class A enzymes, 
the Thr235 residue is part of a conserved element (Lys234-Thr235-Gly236), situated on the 
β3 strand of a β-sheet in the α/β domain, forming the opposite wall of the catalytic cavity site 
(Delmas et al., 2008). The structure and dynamics of other class A β-lactamases shows that 
the presence of Asp240Gly improves the interaction of residues Ser237 and Thr235 with 
ceftazidime. In SHV-107, the amino acid Thr is substituted by a smaller hydrophobic amino 
acid, Ala. Studies with site-directed mutagenesis produced a Ser235Ala substitution in a 
TEM-1 β-lactamase (Imtiaz et al., 1993). In this study, by MIC determination, the E. coli strain 
bearing the mutant TEM-1 presented much lower values for cephalosporins than those of the 
E. coli expressing TEM-1 wild-type. Kinetic determinations showed similar results between 
the Ala235 mutant and TEM-1 wild-type for penicillins, but the cephalosporinase activity was 
highly reduced for the Ala235 mutant (Imtiaz et al., 1993). Considering these results, one 
could suspect that Thr235Ala in SHV-107 may also influence the cephalosporinase activity. 
Nevertheless, future contributions of kinetic determinations of SHV-107 and eventually MDSs 
for the SHV-1 mutant carring the Ala235, will demonstrate the importance of this amino acid 
substitution in the resistance to penicillins and cephalosporins. 
 Despite the importance of ESBLs as a serious clinical problem for treatment of 
patients carrying ESBL-expressing K. pneumoniae, the clinical importance of the non-ESBL 
enzymes is yet to be revealed. Among these non-ESBL enzymes we identified SHV-71 and 
SHV-75 (Chapter V), which were also recently identified in K. pneumoniae isolates from 
Thailand (Kiratisin et al., 2008). The authors demonstrated that these enzymes were co-
expressed with CTX-M-14 and CTX-M-15, respectively. Co-expression of CTX-M enzymes 
and SHV penicillinases in K. pneumoniae strains is becoming very common (Kiratisin et al., 
2008; Romero et al., 2005). However, co-expression of ESBL enzymes with other intrinsic K. 
pneumoniae β-lactamases, like OKP or LEN, is rarer (Hæggman et al., 2004; Remeli et al., 
2007). 
 Until now, a reduced number of studies based on LEN and OKP β-lactamases have 
been published and only a few variants have been detected, when compared to other β-
lactamase families, like TEM, SHV or CTX-M. In Chapter VI, the complete sequencing of 308 
K. pneumoniae bla genes allowed for the identification and charaterization of 20 LEN and 
OKP encoding genes. Overall, 93.5% of our strains expressed SHV enzymes, thus belonging 
to group KpI. This is a higher proportion than previously reported for other collections (80 to 
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88%) (Brisse & Verhoef, 2001; Fu et al., 2007). Groups KpII and KpIII were considerably less 
represented, with no more than 2.9% and 3.5% of the strains, respectively. These groups 
each contained 10% of the strains in another study (Brisse & Verhoef, 2001). 
 Studies based on the phylogeny of bla genes and on the phylogenies of the 
housekeeping genes gyrA and mdh suggest that the most probable origin of the K. 
pneumoniae β-lactamase families was diversification from a common ancestor, along side 
the evolutionary divergence of the phylogenetic groups (Hæggman et al., 2004). More 
recently, the evolutionary divergence of blaOKP subgroups (blaOKP-A and blaOKP-B) has been 
established and phylogenetic studies based on sequencing of rpoB, gyrA, and mdh genes 
showed a concordant subdivision of K. pneumoniae phylogenetic group KpII (Fèvre et al., 
2005). Overall, within the K. pneumoniae species, there has been an evolutionary divergence 
of chromosomal bla genes (Hæggman et al., 2004).  
In addition to the diversity referred to by Hæggman et al. (2004), we also document 
the high diversity of blaSHV genes in Chapter VII; this observation allowed us to establish a 
classification system based on the synonymous mutations plus nonsynonymous mutation 
T92A. In general, among the 297 blaSHV genes studied, 61 were identified as blaSHV-11 with 20 
different nucleotide sequence frameworks and 59 were blaSHV-1 with 18 different nucleotide 
sequence frameworks. This study raised several important questions, such as what is the 
common ancestor of blaSHV-11 and blaSHV-1 derived genes or how long ago did these two 
parental genes diverged or even is there a parental gene more likely to evolve to a gene 
coding for an ESBL or IRS enzyme?  
Although amino acid sequences evolve more slowly than DNA and are easier to align, 
studying protein evolution by modelling the evolutionary process on coding DNA is more 
appealing, because nucleotide sequences contain more information. Nucleotide synonymous 
mutations are always overlooked when performing evolutionary studies based on amino acid 
sequences. Phylogenetic studies that involve synonymous and non-synonymous mutations, 
as well as the presence or absence of mutations associated with antibiotic selective pressure 
– thus conferring ESBL or IRS phenotypes – are of high importance for the understanding of 
the evolution processes of SHV enzymes. However, the value of the phylogenetic 
information carried by nonsynonymous mutations, which are strongly selected, as ESBL and 
IRS genes evolved due to selective pressure to adapt quickly to their environment, may bias 
the overall results of the phylogenetic studies. 
Nevertheless, to improve the outcome of this phylogenetic analysis, it would be of 
most importance to include all intrinsic β-lactamases expressed by K. pneumoniae. Other 
studies have already shown the phylogenetic relation between the SHV, LEN and OKP 
families, however, they did not account for the high diversity within these families (Hæggman 
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et al., 2004). Other evolutionary studies with SHV suggest that the ancestral SHV was 
already an ESBL, from which penicilinases, like SHV-1 and SHV-11, evolved by losing the 
ability to hydrolyse cephalosporins (Hall & Barlow, 2004). Nevertheless, it will be interesting 
to establish the common ancestor of SHV, LEN and OKP enzymes, as well as the 
evolutionary importance of the two SHV enzymes (SHV-1 and SHV-11) considered to be 
parental. Overall, our established classification system will be most usefull as a basis for 
evolutionary studies. 
Another main issue we studied was the production of CTX-M enzymes by E. coli 
isolates. Among β-lactamase families, one of the most important is the rapidly spreading 
worldwide CTX-M family. These ESBLs present more than 80 variants subdivided into five 
major clusters, they derived from the chromosomal β-lactamase of Kluyvera spp., and are 
highly associated with mobile elements. In some geographical areas, CTX-M enzymes are 
already the most prevalent ESBL among Enterobacteriaceae (Rossolini et al., 2008). A 
specific cluster associated with CTX-M-1, which has been shown to have the highest 
diversity, comprises one of the most disseminated β-lactamases – the CTX-M-15 enzyme. 
The gene coding for this enzyme is frequently located downstream of an ISEcp1 mobility 
element which, according to some studies, not only confers mobility to blaCTX-M genes, but 
also probably provides the promoter for their expression (Cao et al., 2002; Karim et al., 2001; 
Poirel et al., 2005).  
 As part of the worldwide dissemination, the CTX-M-15 enzymes were also detected in 
E. coli strains in Portugal, as stated in Chapter VIII. In this study, two genetically unrelated 
clinical strains from different geographical regions of the country, collected in 2004, were 
identified as producers of CTX-M-15, OXA-1 and TEM-1 enzymes. Although CTX-M-15 had 
already been detected in other Enterobacteriaceae in this country (Conceição et al., 2005), it 
was the first time that the now common combination of CTX-M-15, OXA-1 and TEM-1 β-
lactamases was described. As established at the time, it was urgent and essential to 
understand the real dissemination of CTX-M enzymes among Portuguese hospitals and 
community environments. Thus, in Chapter IX, a work to characterize the phenotype, genetic 
relatedness and β-lactamase produced by CTX-M-producing E. coli isolates identified in nine 
hospitals was embraced. 
 Overall, this surveillance study detected more than 65% of CTX-M enzymes among 
181 ESBL-producing E. coli isolates, which is similar to the high rates showed by other 
surveillance studies (Rossolini et al., 2008). However, more recent studies have showed 
even higher rates, like 100% in Thailand and 92% in Sweden (Fang et al., 2008; Kiratisin et 
al., 2008). These higher rates of CTX-M among total ESBLs enzymes, are most probably 
associated with high mobilization of the encoding genes. Barlow et al. (2008) found that the 
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blaCTX-M genes have been mobilized to plasmids almost 10 times more frequently than other 
class A β-lactamases. For example, ISCR1 associated with CTX-M-2 and CTX-M-9 groups 
and ISEcp1 associated with CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-25 groups, 
are both known to contribute to this mobilization process (Poirel et al., 2005; Rossolini et al., 
2008; Toleman et al., 2006). Responsibilities were attributed to both elements for four of 
eight mobilizations from the chromosome of Kluyvera spp. to plasmids, as stated by Barlow 
et al. (2008), although ISCR1 has been also reported to be responsible for mobilization of 
other bla genes (Naas et al., 2006). 
 Intra- and inter-species horizontal spread of blaCTX-M genes is largely promoted by 
plasmids that may carry other resistance determinants (Bonnet, 2004). In fact, the 
percentage of bacterial strains that contained plasmids in the pre-antibiotic drug era and at 
the present, although error-prone, rose from 19% to 58-100% (Barlow et al., 2008).  
 In our study, high level and high percentage of resistance to non-β-lactam antibiotics 
were also present. More than 93% of strains were resistant to fluoroquinolones, 88% were 
resistant to aminoglycosides and 26% were resistant to trimethoprim-sulfamethoxazole. Even 
though other resistance mechanisms besides β-lactamase production were not studied, 
plasmid-mediated fluoroquinolone resistance determinants, like QNR and/or AAC(6’)-Ib-cr 
(aminoglycoside 6’-N-acetyltransferase type Ib-cr) variant, conferring co-resistance to 
aminoglycosides and to certain fluoroquinolones, are likely to be present. In fact, the plasmid 
association of blaCTX-M genes with these two recently identified types of plasmid-mediated 
resistance mechanisms has become quite common (Boyd et al., 2004; Leflon-Guibout et al., 
2004; Machado et al., 2007; Oteo et al., 2006). Another association detected in this work, but 
in this case among bla genes, could be responsible for the lack of resistance of CTX-M 
producing strains towards β-lactamase inhibitors, until now undetected. The co-expression of 
blaOXA-1 genes by 93% of strains possessing blaCTX-M genes implied a 26% of reduced 
susceptibility to amoxicillin plus clavulanic acid combination and 12% to piperacillin plus 
tazobactam combination. Could the co-expression of both these types of enzymes enable 
the emergence of CTX-M β-lactamases capable of conferring resistance to β-lactamase 
inhibitors? 
Site-directed mutagenesis studies tried to establish the role of residue Arg276 of 
CTX-M-type enzymes, which is equivalent to the Arg244 of TEM enzymes, associated to the 
IRT phenotypes (Delmas et al., 2006; Pérez-Llarena et al., 2008). However, none of the 
studies could show an increase in MIC values towards β-lactam/β-lactamase-inhibitor 
combinations associated with substitutions of residue Arg276 and, furthermore, mutants 
showed decreased MIC values to cefotaxime as well as reduced catalytic efficiency to this 
antibiotic. 
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 Overall, all CTX-M-producing strains were susceptible to carbapenems. However, the 
emergence of different types of carbapenemases could compromise the usefulness of this 
class of antibiotics (Walther-Rasmussen & Høiby, 2006; Walsh et al., 2005). Nowadays, 
other types of antibiotics, like fosfomycin, nitrofurantoin and tigecycline, could be valid 
alternatives to carbapenems by reducing the selection pressure for ESBL-producing 
organisms (Garau, 2008). Nevertheless, none of these alternatives present total efficacy 
against ESBL producers and, so, improving antibiotics of current use and discovering new 
anti-Gram-negative drugs continues to be an important challenge. 
 Another important aspect of this work was the detection of dissemination of CTX-M 
producers within a specific hospital (Chapter IX, Table 9.6). Although, CTX-M-producing 
strains have been detected all over the country in nosocomial and community environments, 
the dissemination through the majority of wards in this hospital should raise questions of 
control infections. Classic control measures should be applied, such as avoiding all 
antibiotics to which the spreading strains or plasmid donors are resistant (thus reducing the 
selection pressure), as well as decreasing the use of procedures that are related to the risk 
of infection, and adopting adequate procedures of hand hygiene among clinical staff. Studies 
have shown that these types of interventions are important to infection control, both in 
nosocomial or community environments (Warren et al., 2008). 
 Similar results were obtained in Chapter X, where the phenotypic and genetic profiles 
of 16 clinical E. coli ESBL producers isolated in an Algerian hospital were investigated. In this 
study, only CTX-M enzymes from group 1 were disseminated in different hospital wards, but 
no major epidemic strain was identified, in contrast to the Portuguese situation. Overall, more 
recent studies have also identified the same type of CTX-M enzymes disseminated among 
other Enterobacteriaceae in this country (Iabadene et al. 2008; Messai et al., 2008; Touati et 
al., 2008). The worldwide dissemination of CTX-M β-lactamases should be faced as a very 
serious problem, because these enzymes are now the most prevalent ESBL founded in 
clinical E. coli and K. pneumoniae isolates (Rossolini et al., 2008). 
Overall, we detected a high diversity of β-lactamases among clinical isolates of E. coli 
and K. pneumoniae, namely SHV, GES, LEN, OKP, CTX-M, OXA and TEM enzymes. The 
issues studied in this dissertation are of most importance to the comprehension of the 
general situation of β-lactamases and resistance in Portugal and constitute a contribution to 
the worldwide scenario. Nevertheless, some questions arose from this work that remain to be 
clarified and would constitute an interesting subject for future investigations. 
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